Look up a biomarker to see its clinical significance, testing methodology, disease associations, and a plain-language summary.
| Biomarker▲ | Validation▲ | Aliases▲ | Diseases Indicated▲ | Short Description▲ | Clinical Significance▲ | Test Methodology▲ | Specimen Type▲ |
|---|---|---|---|---|---|---|---|
| Zinc transporter 8 | Emerging | ZnT8, ZnT8A (autoantibody), SLC30A8 | Type 1 diabetes mellitus, Not primarily cancer-associated | ZnT8 autoantibodies are now a standard component of the type 1 diabetes diagnostic autoantibody panel, improving detection rates. | Helps distinguish autoimmune type 1 diabetes from monogenic diabetes, avoiding unnecessary genetic testing in some patients. | Immunoassay (ELISA/RIA) for autoantibody | Serum |
| VWF | Established | VWF, von Willebrand factor | Von Willebrand disease, Not primarily cancer-associated | VWF is central to diagnosing von Willebrand disease, the most common inherited bleeding disorder, via a standardized 2021 algorithm. | Treatment differs critically by VWD subtype; desmopressin can worsen type 2B disease rather than help it. | Immunoassay (ELISA/CLIA) for antigen; functional activity assay (ristocetin cofactor or GPIbM-based) | Plasma (citrate) |
| VEGFC | Emerging | VEGF-C, vascular endothelial growth factor C | Lymphedema (lymphatic development context), Studied across several solid tumors for lymph node metastasis risk (research context) | VEGF-C drives lymphangiogenesis and is studied as a research marker for lymph node metastasis risk in cancer. | An active area of anti-lymphangiogenic drug development research, not yet a standardized clinical test. | Immunoassay (ELISA) | Serum or plasma (primarily research use) |
| Vasoactive intestinal polypeptide | Emerging | VIP, vasoactive intestinal peptide | VIPoma (Verner-Morrison syndrome/WDHA syndrome), Pancreatic neuroendocrine tumor (VIPoma) | VIP excess causes VIPoma, a rare pancreatic tumor syndrome with severe watery diarrhea and low potassium. | Diagnosis combines elevated VIP with the classic watery diarrhea/hypokalemia/achlorhydria clinical triad. | Immunoassay (RIA) | Plasma (EDTA with protease inhibitor, on ice, fasting) |
| Uroporphyrinogen Decarboxylase | Established | UROD, uroporphyrinogen decarboxylase | Porphyria cutanea tarda, Not primarily cancer-associated | UROD deficiency causes porphyria cutanea tarda, the most common porphyria, often triggered by acquired factors. | Frequently acquired/triggered (alcohol, estrogen, hepatitis C, iron overload) rather than purely inherited. | Enzyme fluorometric activity assay; genetic testing | Erythrocytes/whole blood |
| Uric acid | Established | Uric acid, urate | Gout, kidney stones (urate-type), Relevant to tumor lysis syndrome risk assessment in lymphoma/leukemia chemotherapy | Uric acid causes gout via crystal deposition and is also a key pretreatment risk marker for tumor lysis syndrome in oncology. | Connects directly to the LDH/tumor lysis syndrome discussion elsewhere in this set as part of the same pretreatment risk panel. | Enzymatic colorimetric assay | Serum or plasma |
| Tumor necrosis factor | Emerging | TNF-alpha, TNF, cachectin | Rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis, ankylosing spondylitis, Not primarily cancer-associated | TNF-alpha is the direct target of an entire major biologic drug class (anti-TNF agents) across multiple autoimmune diseases. | One of the most therapeutically significant cytokines in modern medicine, despite not being routinely measured itself. | Immunoassay (ELISA) | Serum or plasma |
| Tumor Mutational Burden | Established | TMB, tumor mutation burden, TMB-H | Not primarily disease-indicating outside oncology context, Tissue-agnostic across advanced solid tumors (FDA pembrolizumab indication) | TMB is a tissue-agnostic predictive biomarker for checkpoint inhibitor response, though weaker and more debated than PD-L1 or MSI-H. | Only one specific NGS panel (FoundationOne CDx) carries FDA approval for this particular clinical use. | Next-generation sequencing (large gene panel, FoundationOne CDx is the FDA-approved assay) | Tumor tissue (FFPE biopsy or resection specimen) |
| TTR | Established | TTR, transthyretin, prealbumin | ATTR amyloidosis (hereditary and wild-type), malnutrition (historical use as "prealbumin"), Not primarily cancer-associated | TTR misfolding causes ATTR amyloidosis, an underdiagnosed cause of heart failure with a rapidly expanding treatment landscape. | Treatment options expanded dramatically in 2024-2025, with acoramidis, vutrisiran, and eplontersen joining tafamidis. | Immunoassay (nephelometry/turbidimetry) for level; genetic testing for hereditary ATTR; nuclear scintigraphy or tissue biopsy for amyloid deposition | Serum (level); whole blood (genetic); cardiac tissue biopsy or scintigraphy for amyloidosis diagnosis |
| TSHB | Established | TSH, thyrotropin | Hypothyroidism, hyperthyroidism, subclinical hypothyroidism, Not primarily cancer-associated | TSH is the standard first-line thyroid function test, most sensitive for detecting thyroid dysfunction. | Treatment thresholds for mild (subclinical) elevation remain debated, especially in older adults. | Immunoassay (CLIA/ECLIA) | Serum |
| TSH receptor antibody | Established | TRAb, TSI, thyroid-stimulating immunoglobulin | Graves' disease, neonatal/fetal hyperthyroidism (via placental transfer), Not primarily cancer-associated | TRAb, specifically the stimulating TSI form, is the direct cause of and diagnostic marker for Graves' disease. | Crosses the placenta during pregnancy, requiring monitoring to prevent fetal or neonatal hyperthyroidism. | Immunoassay (functional bioassay for TSI, or binding assay) | Serum |
| Triosephosphate Isomerase | Emerging | TPI, TPI1 | Hereditary non-spherocytic hemolytic anemia with progressive neurological deterioration (TPI deficiency), Not primarily cancer-associated | TPI deficiency is the most severe glycolytic enzyme deficiency, combining hemolytic anemia with progressive neurological decline. | The neurological component doesn't respond to standard anemia treatments, making this a particularly difficult condition to manage. | Enzyme kinetic activity assay; genetic testing | Whole blood (RBC) |
| Transglutaminase IgA antibody | Established | tTG-IgA, tissue transglutaminase antibody | Celiac disease, Not primarily cancer-associated | tTG-IgA is the current first-line, guideline-recommended serologic test for celiac disease. | Requires simultaneous total IgA testing to avoid missing celiac disease in IgA-deficient patients. | Immunoassay (ELISA/CLIA) | Serum |
| TPSAB1 | Established | Tryptase, alpha-tryptase | Mastocytosis, anaphylaxis, hereditary alpha-tryptasemia, Systemic mastocytosis (clonal mast cell neoplasm) | TPSAB1/tryptase is central to diagnosing mastocytosis and anaphylaxis, complicated by a distinct genetic trait (hereditary alpha-tryptasemia). | Distinguishing hereditary alpha-tryptasemia from true mastocytosis requires genetic copy-number testing, not tryptase level alone. | Immunoassay (ImmunoCAP fluoroenzymeimmunoassay) for level; genetic copy-number testing (ddPCR) for hereditary alpha-tryptasemia | Serum (level); whole blood (genetic) |
| Total Protein | Established | Total protein, TP | Chronic liver disease, chronic inflammation, monoclonal gammopathy, Multiple myeloma (via monoclonal gammopathy workup) | Total protein is a basic screening test; the albumin-to-globulin ratio derived from it is often more clinically informative. | An abnormal ratio, especially with elevated globulins, prompts protein electrophoresis to look for a monoclonal spike. | Colorimetric assay (biuret method) | Serum |
| TNNT2 | Established | Cardiac troponin T, cTnT, hs-cTnT | Not primarily disease-indicating outside cardiac context, Not primarily cancer-associated | Cardiac troponin T is clinically equivalent to troponin I as a gold-standard heart attack diagnostic biomarker. | Serial (delta) measurements help distinguish acute from chronic myocardial injury patterns. | Immunoassay (ECLIA, high-sensitivity) | Serum or plasma |
| TNNI3 | Established | Cardiac troponin I, cTnI, hs-cTnI | Not primarily disease-indicating outside cardiac context, Not primarily cancer-associated | Cardiac troponin I is a gold-standard biomarker for diagnosing heart attacks, now used in rapid rule-in/rule-out algorithms. | No single universal cutoff exists; values are assay-specific and increasingly interpreted with sex-specific reference limits. | Immunoassay (CLIA/ECLIA, high-sensitivity) | Serum or plasma |
| Thrombopoietin | Emerging | TPO, thrombopoietin | Chronic immune thrombocytopenia, thrombocytopenia in chronic liver disease, Not primarily cancer-associated | TPO drives platelet production; thrombopoietin receptor agonist drugs are now standard ITP treatment, without TPO itself being routinely measured. | Newer agents (avatrombopag, hetrombopag) continue to refine dosing convenience and reduce side effects like hepatotoxicity. | Immunoassay (ELISA) | Serum or plasma |
| TG | Established | Tg, thyroglobulin | Not primarily disease-indicating outside oncology context, Differentiated thyroid cancer (papillary, follicular) | Thyroglobulin is the standard biomarker for monitoring differentiated thyroid cancer recurrence after treatment. | Thyroglobulin antibodies (up to 25% of patients) and even certain supplements can cause significant test interference. | Immunoassay (CLIA/ECLIA) | Serum |
| TFRC | Emerging | sTfR, soluble transferrin receptor, CD71 | Iron deficiency anemia, anemia of chronic disease (differentiation), Not primarily cancer-associated | TFRC/soluble transferrin receptor helps diagnose iron deficiency even when inflammation confounds standard iron studies. | Not affected by inflammation, unlike ferritin, making it valuable in complex or chronically inflamed patients. | Immunoassay (ELISA/nephelometry) for soluble transferrin receptor | Serum |
| TF | Established | Transferrin | Iron deficiency anemia, anemia of chronic disease, hereditary hemochromatosis, Not primarily cancer-associated | Transferrin, as part of the full iron panel, helps distinguish iron deficiency from chronic disease anemia and hemochromatosis. | Must be interpreted together with serum iron, ferritin, and transferrin saturation, not as a standalone value. | Immunoassay (nephelometry/turbidimetry) | Serum |
| SS-B/La Antibodies | Established | Anti-SS-B, anti-La antibody | Sjogren's syndrome, systemic lupus erythematosus, neonatal lupus/congenital heart block, Not primarily cancer-associated | SS-B/La usually accompanies SS-A/Ro in Sjogren's syndrome; the combination is more diagnostically specific than either alone. | Carries a similar, somewhat lower, congenital heart block risk in pregnancy compared to SS-A/Ro. | Immunoassay (ELISA) | Serum |
| SS-A/Ro Antibodies | Established | Anti-SS-A, anti-Ro antibody | Sjogren's syndrome, systemic lupus erythematosus, neonatal lupus/congenital heart block, Not primarily cancer-associated | SS-A/Ro is the key Sjogren's syndrome marker, with an important congenital heart block risk in pregnancy. | Relevant to prenatal monitoring even in asymptomatic antibody-positive women without a diagnosed autoimmune condition. | Immunoassay (ELISA) | Serum |
| Squamous cell carcinoma antigen | Established | SCC antigen, SCCA | Psoriasis, eczema (benign causes of mild elevation), Cervical cancer, head and neck squamous cell carcinoma, lung squamous cell carcinoma, esophageal cancer | SCC antigen is a monitoring tumor marker for squamous cell carcinomas across several body sites. | Some benign skin conditions can also mildly elevate this marker, since it's a normal squamous epithelium protein. | Immunoassay (CLIA/ECLIA) | Serum |
| SHBG | Established | SHBG, sex hormone-binding globulin | Polycystic ovary syndrome, male hypogonadism, obesity/insulin resistance (low SHBG), hyperthyroidism (high SHBG), Not primarily cancer-associated | SHBG is used to calculate free testosterone, correcting for cases where total testosterone alone would be misleading. | Particularly important in PCOS and hypogonadism evaluation, where SHBG abnormalities can distort total hormone readings. | Immunoassay (CLIA/ECLIA) | Serum |
| SERPINE1 | Emerging | PAI-1, plasminogen activator inhibitor-1 | Cardiovascular disease, metabolic syndrome, thrombosis risk, Breast cancer (historical uPA/PAI-1 prognostic test, largely superseded) | SERPINE1/PAI-1 affects clot breakdown and cardiovascular risk; its breast cancer prognostic test role has been largely superseded. | The uPA/PAI-1 breast cancer test has been overtaken by genomic assays like Oncotype DX and MammaPrint. | Immunoassay (ELISA) | Plasma (cardiovascular context) or fresh/frozen tumor tissue (oncology uPA/PAI-1 test) |
| SERPINC1 | Established | Antithrombin, antithrombin III, AT | Hereditary antithrombin deficiency, liver disease, nephrotic syndrome, DIC (acquired causes), Not primarily cancer-associated | Antithrombin deficiency is a thrombophilia; its deficiency can also cause resistance to heparin therapy. | Heparin's mechanism of action depends on binding antithrombin, making this an important drug-biomarker interaction to recognize. | Functional (chromogenic) assay or antigen immunoassay | Plasma (citrate) |
| SERPINA7 | Established | TBG, thyroxine-binding globulin | TBG excess/deficiency (genetic), pregnancy and estrogen-related thyroid test interference, Not primarily cancer-associated | TBG is the main thyroid hormone carrier protein; its level changes can distort total T4 without reflecting true thyroid function. | Free T4 testing is now generally preferred over total T4 specifically to avoid this interference issue. | Immunoassay (CLIA/ECLIA) | Serum |
| SERPINA1 | Established | AAT, alpha-1 antitrypsin, A1AT | Alpha-1 antitrypsin deficiency, COPD, emphysema, liver cirrhosis, Hepatocellular carcinoma (increased risk in AATD-related cirrhosis) | SERPINA1/AAT deficiency is an underdiagnosed genetic cause of early COPD and liver disease, per a newly updated 2024/2025 guideline. | Augmentation therapy is currently restricted to severe deficiency, though evidence for intermediate-deficiency patients is emerging. | Immunoassay (nephelometry/turbidimetry) for level; genetic/phenotype testing for variants | Serum (level); whole blood (genetic) |
| SELP | Emerging | P-selectin, CD62P | Sickle cell disease (vaso-occlusive crisis), Not primarily cancer-associated | P-selectin drives the abnormal blood cell adhesion behind sickle cell vaso-occlusive crises, now a specific drug target (crizanlizumab). | One of several newer sickle cell therapies that have reshaped treatment in recent years, alongside voxelotor and hydroxyurea updates. | Immunoassay (ELISA) | Serum or plasma |
| SAA1 | Emerging | SAA, serum amyloid A protein | AA (secondary) amyloidosis, chronic inflammatory disease (rheumatoid arthritis, IBD), Not primarily cancer-associated | SAA1 is an acute-phase reactant whose chronic elevation drives AA amyloidosis, distinct from ATTR or AL amyloidosis. | Correct amyloid subtyping (AA vs. ATTR vs. AL) is essential since treatment approaches differ substantially between types. | Immunoassay (nephelometry/turbidimetry/ELISA) | Serum |
| S100A8 | Established | Calprotectin (component), MRP8 | Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Not primarily cancer-associated | S100A8, as part of calprotectin, is a widely used noninvasive marker distinguishing IBD from irritable bowel syndrome. | Also used to monitor treatment response and detect subclinical inflammation in patients with established IBD. | Immunoassay (ELISA) | Stool |
| Rheumatoid Factor | Established | RF, rheumatoid factor | Rheumatoid arthritis, Sjogren's syndrome, hepatitis C, chronic infections, Not primarily cancer-associated | Rheumatoid factor is an older, less specific RA marker, generally considered less reliable than anti-CCP. | Positive in numerous non-RA conditions, including a meaningful fraction of healthy older adults. | Nephelometric/turbidimetric immunoassay or agglutination assay | Serum |
| REN | Established | Renin, plasma renin activity, direct renin concentration | Primary aldosteronism, resistant hypertension, Not primarily cancer-associated | Renin, paired with aldosterone, is central to diagnosing primary aldosteronism, a common cause of hypertension. | A 2025 Endocrine Society guideline shift toward universal hypertension screening represents a major, very current change in practice. | Immunoassay (CLIA) for direct renin concentration; enzymatic assay for plasma renin activity | Plasma (EDTA) |
| Pyruvate Kinase | Established | PK deficiency, PKLR enzyme | Pyruvate kinase deficiency (hereditary hemolytic anemia), Not primarily cancer-associated | Pyruvate kinase deficiency causes chronic hemolytic anemia, now treatable with a novel oral enzyme activator (mitapivat). | Represents a rare case of a previously untreatable enzyme deficiency gaining a genuine disease-modifying drug. | Enzyme kinetic activity assay | Whole blood (RBC hemolysate) |
| PTH | Established | PTH, parathormone, intact PTH | Primary hyperparathyroidism, CKD-mineral and bone disorder, hypoparathyroidism, Parathyroid adenoma/carcinoma | PTH is central to diagnosing hyperparathyroidism and CKD-related bone disease, with genuinely distinct target ranges for each. | The CKD-MBD target range (2-9x upper normal limit) is intentionally wide, not "normal," reflecting real assay and physiologic complexities. | Immunoassay (CLIA/ECLIA, second-generation intact PTH) | Plasma (EDTA) |
| PSA | Established | KLK3, prostate-specific antigen | Benign prostatic hyperplasia, prostatitis, Prostate cancer | PSA is a widely used prostate cancer marker, but its screening role remains a genuinely preference-sensitive decision. | Guidelines emphasize shared decision-making given real overdetection/overtreatment risks, rather than routine screening for all. | Immunoassay (CLIA/ECLIA) | Serum |
| Protein S-100B | Established | S100B, S100 calcium-binding protein B | Traumatic brain injury, Melanoma | S100B serves two unrelated roles: helping triage head injury patients for CT imaging, and monitoring melanoma. | A normal early post-injury S100B has high negative predictive value for ruling out significant brain injury on CT. | Immunoassay (ELISA/ECLIA) | Serum |
| Prostatic Acid Phosphatase | Emerging | PAP, prostatic acid phosphatase | Not primarily disease-indicating outside oncology context, Prostate cancer | PAP is a historical prostate cancer marker now most significant as the target antigen for sipuleucel-T, the first FDA-approved cancer vaccine. | Demonstrated a survival benefit in metastatic castration-resistant prostate cancer as the basis of an approved immunotherapy. | Immunoassay (RIA/ELISA), largely historical | Serum |
| PROS1 | Established | Protein S | Hereditary Protein S deficiency, thrombophilia, Not primarily cancer-associated | Protein S deficiency is a thrombophilia; testing is complicated by physiologic drops during pregnancy and hormonal contraception. | Current guidelines reserve testing for cases where results would meaningfully change management, not routine screening. | Functional clotting assay or antigen immunoassay | Plasma (citrate) |
| Proinsulin C-peptide | Established | C-peptide, connecting peptide | Insulinoma, factitious hypoglycemia, type 1 vs. type 2 diabetes classification, Insulinoma (pancreatic neuroendocrine tumor) | C-peptide distinguishes endogenous from injected insulin sources and helps classify diabetes type. | Central to the insulin-to-C-peptide ratio used in diagnosing insulinoma versus factitious hypoglycemia. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| Procalcitonin | Established | PCT, procalcitonin | Bacterial sepsis, lower respiratory tract infection, Medullary thyroid carcinoma (as the CALCA-derived precursor, connects to the calcitonin entry elsewhere in this set, though PCT itself is not the primary MTC marker) | Procalcitonin helps distinguish bacterial from viral/non-infectious causes of inflammation and guides antibiotic stewardship decisions. | Procalcitonin-guided protocols reduce antibiotic duration in several clinical trials without worsening patient outcomes. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| PROC | Established | Protein C | Hereditary Protein C deficiency, purpura fulminans, thrombophilia, Not primarily cancer-associated | Protein C deficiency is a thrombophilia; starting warfarin without heparin overlap risks warfarin-induced skin necrosis. | Severe homozygous deficiency causes purpura fulminans, a life-threatening neonatal clotting emergency. | Functional clotting assay (chromogenic or clot-based) or antigen immunoassay | Plasma (citrate) |
| PRL | Established | Prolactin | Prolactinoma, hypothyroidism (secondary cause), macroprolactinemia, Prolactinoma (pituitary adenoma) | Elevated prolactin suggests prolactinoma but more often reflects medication effects or a lab-interference artifact (macroprolactin). | Macroprolactin screening is now routine before pursuing pituitary imaging for an isolated elevation. | Immunoassay (CLIA/ECLIA) | Serum |
| Porphobilinogen Deaminase | Established | HMBS, hydroxymethylbilane synthase, PBGD | Acute intermittent porphyria, Not primarily cancer-associated | Porphobilinogen deaminase deficiency causes acute intermittent porphyria, diagnosed via enzyme or genetic testing. | Genetic testing increasingly used for definitive diagnosis and identifying asymptomatic carrier family members. | Enzyme fluorometric activity assay; genetic testing (HMBS) | Whole blood (erythrocytes) |
| Phosphofructokinase | Emerging | PFK, PFKM, Tarui disease enzyme | Hereditary non-spherocytic hemolytic anemia, glycogen storage disease type VII (Tarui disease), Not primarily cancer-associated | PFK deficiency (Tarui disease) uniquely combines hemolytic anemia with a muscle glycogen storage disease. | The combined blood and muscle involvement distinguishes it from other glycolytic enzyme deficiencies in this biomarker set. | Enzyme kinetic activity assay | Whole blood (RBC) or muscle tissue |
| PGR | Established | PR, progesterone receptor | Not primarily disease-indicating outside oncology context, Breast cancer | PGR/progesterone receptor status, paired with ER, guides breast cancer hormone therapy eligibility. | The uncommon PR-positive/ER-negative combination has a less well-established optimal treatment approach. | Immunohistochemistry (IHC) | Tumor tissue (biopsy) |
| Perineuclear Antineutrophil Cytoplasmic Antibodies | Established | p-ANCA, MPO-ANCA (perinuclear pattern) | Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, inflammatory bowel disease, autoimmune hepatitis, Not primarily cancer-associated | p-ANCA is an immunofluorescence pattern typically corresponding to MPO-ANCA, associated with specific vasculitis subtypes. | Distinguishes from the cytoplasmic (c-ANCA/PR3) pattern more typical of granulomatosis with polyangiitis. | Indirect immunofluorescence; antigen-specific immunoassay (MPO-ELISA) | Serum |
| PD-L1 | Established | PD-L1, CD274, B7-H1 | Not primarily disease-indicating outside oncology context, Non-small cell lung cancer, gastric cancer, cervical cancer, head and neck cancer, urothelial carcinoma, triple-negative breast cancer, esophageal cancer | PD-L1 IHC is one of three FDA-approved predictive biomarkers for immune checkpoint inhibitor response. | Each checkpoint drug has its own non-interchangeable companion diagnostic antibody clone and scoring system (TPS vs. CPS). | Immunohistochemistry (IHC) using drug-specific companion diagnostic antibody clones (22C3, SP142, 28-8, SP263) | Tumor tissue (FFPE biopsy or resection specimen) |
| PAPPA | Established | PAPP-A, pregnancy-associated plasma protein A | Down syndrome (screening), preeclampsia and fetal growth restriction (associated risk), Not primarily cancer-associated | PAPP-A is a first-trimester screening marker for chromosomal abnormalities, also linked to later placental complications. | Low levels carry secondary prognostic value for placental-mediated pregnancy complications beyond chromosomal screening. | Immunoassay (CLIA/ECLIA) | Serum (maternal, first trimester) |
| Pancreatic Polypeptide | Emerging | PP, pancreatic polypeptide | Not primarily disease-indicating outside oncology context, PPoma (pancreatic neuroendocrine tumor), other neuroendocrine tumors | Pancreatic polypeptide supports PPoma diagnosis, typically as part of a broader neuroendocrine tumor marker panel. | Rarely diagnostic in isolation; used alongside chromogranin A and other markers for full characterization. | Immunoassay (RIA/ELISA) | Plasma (EDTA, fasting) |
| Pancreatic elastase-1 | Established | Fecal elastase-1, FE-1 | Pancreatic exocrine insufficiency, chronic pancreatitis, cystic fibrosis, Not primarily cancer-associated (relevant after pancreatic cancer surgery) | Fecal elastase-1 is the modern preferred test for pancreatic exocrine insufficiency, replacing fecal chymotrypsin. | Remains accurate even in patients already taking pancreatic enzyme replacement therapy, unlike the older chymotrypsin test. | Immunoassay (ELISA) | Stool |
| Pancreatic Amylase | Established | P-type amylase, pancreatic isoamylase | Acute pancreatitis, chronic pancreatitis, Not primarily cancer-associated | Pancreatic amylase is the pancreas-specific fraction of amylase, sharing amylase's overall decline in favor of lipase. | Rarely ordered in current practice given lipase's superior diagnostic performance for pancreatitis. | Enzyme kinetic activity assay with isoenzyme electrophoresis | Serum |
| OGA | Emerging | O-GlcNAcase, MGEA5 | Not primarily disease-indicating outside neurodegeneration research context, Not primarily cancer-associated | OGA regulates a protein modification relevant to tau pathology; OGA inhibitors are an early-stage neurodegenerative disease drug approach. | Remains investigational; not yet a standard clinical biomarker or approved therapeutic target. | Enzyme activity assay (research use) | Tissue (research context) |
| Nuclear Ribonucleoprotein H1 antibodies | Established | Anti-RNP, anti-U1RNP | Mixed connective tissue disease, systemic lupus erythematosus, Not primarily cancer-associated | High-titer anti-RNP without other lupus-specific antibodies is the serologic hallmark of mixed connective tissue disease. | The specific antibody combination pattern distinguishes MCTD from lupus or other overlap syndromes. | Immunoassay (ELISA) | Serum |
| NPM1 | Established | NPM1, nucleophosmin 1, NPM1c | Not primarily disease-indicating outside oncology context, Acute myeloid leukemia | NPM1 mutation is the most common AML genetic abnormality and, in isolation, one of the most favorable prognostic markers. | Now incorporated as a distinct WHO AML disease entity; prognosis depends heavily on co-occurring mutations, especially FLT3-ITD. | PCR-based mutation testing or next-generation sequencing (NGS) panel | Bone marrow or peripheral blood (whole blood, EDTA) |
| Neurotensin | Emerging | Neurotensin, NT | Not primarily disease-indicating outside oncology research context, Gastrointestinal neuroendocrine tumors, pancreatic cancer (research target) | Neurotensin is elevated in certain GI neuroendocrine tumors; its receptor is an emerging target for radioligand cancer therapy. | Not yet a standardized diagnostic test; primarily relevant in specialized neuroendocrine tumor research and early clinical trials. | Immunoassay (RIA) | Plasma (EDTA, on ice) |
| Neurofilament Light Polypeptide | Emerging | NfL, neurofilament light chain | Multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, other neurodegenerative diseases, Not primarily cancer-associated | NfL is a rapidly emerging blood biomarker of neuroaxonal damage, now guided by a 2024 consensus statement for MS management. | Blood-based testing (rather than only spinal fluid) is a genuinely practical recent advance, expanding accessibility for monitoring. | Immunoassay (Simoa, ultra-sensitive) | Serum or plasma (increasingly preferred) or CSF |
| N-terminal propeptide of type 1 procollagen | Established | P1NP, procollagen type 1 N-terminal propeptide | Osteoporosis, Bone metastases (as part of broader bone turnover assessment) | P1NP is the leading bone formation marker, used to monitor both anabolic and antiresorptive osteoporosis therapy. | Expected direction of change differs by drug class — rising with anabolic drugs, falling with antiresorptive drugs. | Immunoassay (ECLIA/RIA) | Serum |
| N-terminal pro-B-type Natriuretic peptide | Established | NT-proBNP | Heart failure, Not primarily cancer-associated | NT-proBNP is BNP's longer-lasting precursor fragment, often preferred for heart failure diagnosis due to its stability. | Not directly interchangeable with BNP values; each has distinct reference ranges and guideline cutoffs. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| MUC1 | Established | MUC1, CA 15-3, CA 27.29 | Not primarily disease-indicating outside oncology context, Breast cancer | MUC1 underlies CA 15-3/CA 27.29, breast cancer markers used for monitoring, not screening or diagnosis. | Follows the same monitoring-only role pattern as CEA in colorectal cancer and CA 19-9 in pancreatic cancer. | Immunoassay (CLIA/ECLIA) | Serum |
| Mismatch Repair Deficiency / Microsatellite Instability | Established | MMR, MSI-H, dMMR, MLH1, MSH2, MSH6, PMS2 | Lynch syndrome (hereditary nonpolyposis colorectal cancer), Colorectal cancer, endometrial cancer, gastric cancer, and other MSI-H solid tumors (tissue-agnostic) | dMMR/MSI-H is a tissue-agnostic predictive biomarker for checkpoint inhibitor response and the molecular signature of Lynch syndrome. | One of the first FDA drug approvals based purely on a biomarker rather than the cancer's site of origin. | Immunohistochemistry (MMR protein loss); PCR-based fragment analysis or NGS (microsatellite instability) | Tumor tissue (FFPE biopsy or resection specimen) |
| MB | Established | Myoglobin | Rhabdomyolysis, muscular dystrophy, myocardial infarction (historical marker), Not primarily cancer-associated | Myoglobin is an early but nonspecific muscle injury marker, now mainly used to gauge rhabdomyolysis severity. | Its cardiac diagnostic role has been superseded by the far more specific troponin. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| MAPT | Emerging | Tau, MAPT, microtubule-associated protein tau | Alzheimer's disease, frontotemporal dementia, other tauopathies, Not primarily cancer-associated | MAPT/tau blood biomarkers (p-tau217, p-tau181) are central to modern Alzheimer's diagnosis and anti-amyloid treatment monitoring. | May offer an earlier signal of disease reactivation after treatment discontinuation than amyloid PET imaging. | Immunoassay (Simoa/CLIA, ultra-sensitive) | CSF or plasma |
| LYZ | Emerging | Lysozyme, muramidase | Sarcoidosis, Monocytic leukemia, myelomonocytic leukemia | Lysozyme supports sarcoidosis diagnosis and is elevated in monocytic leukemias, where very high levels can injure the kidneys. | A secondary complication in monocytic leukemia: lysozyme-induced kidney tubular injury at very high levels. | Enzyme turbidimetric activity assay; immunoassay | Serum or urine |
| LTF | Established | Lactoferrin, fecal lactoferrin | Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Not primarily cancer-associated | Fecal lactoferrin is a noninvasive inflammation marker that helps distinguish IBD from irritable bowel syndrome. | Often used alongside fecal calprotectin for a similar noninvasive screening purpose before colonoscopy. | Immunoassay (ELISA) | Stool |
| LPL | Emerging | LPL, lipoprotein lipase deficiency | Familial chylomicronemia syndrome, severe hypertriglyceridemia, recurrent pancreatitis, Not primarily cancer-associated | LPL deficiency causes familial chylomicronemia syndrome, now treatable with a December 2024 FDA-approved antisense drug (olezarsen). | Represents a rare condition with a genuinely new treatment option after decades of dietary restriction being the only management. | Genetic testing (sequencing); functional lipolytic activity assay (research, post-heparin plasma) | Whole blood (genetic) or plasma (functional, rarely done) |
| Lipase | Established | Serum lipase, pancreatic lipase | Acute pancreatitis, chronic pancreatitis, Pancreatic cancer (in some contexts of duct obstruction) | Lipase is the current preferred first-line marker for diagnosing acute pancreatitis, replacing amylase. | Should not be repeated serially to monitor disease severity once the diagnosis is established. | Enzyme kinetic (colorimetric) activity assay | Serum |
| LHB | Established | LH, luteinizing hormone | Polycystic ovary syndrome, menopause, male hypogonadism, Not primarily cancer-associated | LH, paired with FSH, helps evaluate PCOS, fertility timing, and menopause, though its role in routine menopause diagnosis is narrowing. | An elevated LH:FSH ratio is a classic supporting (though not required) finding in PCOS. | Immunoassay (CLIA/ECLIA) | Serum |
| LEP | Emerging | Leptin | Congenital leptin deficiency, obesity (leptin resistance), Not primarily cancer-associated | Leptin regulates appetite; rare congenital deficiency is treatable with metreleptin replacement therapy. | One of the few specific hormone deficiencies with its own approved replacement drug (metreleptin). | Immunoassay (RIA/ELISA) | Serum or plasma |
| LCN2 | Emerging | NGAL, lipocalin-2 | Acute kidney injury, Not primarily cancer-associated | LCN2/NGAL is a promising early acute kidney injury marker, rising faster than creatinine after kidney insult. | Not yet universally adopted into routine clinical AKI diagnostic criteria despite strong supporting research. | Immunoassay (ELISA/CLIA) | Urine or serum/plasma |
| Lactate dehydrogenase | Established | LDH, lactic dehydrogenase | Hemolysis, tissue injury, myocardial infarction (historical marker), Non-Hodgkin lymphoma (core IPI component), tumor lysis syndrome risk assessment | LDH is a nonspecific cell-damage marker with specific, well-established prognostic value in lymphoma staging. | Core component of the International Prognostic Index (IPI); also predicts tumor lysis syndrome risk before treatment. | Enzyme kinetic activity assay | Serum |
| KRAS/NRAS | Established | KRAS, NRAS, RAS mutation status, KRAS G12C | Not primarily disease-indicating outside oncology context, Colorectal cancer, non-small cell lung cancer, pancreatic cancer | RAS mutation status determines anti-EGFR therapy eligibility in colorectal cancer; KRAS G12C now has its own targeted drug class. | Sotorasib and adagrasib (2024-2025 approvals) represent a major breakthrough after RAS was long considered an undruggable target. | PCR-based mutation testing or next-generation sequencing (NGS) panel | Tumor tissue (FFPE biopsy); plasma (liquid biopsy/ctDNA) increasingly used |
| Ki-67 (MKI67) | Established | Ki-67, MKI67, MIB-1 | Not primarily disease-indicating outside oncology context, Neuroendocrine tumors (core WHO grading criterion), breast cancer, lymphoma | Ki-67 is the core proliferation marker defining WHO neuroendocrine tumor grade, also widely used (if less formally endorsed) in breast cancer. | Significant inter-laboratory scoring variability remains an active, unresolved standardization challenge. | Immunohistochemistry (IHC), typically clone MIB-1, with manual or digital image analysis | Tumor tissue (FFPE biopsy or resection specimen) |
| Kappa/Lambda light chains | Established | Free light chains, FLC, sFLC | Monoclonal gammopathy of undetermined significance (MGUS), Multiple myeloma, AL amyloidosis, plasmacytoma | The free light chain ratio is a core diagnostic and monitoring test for multiple myeloma and related plasma cell disorders. | Important interpretation caveat: kidney impairment raises both light chains together but usually preserves the ratio's reliability. | Immunoassay (nephelometry/turbidimetry) | Serum |
| JAK2 | Established | JAK2, JAK2 V617F, Janus kinase 2 | Polycythemia vera, essential thrombocythemia, primary myelofibrosis, Myeloproliferative neoplasms (as above); can rarely be associated with AML progression | JAK2 V617F is the molecular hallmark of classic myeloproliferative neoplasms, central to current WHO diagnostic criteria. | Also guides thrombosis risk stratification and JAK-inhibitor treatment decisions in myelofibrosis and polycythemia vera. | PCR-based mutation testing or next-generation sequencing (NGS) panel | Peripheral blood (whole blood, EDTA) or bone marrow |
| Interleukin-10 | Emerging | IL-10, interleukin-10 | Not primarily disease-indicating outside oncology and immunology research context, Primary CNS lymphoma | CSF IL-10, especially the IL-10:IL-6 ratio, is a supportive marker helping diagnose primary CNS lymphoma before biopsy. | An example of an anti-inflammatory cytokine paradoxically serving as a marker of aggressive malignant disease. | Immunoassay (ELISA) | CSF (for CNS lymphoma context) or serum/plasma |
| Interleukin-1 beta | Emerging | IL-1 beta, interleukin-1 beta | Familial Mediterranean fever, cryopyrin-associated periodic syndromes, autoinflammatory diseases, Studied as a cardiovascular inflammation target (CANTOS trial); not primarily a cancer marker | IL-1β drives several autoinflammatory diseases and is a direct target of anakinra/canakinumab; also studied in cardiovascular disease. | The CANTOS trial showed IL-1β blockade reduces cardiovascular events independent of cholesterol, a genuinely novel finding. | Immunoassay (ELISA) | Serum or plasma |
| Interleukin 1-Alpha | Emerging | IL-1 alpha, interleukin-1 alpha | Autoinflammatory diseases (via shared IL-1 receptor pathway), Not primarily cancer-associated | IL-1α is a pro-inflammatory alarm cytokine, indirectly blocked by anakinra alongside its better-known relative IL-1β. | Less directly targeted by current biologic therapies compared to IL-1β, which has more dedicated therapeutic development. | Immunoassay (ELISA) | Serum or plasma |
| Intact Fibroblast Growth Factor 23 | Established | FGF23 | X-linked hypophosphatemia, tumor-induced osteomalacia, hypophosphatemic rickets, Phosphaturic mesenchymal tumor (causative tumor in TIO) | FGF23 excess causes rare hypophosphatemic bone diseases, now treated with a monoclonal antibody built to block it. | TIO diagnosis remains genuinely difficult due to challenges localizing small, hard-to-find causative tumors. | Immunoassay (ELISA) | Plasma (EDTA, on ice) |
| Insulin-like Growth Factor-Binding Protein-1 | Emerging | IGFBP-1, IGF-binding protein 1 | Preterm premature rupture of membranes, PCOS/insulin resistance (research marker), Not primarily cancer-associated | IGFBP-1 is the basis of a rapid bedside test (Actim PROM) for diagnosing preterm rupture of membranes in pregnancy. | A practical clinical application distinct from its research role as a metabolic/insulin sensitivity marker. | Immunochromatographic rapid test (Actim PROM); ELISA (research) | Cervicovaginal fluid (PROM test) or serum (research) |
| Insulin-like Growth Factor 2 | Emerging | IGF2, IGF-2, somatomedin A | Beckwith-Wiedemann syndrome, Non-islet cell tumor hypoglycemia (large mesenchymal and hepatic tumors) | IGF2 overexpression causes non-islet cell tumor hypoglycemia, an important differential when insulin/C-peptide don't explain low blood sugar. | Connects directly to the insulin/C-peptide discussion earlier as a key alternative explanation for tumor-associated hypoglycemia. | Immunoassay (RIA/ELISA) | Serum |
| INS | Established | Insulin | Diabetes mellitus, insulinoma, factitious hypoglycemia, Insulinoma (pancreatic neuroendocrine tumor) | Insulin, paired with C-peptide, is central to diagnosing insulinoma via a supervised fasting test. | A shorter 48-hour fast now diagnoses 90-95% of insulinoma cases, refining the older 72-hour protocol. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| Inhibin B | Established | Inhibin B | Diminished ovarian reserve, male infertility (testicular failure), Granulosa cell tumor of the ovary | Inhibin B assesses ovarian reserve (cycle-dependent, largely superseded by AMH) and male Sertoli cell function. | Requires specific-day cycle timing in women, unlike AMH, which can be measured any day. | Immunoassay (ELISA) | Serum |
| IL6 | Emerging | IL-6, interleukin-6 | Cytokine release syndrome, rheumatoid arthritis, COVID-19 (severe, cytokine storm), CAR-T cell therapy-related toxicity monitoring | IL-6 is the central driver cytokine in CAR-T-related cytokine release syndrome, treated first-line with tocilizumab. | The same IL-6-blocking drug class saw major expanded use in severe COVID-19-associated cytokine storm. | Immunoassay (ELISA/CLIA) | Serum or plasma |
| IL2RA | Emerging | CD25, soluble IL-2 receptor, sIL-2R | Hemophagocytic lymphohistiocytosis, sarcoidosis (activity marker), Lymphoma (prognostic marker, tumor burden) | Soluble CD25 (IL2RA) is one of the formal HLH-2004 diagnostic criteria and the most sensitive specialized adult HLH lab test. | Also used as a lymphoma prognostic marker and to monitor sarcoidosis disease activity. | Immunoassay (ELISA) | Serum |
| IL18 | Emerging | IL-18, interleukin-18 | Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, Relevant to CAR-T cell therapy-related toxicity monitoring in oncology | IL-18 is an emerging marker helping distinguish HLH/MAS from other causes of severe inflammation, including CAR-T toxicity. | The IL-18/CXCL9 ratio is a specific, actively-studied refinement for improving HLH/MAS diagnostic accuracy. | Immunoassay (ELISA) | Serum or plasma |
| IgM | Established | Immunoglobulin M | Acute/recent infection (serology context), Waldenström macroglobulinemia | IgM indicates recent infection in serology testing; monoclonal IgM is diagnostic for Waldenström macroglobulinemia. | MYD88 mutation testing, present in most Waldenström cases, increasingly guides treatment selection. | Immunoassay (nephelometry/turbidimetry) | Serum |
| IgG | Established | Immunoglobulin G | Common variable immunodeficiency, IgG subclass deficiency, recurrent sinopulmonary infections, Not primarily cancer-associated (though relevant to monoclonal gammopathy/myeloma workups) | IgG is the dominant long-term antibody; subclass deficiencies can cause infections despite normal total IgG. | Subclass testing is warranted when recurrent infections persist despite a normal total IgG result. | Immunoassay (nephelometry/turbidimetry) | Serum |
| IGF1 | Established | IGF-1, somatomedin C | Acromegaly, growth hormone deficiency, short stature, Pituitary adenoma (GH-secreting); IGF-1 signaling also studied broadly in cancer biology | IGF-1 is the stable, preferred marker for assessing growth hormone activity, more reliable than a single GH level. | Assay standardization remains an active issue; results are not directly interchangeable across different lab platforms. | Immunoassay (CLIA/ECLIA) | Serum |
| IgE | Established | Immunoglobulin E, total IgE | Allergic asthma, atopic dermatitis, allergic rhinitis, parasitic infection, Not primarily cancer-associated | IgE is central to allergy diagnosis and directly determines dosing eligibility for the biologic drug omalizumab. | A real treatment-access gap exists for patients with IgE levels above current official dosing table limits. | Immunoassay (CLIA/ECLIA/ImmunoCAP) | Serum |
| IgA | Established | Immunoglobulin A | Selective IgA deficiency, IgA nephropathy, celiac disease (testing interference), Not primarily cancer-associated | IgA deficiency is common and usually mild, but affects the reliability of IgA-based celiac disease testing. | Should be checked alongside tTG-IgA testing to avoid false-negative celiac disease results. | Immunoassay (nephelometry/turbidimetry) | Serum |
| IFNG | Emerging | IFN-gamma, interferon gamma | Latent tuberculosis infection, active tuberculosis, Not primarily cancer-associated | IFN-gamma release underlies IGRA testing, now preferred over the tuberculin skin test for diagnosing latent TB. | Not affected by prior BCG vaccination, a key practical advantage over the traditional skin test. | Functional assay (interferon-gamma release assay, ELISA/ELISPOT-based) | Whole blood |
| Iduronate-2-Sulfatase | Established | I2S, IDS enzyme | Mucopolysaccharidosis type II (Hunter syndrome), Not primarily cancer-associated | Iduronate-2-sulfatase deficiency causes Hunter syndrome, now part of expanded US newborn screening since 2022. | Newborn screening has identified some variants with abnormal biochemistry but no clinical disease, an evolving area. | Enzyme fluorometric activity assay; genetic testing | Dried blood spot (newborn screening) or leukocytes |
| IDH1/IDH2 | Established | IDH1, IDH2, isocitrate dehydrogenase | Not primarily disease-indicating outside oncology context, Acute myeloid leukemia, glioma/glioblastoma, cholangiocarcinoma, chondrosarcoma | IDH1/IDH2 mutations define distinct favorable-risk AML and glioma subtypes, each with its own FDA-approved targeted drug. | IDH mutation status is now a core WHO classification criterion for gliomas, defining fundamentally different tumor categories. | PCR-based mutation testing or next-generation sequencing (NGS) panel | Bone marrow or peripheral blood (AML); tumor tissue biopsy (glioma) |
| Human Transforming Growth Factor beta 1 | Emerging | TGF-beta 1, TGFB1 | Radiation-induced fibrosis, other fibrotic conditions, Studied as a tumor immune evasion mechanism across multiple solid tumor types (research context) | TGF-β1 drives tissue fibrosis and tumor immune evasion; blocking it is an active cancer immunotherapy combination research area. | Not yet a standardized clinical diagnostic test; primarily relevant in fibrosis and cancer immunotherapy research settings. | Immunoassay (ELISA) | Serum or plasma |
| Human Epididymis protein 4 | Established | HE4, WFDC2 | Endometriosis (notably does NOT cause false elevation, unlike CA-125), Ovarian cancer (epithelial) | HE4 combined with CA-125 (as ROMA) helps estimate ovarian cancer risk before surgery, improving on CA-125 alone. | Not falsely elevated by endometriosis, a key advantage over CA-125 for distinguishing benign from malignant masses. | Immunoassay (CLIA/ECLIA) | Serum |
| HP | Established | Haptoglobin | Hemolytic anemia (autoimmune, mechanical, hereditary spherocytosis, G6PD deficiency), Not primarily cancer-associated | Haptoglobin helps distinguish hemolytic from non-hemolytic anemia by reflecting free hemoglobin clearance. | Can be falsely normal in patients with concurrent inflammation, since it is also an acute-phase reactant. | Immunoassay (nephelometry/turbidimetry) | Serum |
| Homocysteine | Established | Homocysteine, tHcy | Vitamin B12 deficiency, folate deficiency, homocystinuria (genetic), Not primarily cancer-associated | Homocysteine helps detect B12/folate deficiency, sometimes before classic markers become abnormal. | Large cardiovascular trials found homocysteine-lowering therapy doesn't reduce cardiovascular events despite lowering the biomarker itself. | Immunoassay or HPLC/mass spectrometry | Serum or plasma (fasting preferred) |
| HGF | Emerging | HGF, scatter factor | Not primarily disease-indicating outside oncology context, Non-small cell lung cancer (EGFR-inhibitor resistance context), gastric cancer, hepatocellular carcinoma | HGF/MET pathway activation is a key mechanism of resistance to EGFR-targeted lung cancer therapy. | An active precision oncology drug development target for overcoming treatment resistance. | Immunoassay (ELISA) | Serum or plasma |
| Hexokinase | Emerging | HK, hexokinase 1 | Hereditary non-spherocytic hemolytic anemia (hexokinase deficiency), Not primarily cancer-associated | Hexokinase deficiency is an extremely rare glycolytic enzyme cause of hereditary hemolytic anemia. | Among the rarest of the glycolytic enzyme deficiencies, with very few cases reported in medical literature. | Enzyme kinetic activity assay | Whole blood (RBC hemolysate) |
| Hemoglobin S | Established | HbS, sickle hemoglobin | Sickle cell disease, sickle cell trait, Not primarily cancer-associated | Hemoglobin S is the abnormal variant causing sickle cell disease, detected via newborn screening. | 2024 saw both a major drug withdrawal (voxelotor) and a new approval (oral hydroxyurea solution) in this space. | HPLC, capillary electrophoresis, or isoelectric focusing; genetic confirmation | Whole blood (EDTA) or dried blood spot (newborn screening) |
| HBB | Established | Beta-globin gene | Sickle cell disease, beta-thalassemia, sickle cell trait, Not primarily cancer-associated | HBB is the gene underlying sickle cell disease and beta-thalassemia, confirmed via genetic testing. | Complements hemoglobin electrophoresis for definitive diagnosis and genetic/reproductive counseling. | Genetic testing (sequencing); HPLC or capillary electrophoresis for phenotype | Whole blood (EDTA) |
| HbA1c | Established | HbA1c, glycated hemoglobin, A1C | Diabetes mellitus, prediabetes, Not primarily cancer-associated | HbA1c is the central biomarker for diagnosing and monitoring diabetes, reflecting average blood glucose over 2-3 months. | Unreliable in conditions affecting red blood cell lifespan; current guidelines favor individualized rather than universal targets. | Immunoassay or high-performance liquid chromatography (HPLC) | Whole blood (EDTA) |
| HBA1 | Emerging | Alpha-globin gene 1 | Alpha-thalassemia, Hemoglobin H disease, Hb Bart's hydrops fetalis, Not primarily cancer-associated | HBA1 is one of the duplicated alpha-globin genes; its deletion causes alpha-thalassemia of variable severity. | Genetic testing is standard for carrier screening in at-risk populations, given risk of severe disease in offspring of two carriers. | Genetic testing (gap-PCR/sequencing); HPLC or capillary electrophoresis for phenotype | Whole blood (EDTA) |
| HB | Established | Hb, hemoglobin | Anemia, polycythemia vera, various causes of blood loss or bone marrow disease, Relevant in monitoring hematologic malignancies and chemotherapy-related anemia | Hemoglobin is the core blood test for diagnosing anemia or polycythemia, requiring further workup to find the cause. | A foundational, universally used marker across nearly all areas of medicine. | Spectrophotometric assay (automated hematology analyzer) | Whole blood (EDTA) |
| HAVCR1 | Emerging | KIM-1, TIM-1, HAVCR1, hepatitis A virus cellular receptor 1 | Acute kidney injury (drug-induced nephrotoxicity), Not primarily cancer-associated | HAVCR1/KIM-1 is an FDA-qualified biomarker for early detection of drug-induced kidney injury, outperforming creatinine. | Widely referenced across FDA drug development submissions; also unrelated historical namesake of the hepatitis A virus receptor. | Immunoassay (ELISA) | Urine |
| GPT | Established | ALT, alanine aminotransferase, GPT, SGPT | MASLD (formerly NAFLD), MASH (formerly NASH), viral hepatitis, drug-induced liver injury, Hepatocellular carcinoma (as component of broader liver assessment) | GPT/ALT is a liver-specific enzyme marker, central to MASLD/MASH diagnosis under the 2023-renamed disease framework. | The June 2023 NAFLD-to-MASLD nomenclature change reflects a major, current shift in how fatty liver disease is classified. | Enzyme kinetic activity assay | Serum |
| Glucose Phosphate Isomerase | Emerging | GPI, phosphoglucose isomerase | Hereditary non-spherocytic hemolytic anemia (GPI deficiency), Not primarily cancer-associated | GPI deficiency is a rare glycolytic enzyme cause of hereditary hemolytic anemia, in the same family as pyruvate kinase deficiency. | Management is supportive, following the same general approach as other red cell enzyme deficiencies in this biomarker set. | Enzyme kinetic activity assay | Whole blood (RBC hemolysate) |
| Glucagon | Established | Glucagon | Diabetes mellitus (counter-regulatory context), hypoglycemia, Glucagonoma (pancreatic neuroendocrine tumor) | Glucagon excess is the hallmark of glucagonoma; the hormone is also used therapeutically for severe hypoglycemia. | Diagnostic marker for a rare, distinctive neuroendocrine tumor syndrome. | Immunoassay (RIA/ELISA) | Plasma (EDTA with protease inhibitor, on ice, fasting) |
| Ghrelin | Emerging | Ghrelin | Prader-Willi syndrome (hyperphagia), Not primarily cancer-associated | Ghrelin drives hunger and is markedly elevated in Prader-Willi syndrome, contributing to its characteristic insatiable appetite. | Ghrelin receptor antagonists are an emerging, targeted therapeutic approach specifically for Prader-Willi-related hyperphagia. | Immunoassay (RIA/ELISA) | Plasma (EDTA with protease inhibitor, on ice) |
| GH1 | Established | GH, somatotropin, growth hormone | Acromegaly, gigantism, growth hormone deficiency, Pituitary adenoma (GH-secreting) | GH1/growth hormone testing diagnoses acromegaly or deficiency, though rarely via a single random level. | IGF-1 and dynamic stimulation/suppression testing are the actual diagnostic standards, not isolated GH measurement. | Immunoassay (CLIA/ECLIA) | Serum |
| GGT | Established | GGT, gamma-glutamyltransferase, GGT1 | Alcohol use disorder, biliary obstruction, fatty liver disease, Not primarily cancer-associated | GGT helps localize the source of abnormal alkaline phosphatase and serves as a sensitive alcohol-use marker. | Nonspecific; interpreted alongside other liver enzymes rather than as a standalone test. | Enzyme kinetic activity assay | Serum |
| Gastrin-releasing peptide | Emerging | ProGRP, pro-gastrin-releasing peptide | Not primarily disease-indicating outside oncology context, Small cell lung cancer | ProGRP is a specific small cell lung cancer marker, often used alongside NSE for improved diagnostic accuracy. | Less affected by sample hemolysis than NSE, giving it a practical laboratory reliability advantage. | Immunoassay (CLIA/ECLIA) | Serum |
| GAST | Established | Gastrin, serum gastrin | Zollinger-Ellison syndrome, atrophic gastritis, Gastrinoma (pancreatic/duodenal neuroendocrine tumor) | Gastrin is the key diagnostic marker for Zollinger-Ellison syndrome, complicated by common heartburn medications. | PPI-related false elevation creates real diagnostic and safety tension in confirming or excluding this rare tumor. | Immunoassay (RIA/CLIA) | Plasma (EDTA, fasting) or serum |
| Gamma-Enolase | Established | NSE, neuron-specific enolase | Not primarily disease-indicating outside oncology context, Small cell lung cancer, neuroblastoma, neuroendocrine tumors | NSE is a tumor marker for neuroendocrine-origin cancers, used for diagnosis and treatment monitoring. | Useful supplementary marker when chromogranin A results are confounded by medication interference. | Immunoassay (CLIA/ECLIA) | Serum |
| G6PD | Established | G6PD deficiency, favism | G6PD deficiency, hemolytic anemia (drug/infection/fava bean-triggered), Not primarily cancer-associated | G6PD deficiency causes drug/food-triggered hemolytic anemia; testing is required before certain antimalarial drugs. | Newer antimalarials (tafenoquine) require stricter quantitative testing than older drugs due to greater hemolysis risk. | Enzyme activity assay (quantitative spectrophotometric or qualitative fluorescent spot test) | Whole blood |
| Follicle stimulating hormone | Established | FSH, follitropin | Menopause, premature ovarian insufficiency, male infertility, Not primarily cancer-associated | FSH is a pituitary hormone used selectively to evaluate menopause timing and fertility, per narrowed current guidelines. | Current guidance limits routine testing to younger women or atypical presentations rather than typical menopause. | Immunoassay (CLIA/ECLIA) | Serum |
| FN1 | Emerging | Fibronectin, FN | Wound healing disorders, fibrosis, Studied across several solid tumors as an invasion/fibrosis marker (research context) | FN1/fibronectin is a research marker of tumor invasion and fibrosis, not yet a standardized clinical diagnostic test. | Reflects extracellular matrix remodeling relevant to tumor growth and metastasis in ongoing research. | Immunoassay (ELISA); immunohistochemistry (tissue context) | Serum/plasma or tumor tissue |
| FLT3 | Established | FLT3, FLT3-ITD, FLT3-TKD | Not primarily disease-indicating outside oncology context, Acute myeloid leukemia | FLT3-ITD is a common AML mutation central to risk stratification and eligibility for FLT3-targeted drugs (midostaurin, gilteritinib). | The newly updated 2024 ELN risk classification shows FLT3-ITD substantially worsens otherwise-favorable NPM1-mutated AML prognosis. | PCR-based fragment analysis or next-generation sequencing (NGS) panel | Bone marrow or peripheral blood (whole blood, EDTA) |
| Fibrinogen | Established | Factor I, fibrinogen | Disseminated intravascular coagulation, liver disease, congenital afibrinogenemia, Not primarily cancer-associated | Fibrinogen is a key clotting protein, actively corrected early in modern trauma resuscitation protocols. | Often the first factor depleted in major hemorrhage, prioritized for early repletion in massive transfusion protocols. | Functional clotting assay (Clauss method) | Plasma (citrate) |
| Ferritin | Established | Serum ferritin | Iron deficiency anemia, adult-onset Still's disease, hemophagocytic lymphohistiocytosis, hemochromatosis, Not primarily cancer-associated (though relevant in some hematologic malignancy/HLH-associated cancer workups) | Ferritin reflects iron stores but also rises dramatically with inflammation, aiding diagnosis of AOSD and HLH. | Extreme elevation is a key diagnostic clue for rare adult inflammatory syndromes; can mask coexisting iron deficiency. | Immunoassay (CLIA/ECLIA) | Serum |
| Factor B Complement Antigen | Emerging | Factor B, complement factor B, CFB | Atypical hemolytic uremic syndrome, C3 glomerulopathy, Not primarily cancer-associated | Factor B abnormalities drive alternative complement pathway overactivation in aHUS and C3 glomerulopathy. | Connects to the earlier C5 complement discussion, since aHUS is now treated with C5-blocking drugs (eculizumab, ravulizumab). | Immunoassay (nephelometry); genetic testing (complement gene panel) | Serum (level); whole blood (genetic) |
| F5 | Established | Factor V Leiden, activated protein C resistance | Venous thromboembolism, recurrent pregnancy loss (studied association), thrombophilia, Not primarily cancer-associated | Factor V Leiden is the most common inherited thrombophilia, tested selectively rather than universally. | Most carriers never develop a clot; testing recommendations have narrowed over time, including in pregnancy management guidance. | Genetic testing (PCR, Factor V Leiden) | Whole blood (EDTA) |
| F2 | Established | Prothrombin, prothrombin G20210A mutation | Venous thromboembolism, thrombophilia, Not primarily cancer-associated | F2/prothrombin G20210A is one of five classic inherited thrombophilias, tested selectively rather than universally. | Current guidelines have moved away from using thrombophilia status to guide anticoagulation duration decisions. | Genetic testing (PCR, prothrombin G20210A) | Whole blood (EDTA) |
| ESR1 | Established | ER, estrogen receptor alpha | Not primarily disease-indicating outside oncology context, Breast cancer (hormone receptor-positive metastatic disease) | ESR1 mutations are a major acquired-resistance mechanism in hormone-receptor-positive breast cancer, now a treatment-selection biomarker. | Directly created a new FDA-approved drug class (oral SERDs) built specifically around this mutation. | Molecular testing (NGS or PCR-based mutation analysis) | Tumor tissue biopsy or plasma (liquid biopsy/ctDNA) |
| ERBB2 | Established | HER2, human epidermal growth factor receptor 2, NEU | Not primarily disease-indicating outside oncology context, Breast cancer, gastric cancer, gastroesophageal junction cancer | HER2/ERBB2 overexpression drives aggressive breast cancer but also predicts response to targeted therapy. | The HER2-low/ultralow reclassification since 2022-2025 has significantly expanded eligible patient populations for targeted treatment. | Immunohistochemistry (IHC); FISH/ISH for gene amplification | Tumor tissue (biopsy) |
| Epstein-Barr virus capsid antigen antibody | Established | EBV VCA antibody, EBV IgM/IgG | Infectious mononucleosis, Nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin lymphoma (EBV-associated) | EBV VCA antibodies help diagnose mononucleosis and support nasopharyngeal carcinoma evaluation in endemic regions. | IgM versus IgG pattern is essential for correctly timing infection; supportive, not definitive, for cancer diagnosis. | Immunoassay (ELISA/CLIA) | Serum |
| EPO | Established | Erythropoietin, EPO hormone | Anemia of chronic kidney disease, polycythemia vera, Not primarily cancer-associated (though relevant to some hematologic malignancy workups) | EPO is a kidney hormone used to distinguish causes of abnormal red blood cell counts and guide CKD anemia treatment. | Also a well-known blood-doping target, subject to anti-doping regulation in competitive sports. | Immunoassay (CLIA/ECLIA) | Serum |
| EGFR | Established | EGFR, HER1, ErbB1 | Not primarily disease-indicating outside oncology context, Non-small cell lung cancer | EGFR mutation status guides TKI therapy selection in lung cancer; the exon 20 insertion subtype is often resistant and can be missed by standard PCR testing. | Standard PCR-based tests miss up to ~50% of exon 20 insertion variants, a genuine diagnostic gap requiring NGS for reliable detection. | PCR-based mutation testing or next-generation sequencing (NGS) panel | Tumor tissue (FFPE biopsy) or plasma (liquid biopsy/ctDNA) |
| DNASE1L3 | Emerging | DNase 1-like 3 | Systemic lupus erythematosus (monogenic form), lupus nephritis, Not primarily cancer-associated | DNASE1L3 deficiency (inherited or via autoantibody) impairs DNA clearance, a proposed mechanism generating lupus autoantibodies. | Connects mechanistically to the anti-dsDNA antibody discussion, offering insight into how these antibodies may arise. | Genetic testing (sequencing); autoantibody ELISA (research) | Whole blood (genetic) or serum (autoantibody) |
| Des-gamma-carboxy prothrombin | Established | DCP, PIVKA-II, prothrombin induced by vitamin K absence-II | Vitamin K deficiency/antagonist use (non-cancer cause of elevation), Hepatocellular carcinoma | DCP is a complementary liver cancer marker used alongside AFP within composite scoring systems like GALAD. | FDA-approved as a risk-stratification aid, but not currently approved for standalone HCC surveillance. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| D-dimer | Established | D-dimer, fibrin degradation product | Deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, Cancer-associated venous thromboembolism (elevated in malignancy) | D-dimer is a clot-breakdown product used to rule out venous thromboembolism in low-risk patients. | Requires age-adjusted or pregnancy-specific cutoffs for accurate interpretation in those populations. | Immunoassay (immunoturbidimetric or ELISA) | Plasma (citrate) |
| Cytosolic Beta-Glucosidase | Emerging | GBA3, cytosolic beta-glucosidase, klotho-related protein | No established clinical disease association, Not primarily cancer-associated | GBA3/cytosolic beta-glucosidase deficiency is a benign polymorphism, distinct from the disease-associated lysosomal GBA enzyme. | More of a research and pharmacogenomic curiosity than an actionable clinical biomarker at this time. | Enzyme activity assay (research); genetic testing | Leukocytes or whole blood |
| CST3 | Established | Cystatin C | Chronic kidney disease, Not primarily cancer-associated | Cystatin C is a kidney function marker now central to the 2021 race-free eGFR equations. | Reduces bias from muscle-mass dependence seen with creatinine; part of a major 2021 health-equity-driven guideline change. | Immunoassay (nephelometry/turbidimetry, PENIA/PETIA) | Serum |
| CSF1 | Emerging | CSF1, M-CSF, macrophage colony-stimulating factor | Not primarily disease-indicating outside oncology context, Tenosynovial giant cell tumor | CSF1 overexpression drives tenosynovial giant cell tumor, now treatable with two different CSF1 receptor inhibitor drugs. | A 2025 second-generation CSF1R inhibitor (vimseltinib) reflects an actively evolving targeted therapy area. | Immunoassay (ELISA) | Serum (primarily research use) |
| CRP | Established | hsCRP, high-sensitivity C-reactive protein | Infections, autoimmune disease flares, atherosclerosis, Not primarily cancer-associated (though used in some oncology prognostic scores) | CRP is a general inflammation marker; its high-sensitivity form is now recommended for cardiovascular risk assessment. | 2025 ACC guidance expands its role in routine cardiovascular prevention alongside lipid testing. | Immunoassay (nephelometry/immunoturbidimetric); high-sensitivity CRP uses a more sensitive immunoturbidimetric method | Serum |
| Creatinine | Established | Creatinine, serum creatinine, SCr | Chronic kidney disease, acute kidney injury, Not primarily cancer-associated | Creatinine is the standard kidney function marker, forming the basis of eGFR calculations and AKI diagnostic criteria. | Muscle-mass dependence is a well-known limitation, addressed by cystatin C-based equations discussed elsewhere in this set. | Enzymatic assay or Jaffe colorimetric assay | Serum or plasma |
| Creatine Kinase | Established | CK, CPK, creatine phosphokinase | Rhabdomyolysis, statin-associated myopathy, muscular dystrophy, Not primarily cancer-associated | CK is a muscle injury marker, now mainly used for rhabdomyolysis and statin myopathy rather than heart attack diagnosis. | CK-MB's cardiac role has been superseded by troponin, which is more sensitive and specific. | Enzyme kinetic activity assay | Serum |
| CP | Established | Ceruloplasmin, copper oxidase | Wilson's disease, copper deficiency, aceruloplasminemia, Not primarily cancer-associated | Ceruloplasmin is the first-line screening test for Wilson's disease, a genetic copper-metabolism disorder. | Requires combination with urinary copper and genetic testing within a formal scoring system; not standalone diagnostic. | Immunoassay (nephelometry/turbidimetry) | Serum |
| Complement C4 | Established | C4, C4A, C4B | Systemic lupus erythematosus (via deficiency), Not primarily cancer-associated | C4 deficiency carries one of the strongest known genetic associations with lupus among complement defects. | Note: this overlaps substantially with the C1q/C2/C3/C5-C9 complement group discussed together elsewhere; consider consolidating on a published site. | Immunoassay (nephelometry/turbidimetry) | Serum |
| COL9A1 | Emerging | Collagen type IX alpha 1 | Multiple epiphyseal dysplasia, intervertebral disc degeneration (research association), Not primarily cancer-associated | COL9A1 mutations cause multiple epiphyseal dysplasia, a skeletal cartilage growth disorder, diagnosed via genetic testing. | More of a genetic/research marker than a routine clinical blood test; disc degeneration link remains investigational. | Genetic testing (gene sequencing) | Whole blood (EDTA) |
| Coagulation Factor XII | Established | FXII, Hageman factor | Factor XII deficiency (asymptomatic), hereditary angioedema type III, Not primarily cancer-associated | Factor XII deficiency prolongs lab clotting tests without causing actual bleeding risk. | An important diagnostic pitfall: prolonged aPTT from this cause should not be mistaken for a bleeding disorder. | Functional clotting assay (one-stage, aPTT-based) | Plasma (citrate) |
| Coagulation Factor XI | Established | FXI, plasma thromboplastin antecedent | Hereditary Factor XI deficiency, Not primarily cancer-associated | Factor XI deficiency is a mild bleeding disorder; factor XI inhibitor drugs are a major, still-unsettled anticoagulant research area. | One of the most actively-evolving areas in current cardiology/hematology drug development, with mixed trial results through 2026. | Functional clotting assay (one-stage, aPTT-based) | Plasma (citrate) |
| Coagulation Factor X | Established | FX, Stuart-Prower factor | Hereditary Factor X deficiency, AL amyloidosis (acquired form), Not primarily cancer-associated (amyloidosis is a plasma cell disorder) | Factor X deficiency can be hereditary or acquired via AL amyloidosis, where amyloid fibrils sequester the factor. | Low factor X in an unexplained bleeding patient can be a diagnostic clue pointing toward amyloidosis. | Functional clotting assay (one-stage or chromogenic) | Plasma (citrate) |
| Coagulation Factor VIII | Established | FVIII, antihemophilic factor | Hemophilia A, Not primarily cancer-associated | Factor VIII deficiency causes Hemophilia A; treatment has shifted toward non-factor replacement therapies. | Emicizumab and newer agents have transformed treatment convenience; lab testing requires specialized assays in these patients. | Functional clotting assay (one-stage, aPTT-based) or chromogenic assay | Plasma (citrate) |
| Coagulation Factor VII | Established | FVII, proconvertin | Factor VII deficiency, Not primarily cancer-associated | Factor VII deficiency is a rare bleeding disorder diagnosed by prolonged PT with normal aPTT. | Its approved therapy (rFVIIa) is used far more often off-label for other bleeding emergencies than for its labeled indication. | Functional clotting assay (one-stage, PT-based) | Plasma (citrate) |
| Coagulation Factor IX | Established | FIX, Christmas factor | Hemophilia B, Not primarily cancer-associated | Factor IX deficiency causes Hemophilia B; treatment options have expanded dramatically since 2024. | Multiple new gene therapies and non-factor drugs approved 2024-2025, though not all remain commercially available. | Functional clotting assay (one-stage, aPTT-based) | Plasma (citrate) |
| Cluster of Differentiation 163 | Emerging | sCD163, soluble CD163, macrophage scavenger receptor | Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, chronic liver disease, Not primarily cancer-associated | CD163 is a macrophage activation marker studied as a complementary test for hyperinflammatory syndromes and liver disease. | Part of an evolving, still-developing diagnostic panel rather than a universally standardized clinical test at this time. | Immunoassay (ELISA) | Serum or plasma |
| Clostridium difficile glutamate dehydrogenase | Established | GDH, C. diff GDH antigen | Clostridioides difficile infection, pseudomembranous colitis, Not primarily cancer-associated | GDH is a sensitive but nonspecific screening step in multistep C. difficile testing algorithms. | Excellent negative predictive value; positive results require confirmatory toxin or molecular testing. | Immunoassay (EIA) | Stool |
| Chymotrypsin | Established | Fecal chymotrypsin | Pancreatic exocrine insufficiency, chronic pancreatitis, cystic fibrosis, Not primarily cancer-associated | Chymotrypsin is a stool-based pancreatic function marker, now largely superseded by fecal elastase-1. | An older test whose modern equivalent (fecal elastase-1) is now generally preferred in practice. | Enzyme colorimetric activity assay | Stool |
| CHGA | Established | CgA, chromogranin A | Atrophic gastritis (false-positive cause), Neuroendocrine tumors, carcinoid tumors, pancreatic neuroendocrine tumors, pheochromocytoma | CgA is the most widely used general biomarker for neuroendocrine tumors, though prone to false elevation. | Real risk of false-positive elevation from proton pump inhibitors and other benign conditions. | Immunoassay (ELISA/RIA) | Plasma (EDTA, fasting, preferred over serum) |
| Chemokine interferon inducible protein 10 | Emerging | CXCL10, IP-10, interferon gamma-induced protein 10 | Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, Relevant to CAR-T cell therapy-related toxicity monitoring in oncology | CXCL10, alongside CXCL9, supports HLH/MAS diagnosis as part of the interferon-gamma-driven inflammatory marker panel. | Part of an actively evolving, more sophisticated cytokine panel approach to diagnosing hyperinflammatory syndromes. | Immunoassay (ELISA/multiplex bead assay) | Serum or plasma |
| CGB3 | Established | Beta-hCG, human chorionic gonadotropin beta subunit | Gestational trophoblastic disease, molar pregnancy, Choriocarcinoma, testicular germ cell tumor, ovarian germ cell tumor | Beta-hCG is a tumor marker for germ cell tumors and gestational trophoblastic disease, paired with AFP for staging. | Serial monitoring confirms chemotherapy response; failure to decline as expected signals treatment resistance. | Immunoassay (CLIA/ECLIA) | Serum |
| Carcinoembryonic antigen | Established | CEA, carcinoembryonic antigen | Not primarily disease-indicating outside oncology context, Colorectal cancer, appendiceal cancer, pancreatic cancer, biliary tract cancer, medullary thyroid carcinoma, non-small cell lung cancer | CEA is a standard tumor marker for colorectal cancer surveillance, always used alongside imaging and colonoscopy. | Surveillance compliance for CEA testing is consistently lower than for imaging or colonoscopy in real-world adherence studies. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| Carbohydrate Antigen 19-9 | Established | CA 19-9, sialyl Lewis A antigen | Chronic pancreatitis, biliary obstruction (false-positive causes), Pancreatic cancer, biliary tract cancer, colorectal cancer | CA 19-9 is the best-validated pancreatic cancer marker, but is falsely low/undetectable in Lewis-antigen-negative patients. | A genuine false-negative trap exists in 5-10% of the population due to Lewis blood group status. | Immunoassay (CLIA/ECLIA) | Serum |
| Carbohydrate Antigen 125 | Established | CA-125, cancer antigen 125, MUC16 | Endometriosis, pelvic inflammatory disease (false-positive causes), Ovarian cancer, uterine/endometrial cancer | CA-125 is the standard blood test for ovarian cancer monitoring, though not specific enough for standalone diagnosis. | Best used for treatment response and recurrence monitoring, not as a standalone screening or diagnostic test. | Immunoassay (CLIA/ECLIA) | Serum |
| CALCA | Established | Calcitonin, thyrocalcitonin | C-cell hyperplasia, hypercalcemia disorders (calcium regulation), Medullary thyroid carcinoma | Calcitonin is the primary tumor marker for medullary thyroid carcinoma, guiding surgery and recurrence monitoring. | Highly sensitive and specific for MTC; intermediate elevations require additional testing to distinguish cancer from benign hyperplasia. | Immunoassay (CLIA/ECLIA) | Serum or plasma |
| C9 | Established | Complement component 9 | Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated | C9 completes the membrane attack complex; deficiency causes a generally milder Neisseria susceptibility pattern. | Notably more prevalent in some Asian populations; part of the shared terminal complement deficiency group. | Immunoassay (nephelometry); functional assay (CH50/AH50) | Serum |
| C8 | Established | Complement component 8 | Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated | C8 is a terminal complement component; deficiency causes selective Neisseria infection susceptibility. | Part of the shared C5-C9 terminal pathway deficiency syndrome. | Immunoassay (nephelometry); functional assay (CH50/AH50) | Serum |
| C7 | Established | Complement component 7 | Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated | C7 is a terminal complement/MAC component; deficiency causes selective Neisseria infection susceptibility. | Part of the shared C5-C9 terminal pathway deficiency syndrome. | Immunoassay (nephelometry); functional assay (CH50/AH50) | Serum |
| C6 Complement | Established | Complement component 6 | Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated | C6 is a membrane attack complex component; deficiency causes recurrent Neisseria infections, sometimes atypical serotypes. | Terminal pathway deficiency pattern shared with C5, C7, C8, and C9. | Immunoassay (nephelometry); functional assay (CH50/AH50) | Serum |
| C5 Complement | Established | Complement component 5 | Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated | C5 initiates the terminal complement pathway; its deficiency causes selective susceptibility to Neisseria infections. | Also a therapeutic drug target (eculizumab) in unrelated complement-mediated diseases. | Immunoassay (nephelometry); functional assay (CH50/AH50) | Serum |
| C3 | Established | Complement component 3 | Recurrent severe bacterial infections (via deficiency), Not primarily cancer-associated | C3 is the central complement protein whose deficiency causes severe recurrent bacterial infections. | Central convergence point of all complement pathways; deficiency carries the highest infection-related mortality risk among complement defects. | Immunoassay (nephelometry/turbidimetry) | Serum |
| C2 | Established | Complement component 2 | Systemic lupus erythematosus (via deficiency), recurrent bacterial infections, Not primarily cancer-associated | C2 is an early classical-pathway complement protein; its deficiency is the most common inherited complement defect. | Follows the early-complement pattern of increased both infection risk and autoimmune (lupus) risk. | Immunoassay (nephelometry); functional assay (CH50) | Serum |
| C1q Complement | Established | C1q, Complement C1 | Systemic lupus erythematosus (via deficiency), Not primarily cancer-associated | C1q is the first classical-pathway complement component; its deficiency carries a very high lupus risk. | Roughly 90%+ of C1q-deficient patients develop SLE, one of the strongest known genetic lupus risk factors. | Immunoassay (nephelometry); functional assay (CH50) | Serum |
| C-X-C Motif Chemokine 9 | Emerging | CXCL9, MIG, monokine induced by gamma interferon | Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, Relevant to CAR-T cell therapy-related toxicity monitoring in oncology | CXCL9 supports HLH/MAS diagnosis as part of an interferon-gamma-driven inflammatory marker panel, alongside CXCL10 and IL-18. | The IL-18/CXCL9 ratio specifically improves diagnostic accuracy for distinguishing HLH/MAS from other causes of cytokine storm. | Immunoassay (ELISA/multiplex bead assay) | Serum or plasma |
| C-terminal telopeptide | Established | CTX, CTx, collagen telopeptide, crosslaps | Osteoporosis, medication-related osteonecrosis of the jaw, Bone metastases (as part of broader bone turnover assessment) | CTX is a bone resorption marker used to monitor osteoporosis treatment and estimate jaw osteonecrosis risk. | Its use for predicting individual osteonecrosis risk before dental surgery remains scientifically debated. | Immunoassay (ECLIA/ELISA) | Serum |
| BRCA2 | Established | BRCA2, breast cancer gene 2, FANCD1 | Hereditary breast and ovarian cancer syndrome, Fanconi anemia (biallelic inheritance), Breast cancer, ovarian cancer, pancreatic cancer, prostate cancer | BRCA2 germline mutations confer hereditary cancer risk across multiple organs and determine PARP inhibitor treatment eligibility. | Biallelic (two-copy) inheritance causes Fanconi anemia, an important reproductive counseling consideration distinct from BRCA1. | Germline genetic testing (sequencing, blood or saliva); somatic tumor testing for treatment eligibility | Whole blood or saliva (germline); tumor tissue biopsy (somatic) |
| BRCA1 | Established | BRCA1, breast cancer gene 1 | Hereditary breast and ovarian cancer syndrome, Breast cancer, ovarian cancer, pancreatic cancer, prostate cancer | BRCA1 germline mutations confer major hereditary breast/ovarian cancer risk and determine PARP inhibitor treatment eligibility. | Testing criteria have broadened well beyond family history alone, especially in metastatic prostate cancer. | Germline genetic testing (sequencing, blood or saliva); somatic tumor testing for treatment eligibility | Whole blood or saliva (germline); tumor tissue biopsy (somatic) |
| Brain natriuretic peptide | Established | BNP, NT-proBNP, B-type natriuretic peptide | Heart failure, Not primarily cancer-associated | BNP/NT-proBNP is the primary blood marker for diagnosing and staging heart failure. | Widely used cutoffs may need age- and BMI-adjustment for optimal accuracy per current research. | Immunoassay (CLIA/ECLIA) | Plasma (EDTA) |
| BRAF | Established | BRAF, BRAF V600E, B-Raf | Not primarily disease-indicating outside oncology context, Melanoma, papillary/anaplastic thyroid carcinoma, colorectal cancer, non-small cell lung cancer, hairy cell leukemia | BRAF V600E drives multiple cancers via MAPK pathway activation, with opposite prognostic meaning in melanoma versus colorectal/thyroid cancer. | Effectively universal in hairy cell leukemia, connecting to the historical TRAP/ACP5 diagnostic marker discussed elsewhere in this set. | PCR-based mutation testing, NGS panel, or immunohistochemistry (VE1 clone) | Tumor tissue (FFPE biopsy); plasma (liquid biopsy/ctDNA) increasingly used |
| Biotinidase | Established | BTD enzyme | Biotinidase deficiency, Not primarily cancer-associated | Biotinidase is an enzyme whose deficiency is detected via newborn screening and treated with biotin supplements. | Standard component of newborn screening panels; excellent prognosis when treated before symptom onset. | Enzyme colorimetric activity assay | Dried blood spot (newborn screening) or serum |
| BGLAP | Established | Osteocalcin, bone gamma-carboxyglutamic acid protein, BGP | Osteoporosis, Paget's disease of bone, vitamin K deficiency, Bone metastases (as part of broader bone turnover assessment) | BGLAP encodes osteocalcin, a bone-formation marker used to monitor osteoporosis treatment. | A standard bone formation marker, often paired with a resorption marker like CTX for bisphosphonate monitoring. | Immunoassay (ELISA/CLIA) | Serum |
| Beta-Glucuronidase | Emerging | GUSB, beta-glucuronidase, Sly syndrome enzyme | Mucopolysaccharidosis type VII (Sly syndrome), Not primarily cancer-associated | Beta-glucuronidase (GUSB) deficiency causes Sly syndrome (MPS VII), now treatable with a 2017 FDA-approved enzyme replacement therapy. | Follows the same enzyme replacement therapy model as other lysosomal storage disorders discussed in this biomarker set. | Enzyme fluorometric activity assay | Leukocytes or cultured fibroblasts |
| Beta-Galactosidase | Emerging | GLB1, beta-gal, acid beta-galactosidase | GM1 gangliosidosis, Morquio syndrome type B (mucopolysaccharidosis IVB), Not primarily cancer-associated | Beta-galactosidase (GLB1) deficiency causes GM1 gangliosidosis and Morquio syndrome type B, both rare lysosomal storage disorders. | No approved enzyme replacement therapy yet exists, though gene therapy research is an active area for GM1 gangliosidosis. | Enzyme fluorometric activity assay | Leukocytes or cultured fibroblasts |
| BCR-ABL1 | Established | BCR-ABL1, Philadelphia chromosome, BCR::ABL1 | Not primarily disease-indicating outside oncology context, Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia | BCR-ABL1 transcript monitoring (International Scale) is the standard for tracking CML treatment response and TKI discontinuation eligibility. | Deep molecular response now allows roughly half of eligible CML patients to successfully stop lifelong TKI therapy (treatment-free remission). | Quantitative reverse-transcription PCR (RT-qPCR), standardized to the International Scale (IS); digital PCR increasingly used for higher sensitivity | Peripheral blood or bone marrow (whole blood, EDTA) |
| BCHE | Established | Pseudocholinesterase, plasma cholinesterase | Pseudocholinesterase deficiency, prolonged succinylcholine apnea, Not primarily cancer-associated | BCHE is a plasma enzyme whose deficiency causes prolonged paralysis after certain anesthesia drugs. | One of the earliest-known pharmacogenomic drug-gene interactions; genetic testing remains underutilized. | Enzyme kinetic activity assay; genetic testing for variant alleles | Serum or plasma |
| B2M | Established | Beta-2-microglobulin, β2M | Kidney dysfunction, chronic inflammation, Multiple myeloma, chronic lymphocytic leukemia, lymphoma | B2M is a cell-surface protein used as a key prognostic marker in multiple myeloma staging. | Core component of the International Staging System (ISS) for multiple myeloma. | Immunoassay (CLIA/ELISA) | Serum or urine |
| AVP | Emerging | AVP, antidiuretic hormone, vasopressin, copeptin (surrogate marker) | Diabetes insipidus, SIADH (syndrome of inappropriate antidiuretic hormone secretion), Ectopic AVP/SIADH production (small cell lung cancer and other tumors) | AVP regulates water balance; copeptin, a more stable related marker, is now preferred for diagnosing water-balance disorders. | A copeptin-based diagnostic protocol increasingly replaces the older, more burdensome water deprivation test. | Immunoassay (RIA) for AVP; immunoassay for copeptin surrogate | Plasma (EDTA, on ice) |
| AST | Established | Aspartate transaminase, SGOT, GOT1 (gene symbol) | Hepatitis, alcoholic liver disease, MASLD/NAFLD, liver fibrosis, Hepatocellular carcinoma (as component of broader liver assessment) | AST is a liver enzyme now mainly interpreted as part of the FIB-4 fibrosis risk score rather than alone. | A core input into FIB-4, the first-line noninvasive liver fibrosis assessment recommended by major hepatology societies. | Enzyme kinetic (colorimetric) activity assay | Serum |
| APOE | Emerging | ApoE, APOE genotype (ε2/ε3/ε4) | Alzheimer's disease, cardiovascular disease (lipid metabolism), Relevant to cognitive effects following cancer therapy in some research contexts | APOE ε4 is the strongest common genetic risk factor for Alzheimer's disease and now informs anti-amyloid therapy safety monitoring. | Genotyping before anti-amyloid antibody treatment helps identify patients at higher risk of ARIA (a treatment side effect). | Genetic testing (genotyping, PCR) | Whole blood (EDTA) |
| APOB | Emerging | ApoB, Apo B-100 | Atherosclerotic cardiovascular disease, dyslipidemia, metabolic syndrome, Not primarily cancer-associated | ApoB directly counts atherogenic lipoprotein particles, now considered a superior cardiovascular risk marker to LDL-C in many patients. | A major, very current (2025) cardiology guideline shift toward ApoB as a primary or co-primary lipid target. | Immunoassay (nephelometry/turbidimetry) | Serum |
| APOA1 | Emerging | Apo A-I, ApoA1 | Cardiovascular disease, dyslipidemia, Breast cancer, gastric cancer, pancreatic cancer, hepatocellular carcinoma (prognostic research context) | APOA1 is the main HDL protein; low levels are linked to cardiovascular risk and, in research, worse cancer prognosis. | An active but still largely investigational research marker in oncology prognosis, beyond its established cardiovascular role. | Immunoassay (nephelometry/turbidimetry) | Serum |
| Antineutrophil cytoplasmic antibodies against proteinase 3 | Emerging | PR3-ANCA, c-ANCA (cytoplasmic pattern), anti-proteinase 3 antibody | Granulomatosis with polyangiitis, Not primarily cancer-associated | PR3-ANCA is more specifically associated with granulomatosis with polyangiitis than the MPO-ANCA/p-ANCA pattern. | Current best practice favors antigen-specific (PR3 vs. MPO) testing over immunofluorescence pattern alone for clinical correlation. | Antigen-specific immunoassay (ELISA) | Serum |
| Antineutrophil cytoplasmic antibodies | Established | ANCA, MPO-ANCA, PR3-ANCA | Granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, Not primarily cancer-associated | ANCA is the key serologic marker for a group of small-vessel vasculitis diseases. | Present in ~90% of AAV cases; guides urgent treatment decisions per current 2024/2025 KDIGO guidelines. | Indirect immunofluorescence; antigen-specific immunoassay (ELISA) | Serum |
| Antimitochondrial antibodies | Established | AMA, AMA-M2, anti-PDC-E2 antibody | Primary biliary cholangitis, Not primarily cancer-associated | AMA is the hallmark diagnostic antibody for primary biliary cholangitis, a chronic liver disease. | Highly specific for PBC; apparent AMA-negative cases often resolve as positive with more sensitive testing. | Indirect immunofluorescence; immunoassay (ELISA) for AMA-M2 | Serum |
| Anticardiolipin antibody | Established | Anticardiolipin antibody, aCL | Antiphospholipid syndrome, Not primarily cancer-associated | Anticardiolipin antibody is one of three tests used together to classify antiphospholipid syndrome. | Requires a qualifying clinical thrombotic or pregnancy event alongside positive serology for diagnosis. | Immunoassay (ELISA) | Serum |
| Anti-TPO antibody | Established | Anti-TPO, TPOAb, thyroid peroxidase antibody | Hashimoto's thyroiditis, Graves' disease, postpartum thyroiditis, Not primarily cancer-associated | Anti-TPO is the most common autoimmune thyroid disease marker, found in both Hashimoto's and Graves' disease. | Present in 10-15% of the general population without disease; positivity in pregnancy warrants closer postpartum thyroid monitoring. | Immunoassay (CLIA/ECLIA) | Serum |
| Anti-Streptolysin antibodies | Established | ASO, antistreptolysin O titer | Rheumatic fever, post-streptococcal glomerulonephritis, Not primarily cancer-associated | ASO is an antibody marker of recent strep infection, supporting (not confirming) rheumatic fever diagnosis. | Supportive evidence within the Jones criteria; roughly 15-20% of true rheumatic fever cases show no ASO rise. | Nephelometric/turbidimetric immunoassay | Serum |
| Anti-Smith Antibodies | Established | Anti-Sm, anti-Smith antibody | Systemic lupus erythematosus, Not primarily cancer-associated | Anti-Sm is a highly specific but insensitive autoantibody marker for lupus. | One of two SLE-specific serologic markers in current classification criteria (with anti-dsDNA). | Immunoassay (ELISA) | Serum |
| Anti-Scl-70 | Established | Anti-Scl-70, anti-topoisomerase I antibody | Diffuse cutaneous systemic sclerosis, interstitial lung disease, Not primarily cancer-associated | Anti-Scl-70 is a specific marker for diffuse systemic sclerosis, associated with higher interstitial lung disease risk. | Positivity prompts closer pulmonary surveillance given the strong association with lung involvement and mortality risk. | Immunoassay (ELISA) | Serum |
| Anti-ribosomal P antibodies | Established | Anti-Rib-P, anti-P antibody | Systemic lupus erythematosus, neuropsychiatric lupus, Not primarily cancer-associated | Anti-Rib-P is a specific but insensitive marker for neuropsychiatric lupus, especially psychosis. | No standardized assay exists; prevalence and clinical association vary notably by ethnicity. | Immunoassay (ELISA) | Serum |
| Anti-Jo-1 | Established | Anti-Jo-1, anti-histidyl-tRNA synthetase antibody | Antisynthetase syndrome, polymyositis/dermatomyositis, interstitial lung disease, Not primarily cancer-associated | Anti-Jo-1 is the most common antisynthetase antibody, defining antisynthetase syndrome (myositis plus interstitial lung disease). | Interstitial lung disease, not muscle weakness, is usually the primary driver of long-term prognosis in this syndrome. | Immunoassay (ELISA) or line blot, typically as part of a myositis-specific antibody panel | Serum |
| Anti-gliadin antibody IgG | Established | AGA IgG, anti-gliadin IgG | Celiac disease (historical marker), Not primarily cancer-associated | Anti-gliadin IgG is an outdated celiac marker, superseded by deamidated gliadin peptide (DGP) IgG testing. | Considered low-accuracy by current guidelines; DGP-IgG is the modern equivalent for IgA-deficient patients. | Immunoassay (ELISA) | Serum |
| Anti-gliadin antibody IgA | Established | AGA IgA, anti-gliadin IgA | Celiac disease (historical marker), Not primarily cancer-associated | Anti-gliadin IgA is an outdated celiac disease marker superseded by tTG-IgA testing. | Low diagnostic accuracy per current guidelines; should not be used as a stand-alone celiac test today. | Immunoassay (ELISA) | Serum |
| Anti-double stranded DNA antibodies | Established | Anti-dsDNA, native DNA antibody | Systemic lupus erythematosus, lupus nephritis, Not primarily cancer-associated | Anti-dsDNA is a specific lupus marker often tracking disease activity, especially renal involvement. | Reliability depends on assay specificity; used both diagnostically and to monitor lupus nephritis flares. | Immunoassay (ELISA); indirect immunofluorescence (Crithidia luciliae) | Serum |
| Anti-Dengue virus antibody | Emerging | Anti-dengue IgM, anti-dengue IgG, dengue serology | Dengue fever, severe dengue (dengue hemorrhagic fever/dengue shock syndrome), Not primarily cancer-associated | Combined NS1 antigen and IgM testing, correctly timed, is the current recommended approach for acute dengue diagnosis. | Single-specimen IgG testing is explicitly discouraged due to inability to distinguish current from past infection and flavivirus cross-reactivity. | Immunoassay (ELISA); rapid immunochromatographic test | Serum |
| Anti-cyclic Citrullinated Peptide | Established | Anti-CCP, ACPA, anti-citrullinated protein antibody | Rheumatoid arthritis, Not primarily cancer-associated | Anti-CCP is the most specific serologic marker for rheumatoid arthritis, useful for diagnosis, not monitoring. | Can predate clinical RA onset by years; combined with RF in current classification criteria. | Immunoassay (ELISA/CLIA) | Serum |
| Anti-centromere antibody | Established | ACA, anti-centromere antibody, CREST antibody | Limited cutaneous systemic sclerosis (CREST syndrome), pulmonary arterial hypertension, Not primarily cancer-associated | Anti-centromere antibody is the classic marker for limited systemic sclerosis (CREST syndrome). | Predicts pulmonary arterial hypertension risk specifically, a genuinely different complication profile than anti-Scl-70-positive disease. | Indirect immunofluorescence (centromere pattern) or antigen-specific immunoassay | Serum |
| Anti-beta2 glycoprotein1 | Established | Anti-β2GP1, anti-beta-2-glycoprotein I antibody | Antiphospholipid syndrome, recurrent pregnancy loss, Not primarily cancer-associated | Anti-β2GP1 is one of three antibodies used to classify antiphospholipid syndrome. | Part of the 2023-revised APS classification criteria; requires a clinical event to establish diagnosis. | Immunoassay (ELISA) | Serum or plasma |
| Anti-acetylcholine receptor antibody | Established | Anti-AChR antibody, AChR-Ab | Myasthenia gravis, Thymoma (associated with AChR-antibody-positive MG) | Anti-AChR antibody is the primary diagnostic marker for myasthenia gravis. | Confirms diagnosis in ~80% of generalized MG; titer level does not reliably track disease severity. | Immunoassay (RIA); cell-based assay | Serum |
| Angiotensin I | Emerging | Angiotensin I, Ang I | Hypertension (pathway context), Not primarily cancer-associated | Angiotensin I is the inactive precursor in the renin-angiotensin pathway, the conceptual basis for two major blood pressure drug classes. | Not directly measured clinically; its relevance is entirely as an intermediate step connecting renin and ACE activity. | Immunoassay (RIA) | Plasma (EDTA, rarely measured directly) |
| Amyloid Beta42 | Emerging | A-beta 42, amyloid-beta 1-42 | Alzheimer's disease, mild cognitive impairment, Not primarily cancer-associated | The Aβ42/Aβ40 ratio is central to modern Alzheimer's diagnosis and now gatekeeps eligibility for anti-amyloid antibody treatment. | A rapidly evolving area given very recent (2024-2025) diagnostic criteria updates and new FDA-approved blood tests. | Immunoassay (CLIA/Simoa); mass spectrometry (LC-MS/MS) | CSF or plasma |
| Amylase | Established | Serum amylase, pancreatic amylase (isoenzyme) | Acute pancreatitis, salivary gland disorders, bowel obstruction, Not primarily cancer-associated | Amylase is a pancreatic/salivary enzyme historically used to diagnose pancreatitis, now superseded by lipase. | Largely replaced by lipase in current pancreatitis diagnostic guidelines due to lower specificity. | Enzyme kinetic (colorimetric) activity assay | Serum |
| Aminolevulinic Acid Dehydratase | Emerging | ALAD, delta-ALAD, porphobilinogen synthase | ALAD-deficiency porphyria (rare), lead poisoning/toxicity, Not primarily cancer-associated | ALAD is the most sensitive biological indicator of lead exposure, beyond its rare role in ALAD-deficiency porphyria. | Genetic ALAD variants (ALAD1/ALAD2) influence individual susceptibility to lead toxicity, an active environmental health research area. | Enzyme kinetic activity assay; genotyping (ALAD1/ALAD2) | Whole blood (erythrocytes) |
| AMH | Established | Anti-Mullerian hormone, Mullerian inhibiting substance | Diminished ovarian reserve, premature ovarian insufficiency, polycystic ovary syndrome, Granulosa cell tumor of the ovary | AMH is a reproductive hormone used to assess ovarian reserve and diagnose/monitor granulosa cell tumors. | High diagnostic accuracy for granulosa cell tumor; preferred marker for ovarian reserve assessment. | Immunoassay (ELISA/CLIA) | Serum |
| ALPL | Established | AP-TNAP, TNSALP, tissue-nonspecific alkaline phosphatase | Hypophosphatasia (genetic bone disease), bone mineralization disorders, Breast cancer, colorectal cancer (reduced ALPL linked to progression) | ALPL encodes an enzyme whose reduced levels indicate tumor aggressiveness in breast cancer, and whose mutations cause a distinct genetic bone disease. | Reduced ALPL is linked to cancer progression and metastasis; also the causal gene in hypophosphatasia. | Enzyme kinetic activity assay (serum ALP); genetic testing for hypophosphatasia | Serum (enzyme); whole blood (genetic) |
| Alpha-Galactosidase | Established | Alpha-Gal A, GLA enzyme | Fabry disease, Not primarily cancer-associated | Alpha-galactosidase deficiency is diagnostic for Fabry disease, a lysosomal storage disorder. | Diagnostic in affected males; unreliable in female carriers, who require genetic testing instead. | Enzyme fluorometric activity assay | Dried blood spot or plasma/leukocytes |
| Alpha-2-Macroglobulin | Emerging | Alpha-2-macroglobulin, A2M | Chronic hepatitis, liver fibrosis, Not primarily cancer-associated | Alpha-2-macroglobulin is a component of the FibroTest composite panel, a noninvasive alternative to liver biopsy for fibrosis staging. | Works alongside several other markers (haptoglobin, bilirubin, GGT, ApoA1) as part of a combined fibrosis risk score. | Immunoassay (nephelometry/turbidimetry) | Serum |
| Alkaline Phosphatase | Established | ALP, ALKP | Paget's disease of bone, biliary obstruction, cholestasis, hyperparathyroidism, osteomalacia, Bone metastases, primary or metastatic liver tumors | ALP is a general enzyme marker for liver/biliary disease or increased bone turnover. | Nonspecific but widely used; source (bone vs. liver) must be clarified with additional testing. | Enzyme kinetic (colorimetric) activity assay | Serum |
| ALK | Established | ALK, ALK rearrangement, EML4-ALK fusion | Not primarily disease-indicating outside oncology context, Non-small cell lung cancer, anaplastic large cell lymphoma, neuroblastoma | ALK gene rearrangements define a distinct, highly drug-responsive lung cancer subtype, generally mutually exclusive with other driver mutations. | Sequential ALK inhibitor generations have progressively improved control of brain metastases, a common site of disease progression. | Fluorescence in situ hybridization (FISH), immunohistochemistry, or next-generation sequencing (NGS) panel | Tumor tissue (FFPE biopsy) |
| ALDOB | Emerging | Aldolase B, HFI enzyme | Hereditary fructose intolerance, Not primarily cancer-associated | ALDOB deficiency causes hereditary fructose intolerance, now diagnosed via genetic testing rather than a provocative fructose challenge. | Represents a broader trend across metabolic disorders toward genetic confirmation over risky provocative testing. | Genetic testing (gene sequencing) | Whole blood (EDTA) |
| ALD | Emerging | ALD, ALDP, ABCD1, X-linked adrenoleukodystrophy, X-ALD | X-linked adrenoleukodystrophy, Addison's disease (adrenal insufficiency), cerebral ALD, Not primarily cancer-associated | ALD/ABCD1 encodes a peroxisomal fatty acid transporter; its deficiency causes X-linked adrenoleukodystrophy. | Newborn screening (C26:0-LPC) now covers most US states, enabling time-critical early treatment before irreversible cerebral disease develops. | Newborn screening biomarker assay (C26:0-LPC, tandem mass spectrometry); VLCFA profiling; genetic testing (ABCD1 sequencing) for confirmation | Dried blood spot (newborn screening) or plasma (VLCFA); whole blood (genetic) |
| ALB | Established | Serum albumin | Malnutrition, liver disease, nephrotic syndrome, protein-losing enteropathy, Multiple myeloma (ISS staging component), general oncology prognostication | Albumin is a liver-made blood protein whose low levels signal poor nutrition, liver disease, or severe illness. | A broad, independent prognostic marker across many diseases, not just liver or kidney disorders. | Colorimetric dye-binding assay (bromocresol green/purple) | Serum |
| AFP | Established | Alpha-1-fetoprotein, alpha-fetoglobulin, FETA | Hepatocellular carcinoma, germ cell tumors, Hepatocellular carcinoma, testicular germ cell tumor, ovarian germ cell tumor, cholangiocarcinoma, pancreatic cancer | AFP is a fetal plasma protein used as a biomarker for liver and germ cell tumors. | Elevated in hepatocellular carcinoma and testicular/ovarian germ cell tumors; core to HCC surveillance guidelines. | Immunoassay (CLIA/ECLIA) | Serum |
| Adenylate kinase enzyme | Emerging | AK1, adenylate kinase 1 | Hereditary hemolytic anemia (AK1 deficiency), Not primarily cancer-associated | Adenylate kinase deficiency is a very rare cause of hereditary hemolytic anemia from impaired red blood cell energy metabolism. | Far less common and less well-characterized than other red cell enzyme deficiencies like pyruvate kinase deficiency. | Enzyme kinetic activity assay | Whole blood (RBC hemolysate) |
| ADA | Established | Adenosine aminohydrolase | Tuberculous pleural effusion, tuberculous pleuritis, Malignant pleural effusion (can cause false-positive ADA elevation) | ADA is a fluid-based enzyme test used mainly to diagnose tuberculous pleural effusion. | A well-validated, inexpensive marker for TB pleuritis, with population-dependent optimal cutoffs. | Enzyme kinetic (colorimetric) activity assay | Pleural/body cavity fluid (or serum) |
| ACTH | Established | Corticotropin, adrenocorticotropin | Addison's disease, Cushing's syndrome, secondary adrenal insufficiency, Ectopic ACTH-secreting tumors (small cell lung cancer, carcinoid) | ACTH is a pituitary hormone used to diagnose and localize disorders of cortisol production. | Central to differentiating primary from secondary adrenal disorders and localizing Cushing's syndrome. | Immunoassay (CLIA/ECLIA) | Plasma (EDTA, collected on ice, light-protected) |
| ACP5 | Emerging | TRAP5b, tartrate-resistant acid phosphatase | Osteoporosis, Hairy cell leukemia | ACP5/TRAP5b is a bone resorption marker, with an unrelated historical use as a hairy cell leukemia diagnostic marker. | Less affected by recent food intake than some other bone turnover markers, though less commonly used than CTX or P1NP. | Immunoassay (ELISA) | Serum |
| ACHE | Established | Acetylcholinesterase, RBC cholinesterase, true cholinesterase | Organophosphate/carbamate poisoning, congenital AChE deficiency, Not primarily cancer-associated | AChE is a red-blood-cell enzyme whose depression signals pesticide or nerve-agent exposure. | A key occupational safety biomarker for early detection of cholinesterase-inhibiting toxin exposure. | Enzyme kinetic (colorimetric) activity assay | Whole blood (RBC) |
| ACE | Established | Angiotensin I-converting enzyme, peptidyl-dipeptidase A, CD143 | Sarcoidosis, Gaucher disease, hyperthyroidism, Hodgkin lymphoma (elevated ACE reported) | ACE is a serum enzyme marker used mainly to support diagnosis and monitoring of sarcoidosis. | Elevated in active granulomatous disease, especially sarcoidosis; low sensitivity/specificity limits standalone diagnostic use. | Enzyme kinetic/spectrophotometric activity assay | Serum |
| 5-HIAA | Established | 5-HIAA, 5-hydroxyindoleacetic acid | Carcinoid syndrome, carcinoid heart disease, Neuroendocrine tumors (midgut/small intestinal carcinoid, lung carcinoid) | 5-HIAA is the classic biochemical marker for diagnosing and monitoring carcinoid syndrome from serotonin-secreting neuroendocrine tumors. | A 2025 study shows serum 5-HIAA (single blood draw) performs equivalently to the traditional, more burdensome 24-hour urine collection. | Immunoassay or HPLC/mass spectrometry (quantitative) | 24-hour urine (traditional) or serum (increasingly validated alternative) |
Zinc transporter 8Emerging
ZnT8, ZnT8A (autoantibody), SLC30A8
Diseases indicated
Type 1 diabetes mellitus, Not primarily cancer-associated
Short description
ZnT8 autoantibodies are now a standard component of the type 1 diabetes diagnostic autoantibody panel, improving detection rates.
Clinical significance
Helps distinguish autoimmune type 1 diabetes from monogenic diabetes, avoiding unnecessary genetic testing in some patients.
Test methodology
Immunoassay (ELISA/RIA) for autoantibody
Specimen type
Serum
VWFEstablished
VWF, von Willebrand factor
Diseases indicated
Von Willebrand disease, Not primarily cancer-associated
Short description
VWF is central to diagnosing von Willebrand disease, the most common inherited bleeding disorder, via a standardized 2021 algorithm.
Clinical significance
Treatment differs critically by VWD subtype; desmopressin can worsen type 2B disease rather than help it.
Test methodology
Immunoassay (ELISA/CLIA) for antigen; functional activity assay (ristocetin cofactor or GPIbM-based)
Specimen type
Plasma (citrate)
VEGFCEmerging
VEGF-C, vascular endothelial growth factor C
Diseases indicated
Lymphedema (lymphatic development context), Studied across several solid tumors for lymph node metastasis risk (research context)
Short description
VEGF-C drives lymphangiogenesis and is studied as a research marker for lymph node metastasis risk in cancer.
Clinical significance
An active area of anti-lymphangiogenic drug development research, not yet a standardized clinical test.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma (primarily research use)
Vasoactive intestinal polypeptideEmerging
VIP, vasoactive intestinal peptide
Diseases indicated
VIPoma (Verner-Morrison syndrome/WDHA syndrome), Pancreatic neuroendocrine tumor (VIPoma)
Short description
VIP excess causes VIPoma, a rare pancreatic tumor syndrome with severe watery diarrhea and low potassium.
Clinical significance
Diagnosis combines elevated VIP with the classic watery diarrhea/hypokalemia/achlorhydria clinical triad.
Test methodology
Immunoassay (RIA)
Specimen type
Plasma (EDTA with protease inhibitor, on ice, fasting)
Uroporphyrinogen DecarboxylaseEstablished
UROD, uroporphyrinogen decarboxylase
Diseases indicated
Porphyria cutanea tarda, Not primarily cancer-associated
Short description
UROD deficiency causes porphyria cutanea tarda, the most common porphyria, often triggered by acquired factors.
Clinical significance
Frequently acquired/triggered (alcohol, estrogen, hepatitis C, iron overload) rather than purely inherited.
Test methodology
Enzyme fluorometric activity assay; genetic testing
Specimen type
Erythrocytes/whole blood
Uric acidEstablished
Uric acid, urate
Diseases indicated
Gout, kidney stones (urate-type), Relevant to tumor lysis syndrome risk assessment in lymphoma/leukemia chemotherapy
Short description
Uric acid causes gout via crystal deposition and is also a key pretreatment risk marker for tumor lysis syndrome in oncology.
Clinical significance
Connects directly to the LDH/tumor lysis syndrome discussion elsewhere in this set as part of the same pretreatment risk panel.
Test methodology
Enzymatic colorimetric assay
Specimen type
Serum or plasma
Tumor necrosis factorEmerging
TNF-alpha, TNF, cachectin
Diseases indicated
Rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis, ankylosing spondylitis, Not primarily cancer-associated
Short description
TNF-alpha is the direct target of an entire major biologic drug class (anti-TNF agents) across multiple autoimmune diseases.
Clinical significance
One of the most therapeutically significant cytokines in modern medicine, despite not being routinely measured itself.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
Tumor Mutational BurdenEstablished
TMB, tumor mutation burden, TMB-H
Diseases indicated
Not primarily disease-indicating outside oncology context, Tissue-agnostic across advanced solid tumors (FDA pembrolizumab indication)
Short description
TMB is a tissue-agnostic predictive biomarker for checkpoint inhibitor response, though weaker and more debated than PD-L1 or MSI-H.
Clinical significance
Only one specific NGS panel (FoundationOne CDx) carries FDA approval for this particular clinical use.
Test methodology
Next-generation sequencing (large gene panel, FoundationOne CDx is the FDA-approved assay)
Specimen type
Tumor tissue (FFPE biopsy or resection specimen)
TTREstablished
TTR, transthyretin, prealbumin
Diseases indicated
ATTR amyloidosis (hereditary and wild-type), malnutrition (historical use as "prealbumin"), Not primarily cancer-associated
Short description
TTR misfolding causes ATTR amyloidosis, an underdiagnosed cause of heart failure with a rapidly expanding treatment landscape.
Clinical significance
Treatment options expanded dramatically in 2024-2025, with acoramidis, vutrisiran, and eplontersen joining tafamidis.
Test methodology
Immunoassay (nephelometry/turbidimetry) for level; genetic testing for hereditary ATTR; nuclear scintigraphy or tissue biopsy for amyloid deposition
Specimen type
Serum (level); whole blood (genetic); cardiac tissue biopsy or scintigraphy for amyloidosis diagnosis
TSHBEstablished
TSH, thyrotropin
Diseases indicated
Hypothyroidism, hyperthyroidism, subclinical hypothyroidism, Not primarily cancer-associated
Short description
TSH is the standard first-line thyroid function test, most sensitive for detecting thyroid dysfunction.
Clinical significance
Treatment thresholds for mild (subclinical) elevation remain debated, especially in older adults.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
TSH receptor antibodyEstablished
TRAb, TSI, thyroid-stimulating immunoglobulin
Diseases indicated
Graves' disease, neonatal/fetal hyperthyroidism (via placental transfer), Not primarily cancer-associated
Short description
TRAb, specifically the stimulating TSI form, is the direct cause of and diagnostic marker for Graves' disease.
Clinical significance
Crosses the placenta during pregnancy, requiring monitoring to prevent fetal or neonatal hyperthyroidism.
Test methodology
Immunoassay (functional bioassay for TSI, or binding assay)
Specimen type
Serum
Triosephosphate IsomeraseEmerging
TPI, TPI1
Diseases indicated
Hereditary non-spherocytic hemolytic anemia with progressive neurological deterioration (TPI deficiency), Not primarily cancer-associated
Short description
TPI deficiency is the most severe glycolytic enzyme deficiency, combining hemolytic anemia with progressive neurological decline.
Clinical significance
The neurological component doesn't respond to standard anemia treatments, making this a particularly difficult condition to manage.
Test methodology
Enzyme kinetic activity assay; genetic testing
Specimen type
Whole blood (RBC)
Transglutaminase IgA antibodyEstablished
tTG-IgA, tissue transglutaminase antibody
Diseases indicated
Celiac disease, Not primarily cancer-associated
Short description
tTG-IgA is the current first-line, guideline-recommended serologic test for celiac disease.
Clinical significance
Requires simultaneous total IgA testing to avoid missing celiac disease in IgA-deficient patients.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Serum
TPSAB1Established
Tryptase, alpha-tryptase
Diseases indicated
Mastocytosis, anaphylaxis, hereditary alpha-tryptasemia, Systemic mastocytosis (clonal mast cell neoplasm)
Short description
TPSAB1/tryptase is central to diagnosing mastocytosis and anaphylaxis, complicated by a distinct genetic trait (hereditary alpha-tryptasemia).
Clinical significance
Distinguishing hereditary alpha-tryptasemia from true mastocytosis requires genetic copy-number testing, not tryptase level alone.
Test methodology
Immunoassay (ImmunoCAP fluoroenzymeimmunoassay) for level; genetic copy-number testing (ddPCR) for hereditary alpha-tryptasemia
Specimen type
Serum (level); whole blood (genetic)
Total ProteinEstablished
Total protein, TP
Diseases indicated
Chronic liver disease, chronic inflammation, monoclonal gammopathy, Multiple myeloma (via monoclonal gammopathy workup)
Short description
Total protein is a basic screening test; the albumin-to-globulin ratio derived from it is often more clinically informative.
Clinical significance
An abnormal ratio, especially with elevated globulins, prompts protein electrophoresis to look for a monoclonal spike.
Test methodology
Colorimetric assay (biuret method)
Specimen type
Serum
TNNT2Established
Cardiac troponin T, cTnT, hs-cTnT
Diseases indicated
Not primarily disease-indicating outside cardiac context, Not primarily cancer-associated
Short description
Cardiac troponin T is clinically equivalent to troponin I as a gold-standard heart attack diagnostic biomarker.
Clinical significance
Serial (delta) measurements help distinguish acute from chronic myocardial injury patterns.
Test methodology
Immunoassay (ECLIA, high-sensitivity)
Specimen type
Serum or plasma
TNNI3Established
Cardiac troponin I, cTnI, hs-cTnI
Diseases indicated
Not primarily disease-indicating outside cardiac context, Not primarily cancer-associated
Short description
Cardiac troponin I is a gold-standard biomarker for diagnosing heart attacks, now used in rapid rule-in/rule-out algorithms.
Clinical significance
No single universal cutoff exists; values are assay-specific and increasingly interpreted with sex-specific reference limits.
Test methodology
Immunoassay (CLIA/ECLIA, high-sensitivity)
Specimen type
Serum or plasma
ThrombopoietinEmerging
TPO, thrombopoietin
Diseases indicated
Chronic immune thrombocytopenia, thrombocytopenia in chronic liver disease, Not primarily cancer-associated
Short description
TPO drives platelet production; thrombopoietin receptor agonist drugs are now standard ITP treatment, without TPO itself being routinely measured.
Clinical significance
Newer agents (avatrombopag, hetrombopag) continue to refine dosing convenience and reduce side effects like hepatotoxicity.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
TGEstablished
Tg, thyroglobulin
Diseases indicated
Not primarily disease-indicating outside oncology context, Differentiated thyroid cancer (papillary, follicular)
Short description
Thyroglobulin is the standard biomarker for monitoring differentiated thyroid cancer recurrence after treatment.
Clinical significance
Thyroglobulin antibodies (up to 25% of patients) and even certain supplements can cause significant test interference.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
TFRCEmerging
sTfR, soluble transferrin receptor, CD71
Diseases indicated
Iron deficiency anemia, anemia of chronic disease (differentiation), Not primarily cancer-associated
Short description
TFRC/soluble transferrin receptor helps diagnose iron deficiency even when inflammation confounds standard iron studies.
Clinical significance
Not affected by inflammation, unlike ferritin, making it valuable in complex or chronically inflamed patients.
Test methodology
Immunoassay (ELISA/nephelometry) for soluble transferrin receptor
Specimen type
Serum
TFEstablished
Transferrin
Diseases indicated
Iron deficiency anemia, anemia of chronic disease, hereditary hemochromatosis, Not primarily cancer-associated
Short description
Transferrin, as part of the full iron panel, helps distinguish iron deficiency from chronic disease anemia and hemochromatosis.
Clinical significance
Must be interpreted together with serum iron, ferritin, and transferrin saturation, not as a standalone value.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
SS-B/La AntibodiesEstablished
Anti-SS-B, anti-La antibody
Diseases indicated
Sjogren's syndrome, systemic lupus erythematosus, neonatal lupus/congenital heart block, Not primarily cancer-associated
Short description
SS-B/La usually accompanies SS-A/Ro in Sjogren's syndrome; the combination is more diagnostically specific than either alone.
Clinical significance
Carries a similar, somewhat lower, congenital heart block risk in pregnancy compared to SS-A/Ro.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
SS-A/Ro AntibodiesEstablished
Anti-SS-A, anti-Ro antibody
Diseases indicated
Sjogren's syndrome, systemic lupus erythematosus, neonatal lupus/congenital heart block, Not primarily cancer-associated
Short description
SS-A/Ro is the key Sjogren's syndrome marker, with an important congenital heart block risk in pregnancy.
Clinical significance
Relevant to prenatal monitoring even in asymptomatic antibody-positive women without a diagnosed autoimmune condition.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Squamous cell carcinoma antigenEstablished
SCC antigen, SCCA
Diseases indicated
Psoriasis, eczema (benign causes of mild elevation), Cervical cancer, head and neck squamous cell carcinoma, lung squamous cell carcinoma, esophageal cancer
Short description
SCC antigen is a monitoring tumor marker for squamous cell carcinomas across several body sites.
Clinical significance
Some benign skin conditions can also mildly elevate this marker, since it's a normal squamous epithelium protein.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
SHBGEstablished
SHBG, sex hormone-binding globulin
Diseases indicated
Polycystic ovary syndrome, male hypogonadism, obesity/insulin resistance (low SHBG), hyperthyroidism (high SHBG), Not primarily cancer-associated
Short description
SHBG is used to calculate free testosterone, correcting for cases where total testosterone alone would be misleading.
Clinical significance
Particularly important in PCOS and hypogonadism evaluation, where SHBG abnormalities can distort total hormone readings.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
SERPINE1Emerging
PAI-1, plasminogen activator inhibitor-1
Diseases indicated
Cardiovascular disease, metabolic syndrome, thrombosis risk, Breast cancer (historical uPA/PAI-1 prognostic test, largely superseded)
Short description
SERPINE1/PAI-1 affects clot breakdown and cardiovascular risk; its breast cancer prognostic test role has been largely superseded.
Clinical significance
The uPA/PAI-1 breast cancer test has been overtaken by genomic assays like Oncotype DX and MammaPrint.
Test methodology
Immunoassay (ELISA)
Specimen type
Plasma (cardiovascular context) or fresh/frozen tumor tissue (oncology uPA/PAI-1 test)
SERPINC1Established
Antithrombin, antithrombin III, AT
Diseases indicated
Hereditary antithrombin deficiency, liver disease, nephrotic syndrome, DIC (acquired causes), Not primarily cancer-associated
Short description
Antithrombin deficiency is a thrombophilia; its deficiency can also cause resistance to heparin therapy.
Clinical significance
Heparin's mechanism of action depends on binding antithrombin, making this an important drug-biomarker interaction to recognize.
Test methodology
Functional (chromogenic) assay or antigen immunoassay
Specimen type
Plasma (citrate)
SERPINA7Established
TBG, thyroxine-binding globulin
Diseases indicated
TBG excess/deficiency (genetic), pregnancy and estrogen-related thyroid test interference, Not primarily cancer-associated
Short description
TBG is the main thyroid hormone carrier protein; its level changes can distort total T4 without reflecting true thyroid function.
Clinical significance
Free T4 testing is now generally preferred over total T4 specifically to avoid this interference issue.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
SERPINA1Established
AAT, alpha-1 antitrypsin, A1AT
Diseases indicated
Alpha-1 antitrypsin deficiency, COPD, emphysema, liver cirrhosis, Hepatocellular carcinoma (increased risk in AATD-related cirrhosis)
Short description
SERPINA1/AAT deficiency is an underdiagnosed genetic cause of early COPD and liver disease, per a newly updated 2024/2025 guideline.
Clinical significance
Augmentation therapy is currently restricted to severe deficiency, though evidence for intermediate-deficiency patients is emerging.
Test methodology
Immunoassay (nephelometry/turbidimetry) for level; genetic/phenotype testing for variants
Specimen type
Serum (level); whole blood (genetic)
SELPEmerging
P-selectin, CD62P
Diseases indicated
Sickle cell disease (vaso-occlusive crisis), Not primarily cancer-associated
Short description
P-selectin drives the abnormal blood cell adhesion behind sickle cell vaso-occlusive crises, now a specific drug target (crizanlizumab).
Clinical significance
One of several newer sickle cell therapies that have reshaped treatment in recent years, alongside voxelotor and hydroxyurea updates.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
SAA1Emerging
SAA, serum amyloid A protein
Diseases indicated
AA (secondary) amyloidosis, chronic inflammatory disease (rheumatoid arthritis, IBD), Not primarily cancer-associated
Short description
SAA1 is an acute-phase reactant whose chronic elevation drives AA amyloidosis, distinct from ATTR or AL amyloidosis.
Clinical significance
Correct amyloid subtyping (AA vs. ATTR vs. AL) is essential since treatment approaches differ substantially between types.
Test methodology
Immunoassay (nephelometry/turbidimetry/ELISA)
Specimen type
Serum
S100A8Established
Calprotectin (component), MRP8
Diseases indicated
Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Not primarily cancer-associated
Short description
S100A8, as part of calprotectin, is a widely used noninvasive marker distinguishing IBD from irritable bowel syndrome.
Clinical significance
Also used to monitor treatment response and detect subclinical inflammation in patients with established IBD.
Test methodology
Immunoassay (ELISA)
Specimen type
Stool
Rheumatoid FactorEstablished
RF, rheumatoid factor
Diseases indicated
Rheumatoid arthritis, Sjogren's syndrome, hepatitis C, chronic infections, Not primarily cancer-associated
Short description
Rheumatoid factor is an older, less specific RA marker, generally considered less reliable than anti-CCP.
Clinical significance
Positive in numerous non-RA conditions, including a meaningful fraction of healthy older adults.
Test methodology
Nephelometric/turbidimetric immunoassay or agglutination assay
Specimen type
Serum
RENEstablished
Renin, plasma renin activity, direct renin concentration
Diseases indicated
Primary aldosteronism, resistant hypertension, Not primarily cancer-associated
Short description
Renin, paired with aldosterone, is central to diagnosing primary aldosteronism, a common cause of hypertension.
Clinical significance
A 2025 Endocrine Society guideline shift toward universal hypertension screening represents a major, very current change in practice.
Test methodology
Immunoassay (CLIA) for direct renin concentration; enzymatic assay for plasma renin activity
Specimen type
Plasma (EDTA)
Pyruvate KinaseEstablished
PK deficiency, PKLR enzyme
Diseases indicated
Pyruvate kinase deficiency (hereditary hemolytic anemia), Not primarily cancer-associated
Short description
Pyruvate kinase deficiency causes chronic hemolytic anemia, now treatable with a novel oral enzyme activator (mitapivat).
Clinical significance
Represents a rare case of a previously untreatable enzyme deficiency gaining a genuine disease-modifying drug.
Test methodology
Enzyme kinetic activity assay
Specimen type
Whole blood (RBC hemolysate)
PTHEstablished
PTH, parathormone, intact PTH
Diseases indicated
Primary hyperparathyroidism, CKD-mineral and bone disorder, hypoparathyroidism, Parathyroid adenoma/carcinoma
Short description
PTH is central to diagnosing hyperparathyroidism and CKD-related bone disease, with genuinely distinct target ranges for each.
Clinical significance
The CKD-MBD target range (2-9x upper normal limit) is intentionally wide, not "normal," reflecting real assay and physiologic complexities.
Test methodology
Immunoassay (CLIA/ECLIA, second-generation intact PTH)
Specimen type
Plasma (EDTA)
PSAEstablished
KLK3, prostate-specific antigen
Diseases indicated
Benign prostatic hyperplasia, prostatitis, Prostate cancer
Short description
PSA is a widely used prostate cancer marker, but its screening role remains a genuinely preference-sensitive decision.
Clinical significance
Guidelines emphasize shared decision-making given real overdetection/overtreatment risks, rather than routine screening for all.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Protein S-100BEstablished
S100B, S100 calcium-binding protein B
Diseases indicated
Traumatic brain injury, Melanoma
Short description
S100B serves two unrelated roles: helping triage head injury patients for CT imaging, and monitoring melanoma.
Clinical significance
A normal early post-injury S100B has high negative predictive value for ruling out significant brain injury on CT.
Test methodology
Immunoassay (ELISA/ECLIA)
Specimen type
Serum
Prostatic Acid PhosphataseEmerging
PAP, prostatic acid phosphatase
Diseases indicated
Not primarily disease-indicating outside oncology context, Prostate cancer
Short description
PAP is a historical prostate cancer marker now most significant as the target antigen for sipuleucel-T, the first FDA-approved cancer vaccine.
Clinical significance
Demonstrated a survival benefit in metastatic castration-resistant prostate cancer as the basis of an approved immunotherapy.
Test methodology
Immunoassay (RIA/ELISA), largely historical
Specimen type
Serum
PROS1Established
Protein S
Diseases indicated
Hereditary Protein S deficiency, thrombophilia, Not primarily cancer-associated
Short description
Protein S deficiency is a thrombophilia; testing is complicated by physiologic drops during pregnancy and hormonal contraception.
Clinical significance
Current guidelines reserve testing for cases where results would meaningfully change management, not routine screening.
Test methodology
Functional clotting assay or antigen immunoassay
Specimen type
Plasma (citrate)
Proinsulin C-peptideEstablished
C-peptide, connecting peptide
Diseases indicated
Insulinoma, factitious hypoglycemia, type 1 vs. type 2 diabetes classification, Insulinoma (pancreatic neuroendocrine tumor)
Short description
C-peptide distinguishes endogenous from injected insulin sources and helps classify diabetes type.
Clinical significance
Central to the insulin-to-C-peptide ratio used in diagnosing insulinoma versus factitious hypoglycemia.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
ProcalcitoninEstablished
PCT, procalcitonin
Diseases indicated
Bacterial sepsis, lower respiratory tract infection, Medullary thyroid carcinoma (as the CALCA-derived precursor, connects to the calcitonin entry elsewhere in this set, though PCT itself is not the primary MTC marker)
Short description
Procalcitonin helps distinguish bacterial from viral/non-infectious causes of inflammation and guides antibiotic stewardship decisions.
Clinical significance
Procalcitonin-guided protocols reduce antibiotic duration in several clinical trials without worsening patient outcomes.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
PROCEstablished
Protein C
Diseases indicated
Hereditary Protein C deficiency, purpura fulminans, thrombophilia, Not primarily cancer-associated
Short description
Protein C deficiency is a thrombophilia; starting warfarin without heparin overlap risks warfarin-induced skin necrosis.
Clinical significance
Severe homozygous deficiency causes purpura fulminans, a life-threatening neonatal clotting emergency.
Test methodology
Functional clotting assay (chromogenic or clot-based) or antigen immunoassay
Specimen type
Plasma (citrate)
PRLEstablished
Prolactin
Diseases indicated
Prolactinoma, hypothyroidism (secondary cause), macroprolactinemia, Prolactinoma (pituitary adenoma)
Short description
Elevated prolactin suggests prolactinoma but more often reflects medication effects or a lab-interference artifact (macroprolactin).
Clinical significance
Macroprolactin screening is now routine before pursuing pituitary imaging for an isolated elevation.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Porphobilinogen DeaminaseEstablished
HMBS, hydroxymethylbilane synthase, PBGD
Diseases indicated
Acute intermittent porphyria, Not primarily cancer-associated
Short description
Porphobilinogen deaminase deficiency causes acute intermittent porphyria, diagnosed via enzyme or genetic testing.
Clinical significance
Genetic testing increasingly used for definitive diagnosis and identifying asymptomatic carrier family members.
Test methodology
Enzyme fluorometric activity assay; genetic testing (HMBS)
Specimen type
Whole blood (erythrocytes)
PhosphofructokinaseEmerging
PFK, PFKM, Tarui disease enzyme
Diseases indicated
Hereditary non-spherocytic hemolytic anemia, glycogen storage disease type VII (Tarui disease), Not primarily cancer-associated
Short description
PFK deficiency (Tarui disease) uniquely combines hemolytic anemia with a muscle glycogen storage disease.
Clinical significance
The combined blood and muscle involvement distinguishes it from other glycolytic enzyme deficiencies in this biomarker set.
Test methodology
Enzyme kinetic activity assay
Specimen type
Whole blood (RBC) or muscle tissue
PGREstablished
PR, progesterone receptor
Diseases indicated
Not primarily disease-indicating outside oncology context, Breast cancer
Short description
PGR/progesterone receptor status, paired with ER, guides breast cancer hormone therapy eligibility.
Clinical significance
The uncommon PR-positive/ER-negative combination has a less well-established optimal treatment approach.
Test methodology
Immunohistochemistry (IHC)
Specimen type
Tumor tissue (biopsy)
Perineuclear Antineutrophil Cytoplasmic AntibodiesEstablished
p-ANCA, MPO-ANCA (perinuclear pattern)
Diseases indicated
Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, inflammatory bowel disease, autoimmune hepatitis, Not primarily cancer-associated
Short description
p-ANCA is an immunofluorescence pattern typically corresponding to MPO-ANCA, associated with specific vasculitis subtypes.
Clinical significance
Distinguishes from the cytoplasmic (c-ANCA/PR3) pattern more typical of granulomatosis with polyangiitis.
Test methodology
Indirect immunofluorescence; antigen-specific immunoassay (MPO-ELISA)
Specimen type
Serum
PD-L1Established
PD-L1, CD274, B7-H1
Diseases indicated
Not primarily disease-indicating outside oncology context, Non-small cell lung cancer, gastric cancer, cervical cancer, head and neck cancer, urothelial carcinoma, triple-negative breast cancer, esophageal cancer
Short description
PD-L1 IHC is one of three FDA-approved predictive biomarkers for immune checkpoint inhibitor response.
Clinical significance
Each checkpoint drug has its own non-interchangeable companion diagnostic antibody clone and scoring system (TPS vs. CPS).
Test methodology
Immunohistochemistry (IHC) using drug-specific companion diagnostic antibody clones (22C3, SP142, 28-8, SP263)
Specimen type
Tumor tissue (FFPE biopsy or resection specimen)
PAPPAEstablished
PAPP-A, pregnancy-associated plasma protein A
Diseases indicated
Down syndrome (screening), preeclampsia and fetal growth restriction (associated risk), Not primarily cancer-associated
Short description
PAPP-A is a first-trimester screening marker for chromosomal abnormalities, also linked to later placental complications.
Clinical significance
Low levels carry secondary prognostic value for placental-mediated pregnancy complications beyond chromosomal screening.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum (maternal, first trimester)
Pancreatic PolypeptideEmerging
PP, pancreatic polypeptide
Diseases indicated
Not primarily disease-indicating outside oncology context, PPoma (pancreatic neuroendocrine tumor), other neuroendocrine tumors
Short description
Pancreatic polypeptide supports PPoma diagnosis, typically as part of a broader neuroendocrine tumor marker panel.
Clinical significance
Rarely diagnostic in isolation; used alongside chromogranin A and other markers for full characterization.
Test methodology
Immunoassay (RIA/ELISA)
Specimen type
Plasma (EDTA, fasting)
Pancreatic elastase-1Established
Fecal elastase-1, FE-1
Diseases indicated
Pancreatic exocrine insufficiency, chronic pancreatitis, cystic fibrosis, Not primarily cancer-associated (relevant after pancreatic cancer surgery)
Short description
Fecal elastase-1 is the modern preferred test for pancreatic exocrine insufficiency, replacing fecal chymotrypsin.
Clinical significance
Remains accurate even in patients already taking pancreatic enzyme replacement therapy, unlike the older chymotrypsin test.
Test methodology
Immunoassay (ELISA)
Specimen type
Stool
Pancreatic AmylaseEstablished
P-type amylase, pancreatic isoamylase
Diseases indicated
Acute pancreatitis, chronic pancreatitis, Not primarily cancer-associated
Short description
Pancreatic amylase is the pancreas-specific fraction of amylase, sharing amylase's overall decline in favor of lipase.
Clinical significance
Rarely ordered in current practice given lipase's superior diagnostic performance for pancreatitis.
Test methodology
Enzyme kinetic activity assay with isoenzyme electrophoresis
Specimen type
Serum
OGAEmerging
O-GlcNAcase, MGEA5
Diseases indicated
Not primarily disease-indicating outside neurodegeneration research context, Not primarily cancer-associated
Short description
OGA regulates a protein modification relevant to tau pathology; OGA inhibitors are an early-stage neurodegenerative disease drug approach.
Clinical significance
Remains investigational; not yet a standard clinical biomarker or approved therapeutic target.
Test methodology
Enzyme activity assay (research use)
Specimen type
Tissue (research context)
Nuclear Ribonucleoprotein H1 antibodiesEstablished
Anti-RNP, anti-U1RNP
Diseases indicated
Mixed connective tissue disease, systemic lupus erythematosus, Not primarily cancer-associated
Short description
High-titer anti-RNP without other lupus-specific antibodies is the serologic hallmark of mixed connective tissue disease.
Clinical significance
The specific antibody combination pattern distinguishes MCTD from lupus or other overlap syndromes.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
NPM1Established
NPM1, nucleophosmin 1, NPM1c
Diseases indicated
Not primarily disease-indicating outside oncology context, Acute myeloid leukemia
Short description
NPM1 mutation is the most common AML genetic abnormality and, in isolation, one of the most favorable prognostic markers.
Clinical significance
Now incorporated as a distinct WHO AML disease entity; prognosis depends heavily on co-occurring mutations, especially FLT3-ITD.
Test methodology
PCR-based mutation testing or next-generation sequencing (NGS) panel
Specimen type
Bone marrow or peripheral blood (whole blood, EDTA)
NeurotensinEmerging
Neurotensin, NT
Diseases indicated
Not primarily disease-indicating outside oncology research context, Gastrointestinal neuroendocrine tumors, pancreatic cancer (research target)
Short description
Neurotensin is elevated in certain GI neuroendocrine tumors; its receptor is an emerging target for radioligand cancer therapy.
Clinical significance
Not yet a standardized diagnostic test; primarily relevant in specialized neuroendocrine tumor research and early clinical trials.
Test methodology
Immunoassay (RIA)
Specimen type
Plasma (EDTA, on ice)
Neurofilament Light PolypeptideEmerging
NfL, neurofilament light chain
Diseases indicated
Multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, other neurodegenerative diseases, Not primarily cancer-associated
Short description
NfL is a rapidly emerging blood biomarker of neuroaxonal damage, now guided by a 2024 consensus statement for MS management.
Clinical significance
Blood-based testing (rather than only spinal fluid) is a genuinely practical recent advance, expanding accessibility for monitoring.
Test methodology
Immunoassay (Simoa, ultra-sensitive)
Specimen type
Serum or plasma (increasingly preferred) or CSF
N-terminal propeptide of type 1 procollagenEstablished
P1NP, procollagen type 1 N-terminal propeptide
Diseases indicated
Osteoporosis, Bone metastases (as part of broader bone turnover assessment)
Short description
P1NP is the leading bone formation marker, used to monitor both anabolic and antiresorptive osteoporosis therapy.
Clinical significance
Expected direction of change differs by drug class — rising with anabolic drugs, falling with antiresorptive drugs.
Test methodology
Immunoassay (ECLIA/RIA)
Specimen type
Serum
N-terminal pro-B-type Natriuretic peptideEstablished
NT-proBNP
Diseases indicated
Heart failure, Not primarily cancer-associated
Short description
NT-proBNP is BNP's longer-lasting precursor fragment, often preferred for heart failure diagnosis due to its stability.
Clinical significance
Not directly interchangeable with BNP values; each has distinct reference ranges and guideline cutoffs.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
MUC1Established
MUC1, CA 15-3, CA 27.29
Diseases indicated
Not primarily disease-indicating outside oncology context, Breast cancer
Short description
MUC1 underlies CA 15-3/CA 27.29, breast cancer markers used for monitoring, not screening or diagnosis.
Clinical significance
Follows the same monitoring-only role pattern as CEA in colorectal cancer and CA 19-9 in pancreatic cancer.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Mismatch Repair Deficiency / Microsatellite InstabilityEstablished
MMR, MSI-H, dMMR, MLH1, MSH2, MSH6, PMS2
Diseases indicated
Lynch syndrome (hereditary nonpolyposis colorectal cancer), Colorectal cancer, endometrial cancer, gastric cancer, and other MSI-H solid tumors (tissue-agnostic)
Short description
dMMR/MSI-H is a tissue-agnostic predictive biomarker for checkpoint inhibitor response and the molecular signature of Lynch syndrome.
Clinical significance
One of the first FDA drug approvals based purely on a biomarker rather than the cancer's site of origin.
Test methodology
Immunohistochemistry (MMR protein loss); PCR-based fragment analysis or NGS (microsatellite instability)
Specimen type
Tumor tissue (FFPE biopsy or resection specimen)
MBEstablished
Myoglobin
Diseases indicated
Rhabdomyolysis, muscular dystrophy, myocardial infarction (historical marker), Not primarily cancer-associated
Short description
Myoglobin is an early but nonspecific muscle injury marker, now mainly used to gauge rhabdomyolysis severity.
Clinical significance
Its cardiac diagnostic role has been superseded by the far more specific troponin.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
MAPTEmerging
Tau, MAPT, microtubule-associated protein tau
Diseases indicated
Alzheimer's disease, frontotemporal dementia, other tauopathies, Not primarily cancer-associated
Short description
MAPT/tau blood biomarkers (p-tau217, p-tau181) are central to modern Alzheimer's diagnosis and anti-amyloid treatment monitoring.
Clinical significance
May offer an earlier signal of disease reactivation after treatment discontinuation than amyloid PET imaging.
Test methodology
Immunoassay (Simoa/CLIA, ultra-sensitive)
Specimen type
CSF or plasma
LYZEmerging
Lysozyme, muramidase
Diseases indicated
Sarcoidosis, Monocytic leukemia, myelomonocytic leukemia
Short description
Lysozyme supports sarcoidosis diagnosis and is elevated in monocytic leukemias, where very high levels can injure the kidneys.
Clinical significance
A secondary complication in monocytic leukemia: lysozyme-induced kidney tubular injury at very high levels.
Test methodology
Enzyme turbidimetric activity assay; immunoassay
Specimen type
Serum or urine
LTFEstablished
Lactoferrin, fecal lactoferrin
Diseases indicated
Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Not primarily cancer-associated
Short description
Fecal lactoferrin is a noninvasive inflammation marker that helps distinguish IBD from irritable bowel syndrome.
Clinical significance
Often used alongside fecal calprotectin for a similar noninvasive screening purpose before colonoscopy.
Test methodology
Immunoassay (ELISA)
Specimen type
Stool
LPLEmerging
LPL, lipoprotein lipase deficiency
Diseases indicated
Familial chylomicronemia syndrome, severe hypertriglyceridemia, recurrent pancreatitis, Not primarily cancer-associated
Short description
LPL deficiency causes familial chylomicronemia syndrome, now treatable with a December 2024 FDA-approved antisense drug (olezarsen).
Clinical significance
Represents a rare condition with a genuinely new treatment option after decades of dietary restriction being the only management.
Test methodology
Genetic testing (sequencing); functional lipolytic activity assay (research, post-heparin plasma)
Specimen type
Whole blood (genetic) or plasma (functional, rarely done)
LipaseEstablished
Serum lipase, pancreatic lipase
Diseases indicated
Acute pancreatitis, chronic pancreatitis, Pancreatic cancer (in some contexts of duct obstruction)
Short description
Lipase is the current preferred first-line marker for diagnosing acute pancreatitis, replacing amylase.
Clinical significance
Should not be repeated serially to monitor disease severity once the diagnosis is established.
Test methodology
Enzyme kinetic (colorimetric) activity assay
Specimen type
Serum
LHBEstablished
LH, luteinizing hormone
Diseases indicated
Polycystic ovary syndrome, menopause, male hypogonadism, Not primarily cancer-associated
Short description
LH, paired with FSH, helps evaluate PCOS, fertility timing, and menopause, though its role in routine menopause diagnosis is narrowing.
Clinical significance
An elevated LH:FSH ratio is a classic supporting (though not required) finding in PCOS.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
LEPEmerging
Leptin
Diseases indicated
Congenital leptin deficiency, obesity (leptin resistance), Not primarily cancer-associated
Short description
Leptin regulates appetite; rare congenital deficiency is treatable with metreleptin replacement therapy.
Clinical significance
One of the few specific hormone deficiencies with its own approved replacement drug (metreleptin).
Test methodology
Immunoassay (RIA/ELISA)
Specimen type
Serum or plasma
LCN2Emerging
NGAL, lipocalin-2
Diseases indicated
Acute kidney injury, Not primarily cancer-associated
Short description
LCN2/NGAL is a promising early acute kidney injury marker, rising faster than creatinine after kidney insult.
Clinical significance
Not yet universally adopted into routine clinical AKI diagnostic criteria despite strong supporting research.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Urine or serum/plasma
Lactate dehydrogenaseEstablished
LDH, lactic dehydrogenase
Diseases indicated
Hemolysis, tissue injury, myocardial infarction (historical marker), Non-Hodgkin lymphoma (core IPI component), tumor lysis syndrome risk assessment
Short description
LDH is a nonspecific cell-damage marker with specific, well-established prognostic value in lymphoma staging.
Clinical significance
Core component of the International Prognostic Index (IPI); also predicts tumor lysis syndrome risk before treatment.
Test methodology
Enzyme kinetic activity assay
Specimen type
Serum
KRAS/NRASEstablished
KRAS, NRAS, RAS mutation status, KRAS G12C
Diseases indicated
Not primarily disease-indicating outside oncology context, Colorectal cancer, non-small cell lung cancer, pancreatic cancer
Short description
RAS mutation status determines anti-EGFR therapy eligibility in colorectal cancer; KRAS G12C now has its own targeted drug class.
Clinical significance
Sotorasib and adagrasib (2024-2025 approvals) represent a major breakthrough after RAS was long considered an undruggable target.
Test methodology
PCR-based mutation testing or next-generation sequencing (NGS) panel
Specimen type
Tumor tissue (FFPE biopsy); plasma (liquid biopsy/ctDNA) increasingly used
Ki-67 (MKI67)Established
Ki-67, MKI67, MIB-1
Diseases indicated
Not primarily disease-indicating outside oncology context, Neuroendocrine tumors (core WHO grading criterion), breast cancer, lymphoma
Short description
Ki-67 is the core proliferation marker defining WHO neuroendocrine tumor grade, also widely used (if less formally endorsed) in breast cancer.
Clinical significance
Significant inter-laboratory scoring variability remains an active, unresolved standardization challenge.
Test methodology
Immunohistochemistry (IHC), typically clone MIB-1, with manual or digital image analysis
Specimen type
Tumor tissue (FFPE biopsy or resection specimen)
Kappa/Lambda light chainsEstablished
Free light chains, FLC, sFLC
Diseases indicated
Monoclonal gammopathy of undetermined significance (MGUS), Multiple myeloma, AL amyloidosis, plasmacytoma
Short description
The free light chain ratio is a core diagnostic and monitoring test for multiple myeloma and related plasma cell disorders.
Clinical significance
Important interpretation caveat: kidney impairment raises both light chains together but usually preserves the ratio's reliability.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
JAK2Established
JAK2, JAK2 V617F, Janus kinase 2
Diseases indicated
Polycythemia vera, essential thrombocythemia, primary myelofibrosis, Myeloproliferative neoplasms (as above); can rarely be associated with AML progression
Short description
JAK2 V617F is the molecular hallmark of classic myeloproliferative neoplasms, central to current WHO diagnostic criteria.
Clinical significance
Also guides thrombosis risk stratification and JAK-inhibitor treatment decisions in myelofibrosis and polycythemia vera.
Test methodology
PCR-based mutation testing or next-generation sequencing (NGS) panel
Specimen type
Peripheral blood (whole blood, EDTA) or bone marrow
Interleukin-10Emerging
IL-10, interleukin-10
Diseases indicated
Not primarily disease-indicating outside oncology and immunology research context, Primary CNS lymphoma
Short description
CSF IL-10, especially the IL-10:IL-6 ratio, is a supportive marker helping diagnose primary CNS lymphoma before biopsy.
Clinical significance
An example of an anti-inflammatory cytokine paradoxically serving as a marker of aggressive malignant disease.
Test methodology
Immunoassay (ELISA)
Specimen type
CSF (for CNS lymphoma context) or serum/plasma
Interleukin-1 betaEmerging
IL-1 beta, interleukin-1 beta
Diseases indicated
Familial Mediterranean fever, cryopyrin-associated periodic syndromes, autoinflammatory diseases, Studied as a cardiovascular inflammation target (CANTOS trial); not primarily a cancer marker
Short description
IL-1β drives several autoinflammatory diseases and is a direct target of anakinra/canakinumab; also studied in cardiovascular disease.
Clinical significance
The CANTOS trial showed IL-1β blockade reduces cardiovascular events independent of cholesterol, a genuinely novel finding.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
Interleukin 1-AlphaEmerging
IL-1 alpha, interleukin-1 alpha
Diseases indicated
Autoinflammatory diseases (via shared IL-1 receptor pathway), Not primarily cancer-associated
Short description
IL-1α is a pro-inflammatory alarm cytokine, indirectly blocked by anakinra alongside its better-known relative IL-1β.
Clinical significance
Less directly targeted by current biologic therapies compared to IL-1β, which has more dedicated therapeutic development.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
Intact Fibroblast Growth Factor 23Established
FGF23
Diseases indicated
X-linked hypophosphatemia, tumor-induced osteomalacia, hypophosphatemic rickets, Phosphaturic mesenchymal tumor (causative tumor in TIO)
Short description
FGF23 excess causes rare hypophosphatemic bone diseases, now treated with a monoclonal antibody built to block it.
Clinical significance
TIO diagnosis remains genuinely difficult due to challenges localizing small, hard-to-find causative tumors.
Test methodology
Immunoassay (ELISA)
Specimen type
Plasma (EDTA, on ice)
Insulin-like Growth Factor-Binding Protein-1Emerging
IGFBP-1, IGF-binding protein 1
Diseases indicated
Preterm premature rupture of membranes, PCOS/insulin resistance (research marker), Not primarily cancer-associated
Short description
IGFBP-1 is the basis of a rapid bedside test (Actim PROM) for diagnosing preterm rupture of membranes in pregnancy.
Clinical significance
A practical clinical application distinct from its research role as a metabolic/insulin sensitivity marker.
Test methodology
Immunochromatographic rapid test (Actim PROM); ELISA (research)
Specimen type
Cervicovaginal fluid (PROM test) or serum (research)
Insulin-like Growth Factor 2Emerging
IGF2, IGF-2, somatomedin A
Diseases indicated
Beckwith-Wiedemann syndrome, Non-islet cell tumor hypoglycemia (large mesenchymal and hepatic tumors)
Short description
IGF2 overexpression causes non-islet cell tumor hypoglycemia, an important differential when insulin/C-peptide don't explain low blood sugar.
Clinical significance
Connects directly to the insulin/C-peptide discussion earlier as a key alternative explanation for tumor-associated hypoglycemia.
Test methodology
Immunoassay (RIA/ELISA)
Specimen type
Serum
INSEstablished
Insulin
Diseases indicated
Diabetes mellitus, insulinoma, factitious hypoglycemia, Insulinoma (pancreatic neuroendocrine tumor)
Short description
Insulin, paired with C-peptide, is central to diagnosing insulinoma via a supervised fasting test.
Clinical significance
A shorter 48-hour fast now diagnoses 90-95% of insulinoma cases, refining the older 72-hour protocol.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
Inhibin BEstablished
Inhibin B
Diseases indicated
Diminished ovarian reserve, male infertility (testicular failure), Granulosa cell tumor of the ovary
Short description
Inhibin B assesses ovarian reserve (cycle-dependent, largely superseded by AMH) and male Sertoli cell function.
Clinical significance
Requires specific-day cycle timing in women, unlike AMH, which can be measured any day.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
IL6Emerging
IL-6, interleukin-6
Diseases indicated
Cytokine release syndrome, rheumatoid arthritis, COVID-19 (severe, cytokine storm), CAR-T cell therapy-related toxicity monitoring
Short description
IL-6 is the central driver cytokine in CAR-T-related cytokine release syndrome, treated first-line with tocilizumab.
Clinical significance
The same IL-6-blocking drug class saw major expanded use in severe COVID-19-associated cytokine storm.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Serum or plasma
IL2RAEmerging
CD25, soluble IL-2 receptor, sIL-2R
Diseases indicated
Hemophagocytic lymphohistiocytosis, sarcoidosis (activity marker), Lymphoma (prognostic marker, tumor burden)
Short description
Soluble CD25 (IL2RA) is one of the formal HLH-2004 diagnostic criteria and the most sensitive specialized adult HLH lab test.
Clinical significance
Also used as a lymphoma prognostic marker and to monitor sarcoidosis disease activity.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
IL18Emerging
IL-18, interleukin-18
Diseases indicated
Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, Relevant to CAR-T cell therapy-related toxicity monitoring in oncology
Short description
IL-18 is an emerging marker helping distinguish HLH/MAS from other causes of severe inflammation, including CAR-T toxicity.
Clinical significance
The IL-18/CXCL9 ratio is a specific, actively-studied refinement for improving HLH/MAS diagnostic accuracy.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
IgMEstablished
Immunoglobulin M
Diseases indicated
Acute/recent infection (serology context), Waldenström macroglobulinemia
Short description
IgM indicates recent infection in serology testing; monoclonal IgM is diagnostic for Waldenström macroglobulinemia.
Clinical significance
MYD88 mutation testing, present in most Waldenström cases, increasingly guides treatment selection.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
IgGEstablished
Immunoglobulin G
Diseases indicated
Common variable immunodeficiency, IgG subclass deficiency, recurrent sinopulmonary infections, Not primarily cancer-associated (though relevant to monoclonal gammopathy/myeloma workups)
Short description
IgG is the dominant long-term antibody; subclass deficiencies can cause infections despite normal total IgG.
Clinical significance
Subclass testing is warranted when recurrent infections persist despite a normal total IgG result.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
IGF1Established
IGF-1, somatomedin C
Diseases indicated
Acromegaly, growth hormone deficiency, short stature, Pituitary adenoma (GH-secreting); IGF-1 signaling also studied broadly in cancer biology
Short description
IGF-1 is the stable, preferred marker for assessing growth hormone activity, more reliable than a single GH level.
Clinical significance
Assay standardization remains an active issue; results are not directly interchangeable across different lab platforms.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
IgEEstablished
Immunoglobulin E, total IgE
Diseases indicated
Allergic asthma, atopic dermatitis, allergic rhinitis, parasitic infection, Not primarily cancer-associated
Short description
IgE is central to allergy diagnosis and directly determines dosing eligibility for the biologic drug omalizumab.
Clinical significance
A real treatment-access gap exists for patients with IgE levels above current official dosing table limits.
Test methodology
Immunoassay (CLIA/ECLIA/ImmunoCAP)
Specimen type
Serum
IgAEstablished
Immunoglobulin A
Diseases indicated
Selective IgA deficiency, IgA nephropathy, celiac disease (testing interference), Not primarily cancer-associated
Short description
IgA deficiency is common and usually mild, but affects the reliability of IgA-based celiac disease testing.
Clinical significance
Should be checked alongside tTG-IgA testing to avoid false-negative celiac disease results.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
IFNGEmerging
IFN-gamma, interferon gamma
Diseases indicated
Latent tuberculosis infection, active tuberculosis, Not primarily cancer-associated
Short description
IFN-gamma release underlies IGRA testing, now preferred over the tuberculin skin test for diagnosing latent TB.
Clinical significance
Not affected by prior BCG vaccination, a key practical advantage over the traditional skin test.
Test methodology
Functional assay (interferon-gamma release assay, ELISA/ELISPOT-based)
Specimen type
Whole blood
Iduronate-2-SulfataseEstablished
I2S, IDS enzyme
Diseases indicated
Mucopolysaccharidosis type II (Hunter syndrome), Not primarily cancer-associated
Short description
Iduronate-2-sulfatase deficiency causes Hunter syndrome, now part of expanded US newborn screening since 2022.
Clinical significance
Newborn screening has identified some variants with abnormal biochemistry but no clinical disease, an evolving area.
Test methodology
Enzyme fluorometric activity assay; genetic testing
Specimen type
Dried blood spot (newborn screening) or leukocytes
IDH1/IDH2Established
IDH1, IDH2, isocitrate dehydrogenase
Diseases indicated
Not primarily disease-indicating outside oncology context, Acute myeloid leukemia, glioma/glioblastoma, cholangiocarcinoma, chondrosarcoma
Short description
IDH1/IDH2 mutations define distinct favorable-risk AML and glioma subtypes, each with its own FDA-approved targeted drug.
Clinical significance
IDH mutation status is now a core WHO classification criterion for gliomas, defining fundamentally different tumor categories.
Test methodology
PCR-based mutation testing or next-generation sequencing (NGS) panel
Specimen type
Bone marrow or peripheral blood (AML); tumor tissue biopsy (glioma)
Human Transforming Growth Factor beta 1Emerging
TGF-beta 1, TGFB1
Diseases indicated
Radiation-induced fibrosis, other fibrotic conditions, Studied as a tumor immune evasion mechanism across multiple solid tumor types (research context)
Short description
TGF-β1 drives tissue fibrosis and tumor immune evasion; blocking it is an active cancer immunotherapy combination research area.
Clinical significance
Not yet a standardized clinical diagnostic test; primarily relevant in fibrosis and cancer immunotherapy research settings.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
Human Epididymis protein 4Established
HE4, WFDC2
Diseases indicated
Endometriosis (notably does NOT cause false elevation, unlike CA-125), Ovarian cancer (epithelial)
Short description
HE4 combined with CA-125 (as ROMA) helps estimate ovarian cancer risk before surgery, improving on CA-125 alone.
Clinical significance
Not falsely elevated by endometriosis, a key advantage over CA-125 for distinguishing benign from malignant masses.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
HPEstablished
Haptoglobin
Diseases indicated
Hemolytic anemia (autoimmune, mechanical, hereditary spherocytosis, G6PD deficiency), Not primarily cancer-associated
Short description
Haptoglobin helps distinguish hemolytic from non-hemolytic anemia by reflecting free hemoglobin clearance.
Clinical significance
Can be falsely normal in patients with concurrent inflammation, since it is also an acute-phase reactant.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
HomocysteineEstablished
Homocysteine, tHcy
Diseases indicated
Vitamin B12 deficiency, folate deficiency, homocystinuria (genetic), Not primarily cancer-associated
Short description
Homocysteine helps detect B12/folate deficiency, sometimes before classic markers become abnormal.
Clinical significance
Large cardiovascular trials found homocysteine-lowering therapy doesn't reduce cardiovascular events despite lowering the biomarker itself.
Test methodology
Immunoassay or HPLC/mass spectrometry
Specimen type
Serum or plasma (fasting preferred)
HGFEmerging
HGF, scatter factor
Diseases indicated
Not primarily disease-indicating outside oncology context, Non-small cell lung cancer (EGFR-inhibitor resistance context), gastric cancer, hepatocellular carcinoma
Short description
HGF/MET pathway activation is a key mechanism of resistance to EGFR-targeted lung cancer therapy.
Clinical significance
An active precision oncology drug development target for overcoming treatment resistance.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
HexokinaseEmerging
HK, hexokinase 1
Diseases indicated
Hereditary non-spherocytic hemolytic anemia (hexokinase deficiency), Not primarily cancer-associated
Short description
Hexokinase deficiency is an extremely rare glycolytic enzyme cause of hereditary hemolytic anemia.
Clinical significance
Among the rarest of the glycolytic enzyme deficiencies, with very few cases reported in medical literature.
Test methodology
Enzyme kinetic activity assay
Specimen type
Whole blood (RBC hemolysate)
Hemoglobin SEstablished
HbS, sickle hemoglobin
Diseases indicated
Sickle cell disease, sickle cell trait, Not primarily cancer-associated
Short description
Hemoglobin S is the abnormal variant causing sickle cell disease, detected via newborn screening.
Clinical significance
2024 saw both a major drug withdrawal (voxelotor) and a new approval (oral hydroxyurea solution) in this space.
Test methodology
HPLC, capillary electrophoresis, or isoelectric focusing; genetic confirmation
Specimen type
Whole blood (EDTA) or dried blood spot (newborn screening)
HBBEstablished
Beta-globin gene
Diseases indicated
Sickle cell disease, beta-thalassemia, sickle cell trait, Not primarily cancer-associated
Short description
HBB is the gene underlying sickle cell disease and beta-thalassemia, confirmed via genetic testing.
Clinical significance
Complements hemoglobin electrophoresis for definitive diagnosis and genetic/reproductive counseling.
Test methodology
Genetic testing (sequencing); HPLC or capillary electrophoresis for phenotype
Specimen type
Whole blood (EDTA)
HbA1cEstablished
HbA1c, glycated hemoglobin, A1C
Diseases indicated
Diabetes mellitus, prediabetes, Not primarily cancer-associated
Short description
HbA1c is the central biomarker for diagnosing and monitoring diabetes, reflecting average blood glucose over 2-3 months.
Clinical significance
Unreliable in conditions affecting red blood cell lifespan; current guidelines favor individualized rather than universal targets.
Test methodology
Immunoassay or high-performance liquid chromatography (HPLC)
Specimen type
Whole blood (EDTA)
HBA1Emerging
Alpha-globin gene 1
Diseases indicated
Alpha-thalassemia, Hemoglobin H disease, Hb Bart's hydrops fetalis, Not primarily cancer-associated
Short description
HBA1 is one of the duplicated alpha-globin genes; its deletion causes alpha-thalassemia of variable severity.
Clinical significance
Genetic testing is standard for carrier screening in at-risk populations, given risk of severe disease in offspring of two carriers.
Test methodology
Genetic testing (gap-PCR/sequencing); HPLC or capillary electrophoresis for phenotype
Specimen type
Whole blood (EDTA)
HBEstablished
Hb, hemoglobin
Diseases indicated
Anemia, polycythemia vera, various causes of blood loss or bone marrow disease, Relevant in monitoring hematologic malignancies and chemotherapy-related anemia
Short description
Hemoglobin is the core blood test for diagnosing anemia or polycythemia, requiring further workup to find the cause.
Clinical significance
A foundational, universally used marker across nearly all areas of medicine.
Test methodology
Spectrophotometric assay (automated hematology analyzer)
Specimen type
Whole blood (EDTA)
HAVCR1Emerging
KIM-1, TIM-1, HAVCR1, hepatitis A virus cellular receptor 1
Diseases indicated
Acute kidney injury (drug-induced nephrotoxicity), Not primarily cancer-associated
Short description
HAVCR1/KIM-1 is an FDA-qualified biomarker for early detection of drug-induced kidney injury, outperforming creatinine.
Clinical significance
Widely referenced across FDA drug development submissions; also unrelated historical namesake of the hepatitis A virus receptor.
Test methodology
Immunoassay (ELISA)
Specimen type
Urine
GPTEstablished
ALT, alanine aminotransferase, GPT, SGPT
Diseases indicated
MASLD (formerly NAFLD), MASH (formerly NASH), viral hepatitis, drug-induced liver injury, Hepatocellular carcinoma (as component of broader liver assessment)
Short description
GPT/ALT is a liver-specific enzyme marker, central to MASLD/MASH diagnosis under the 2023-renamed disease framework.
Clinical significance
The June 2023 NAFLD-to-MASLD nomenclature change reflects a major, current shift in how fatty liver disease is classified.
Test methodology
Enzyme kinetic activity assay
Specimen type
Serum
Glucose Phosphate IsomeraseEmerging
GPI, phosphoglucose isomerase
Diseases indicated
Hereditary non-spherocytic hemolytic anemia (GPI deficiency), Not primarily cancer-associated
Short description
GPI deficiency is a rare glycolytic enzyme cause of hereditary hemolytic anemia, in the same family as pyruvate kinase deficiency.
Clinical significance
Management is supportive, following the same general approach as other red cell enzyme deficiencies in this biomarker set.
Test methodology
Enzyme kinetic activity assay
Specimen type
Whole blood (RBC hemolysate)
GlucagonEstablished
Glucagon
Diseases indicated
Diabetes mellitus (counter-regulatory context), hypoglycemia, Glucagonoma (pancreatic neuroendocrine tumor)
Short description
Glucagon excess is the hallmark of glucagonoma; the hormone is also used therapeutically for severe hypoglycemia.
Clinical significance
Diagnostic marker for a rare, distinctive neuroendocrine tumor syndrome.
Test methodology
Immunoassay (RIA/ELISA)
Specimen type
Plasma (EDTA with protease inhibitor, on ice, fasting)
GhrelinEmerging
Ghrelin
Diseases indicated
Prader-Willi syndrome (hyperphagia), Not primarily cancer-associated
Short description
Ghrelin drives hunger and is markedly elevated in Prader-Willi syndrome, contributing to its characteristic insatiable appetite.
Clinical significance
Ghrelin receptor antagonists are an emerging, targeted therapeutic approach specifically for Prader-Willi-related hyperphagia.
Test methodology
Immunoassay (RIA/ELISA)
Specimen type
Plasma (EDTA with protease inhibitor, on ice)
GH1Established
GH, somatotropin, growth hormone
Diseases indicated
Acromegaly, gigantism, growth hormone deficiency, Pituitary adenoma (GH-secreting)
Short description
GH1/growth hormone testing diagnoses acromegaly or deficiency, though rarely via a single random level.
Clinical significance
IGF-1 and dynamic stimulation/suppression testing are the actual diagnostic standards, not isolated GH measurement.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
GGTEstablished
GGT, gamma-glutamyltransferase, GGT1
Diseases indicated
Alcohol use disorder, biliary obstruction, fatty liver disease, Not primarily cancer-associated
Short description
GGT helps localize the source of abnormal alkaline phosphatase and serves as a sensitive alcohol-use marker.
Clinical significance
Nonspecific; interpreted alongside other liver enzymes rather than as a standalone test.
Test methodology
Enzyme kinetic activity assay
Specimen type
Serum
Gastrin-releasing peptideEmerging
ProGRP, pro-gastrin-releasing peptide
Diseases indicated
Not primarily disease-indicating outside oncology context, Small cell lung cancer
Short description
ProGRP is a specific small cell lung cancer marker, often used alongside NSE for improved diagnostic accuracy.
Clinical significance
Less affected by sample hemolysis than NSE, giving it a practical laboratory reliability advantage.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
GASTEstablished
Gastrin, serum gastrin
Diseases indicated
Zollinger-Ellison syndrome, atrophic gastritis, Gastrinoma (pancreatic/duodenal neuroendocrine tumor)
Short description
Gastrin is the key diagnostic marker for Zollinger-Ellison syndrome, complicated by common heartburn medications.
Clinical significance
PPI-related false elevation creates real diagnostic and safety tension in confirming or excluding this rare tumor.
Test methodology
Immunoassay (RIA/CLIA)
Specimen type
Plasma (EDTA, fasting) or serum
Gamma-EnolaseEstablished
NSE, neuron-specific enolase
Diseases indicated
Not primarily disease-indicating outside oncology context, Small cell lung cancer, neuroblastoma, neuroendocrine tumors
Short description
NSE is a tumor marker for neuroendocrine-origin cancers, used for diagnosis and treatment monitoring.
Clinical significance
Useful supplementary marker when chromogranin A results are confounded by medication interference.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
G6PDEstablished
G6PD deficiency, favism
Diseases indicated
G6PD deficiency, hemolytic anemia (drug/infection/fava bean-triggered), Not primarily cancer-associated
Short description
G6PD deficiency causes drug/food-triggered hemolytic anemia; testing is required before certain antimalarial drugs.
Clinical significance
Newer antimalarials (tafenoquine) require stricter quantitative testing than older drugs due to greater hemolysis risk.
Test methodology
Enzyme activity assay (quantitative spectrophotometric or qualitative fluorescent spot test)
Specimen type
Whole blood
Follicle stimulating hormoneEstablished
FSH, follitropin
Diseases indicated
Menopause, premature ovarian insufficiency, male infertility, Not primarily cancer-associated
Short description
FSH is a pituitary hormone used selectively to evaluate menopause timing and fertility, per narrowed current guidelines.
Clinical significance
Current guidance limits routine testing to younger women or atypical presentations rather than typical menopause.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
FN1Emerging
Fibronectin, FN
Diseases indicated
Wound healing disorders, fibrosis, Studied across several solid tumors as an invasion/fibrosis marker (research context)
Short description
FN1/fibronectin is a research marker of tumor invasion and fibrosis, not yet a standardized clinical diagnostic test.
Clinical significance
Reflects extracellular matrix remodeling relevant to tumor growth and metastasis in ongoing research.
Test methodology
Immunoassay (ELISA); immunohistochemistry (tissue context)
Specimen type
Serum/plasma or tumor tissue
FLT3Established
FLT3, FLT3-ITD, FLT3-TKD
Diseases indicated
Not primarily disease-indicating outside oncology context, Acute myeloid leukemia
Short description
FLT3-ITD is a common AML mutation central to risk stratification and eligibility for FLT3-targeted drugs (midostaurin, gilteritinib).
Clinical significance
The newly updated 2024 ELN risk classification shows FLT3-ITD substantially worsens otherwise-favorable NPM1-mutated AML prognosis.
Test methodology
PCR-based fragment analysis or next-generation sequencing (NGS) panel
Specimen type
Bone marrow or peripheral blood (whole blood, EDTA)
FibrinogenEstablished
Factor I, fibrinogen
Diseases indicated
Disseminated intravascular coagulation, liver disease, congenital afibrinogenemia, Not primarily cancer-associated
Short description
Fibrinogen is a key clotting protein, actively corrected early in modern trauma resuscitation protocols.
Clinical significance
Often the first factor depleted in major hemorrhage, prioritized for early repletion in massive transfusion protocols.
Test methodology
Functional clotting assay (Clauss method)
Specimen type
Plasma (citrate)
FerritinEstablished
Serum ferritin
Diseases indicated
Iron deficiency anemia, adult-onset Still's disease, hemophagocytic lymphohistiocytosis, hemochromatosis, Not primarily cancer-associated (though relevant in some hematologic malignancy/HLH-associated cancer workups)
Short description
Ferritin reflects iron stores but also rises dramatically with inflammation, aiding diagnosis of AOSD and HLH.
Clinical significance
Extreme elevation is a key diagnostic clue for rare adult inflammatory syndromes; can mask coexisting iron deficiency.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Factor B Complement AntigenEmerging
Factor B, complement factor B, CFB
Diseases indicated
Atypical hemolytic uremic syndrome, C3 glomerulopathy, Not primarily cancer-associated
Short description
Factor B abnormalities drive alternative complement pathway overactivation in aHUS and C3 glomerulopathy.
Clinical significance
Connects to the earlier C5 complement discussion, since aHUS is now treated with C5-blocking drugs (eculizumab, ravulizumab).
Test methodology
Immunoassay (nephelometry); genetic testing (complement gene panel)
Specimen type
Serum (level); whole blood (genetic)
F5Established
Factor V Leiden, activated protein C resistance
Diseases indicated
Venous thromboembolism, recurrent pregnancy loss (studied association), thrombophilia, Not primarily cancer-associated
Short description
Factor V Leiden is the most common inherited thrombophilia, tested selectively rather than universally.
Clinical significance
Most carriers never develop a clot; testing recommendations have narrowed over time, including in pregnancy management guidance.
Test methodology
Genetic testing (PCR, Factor V Leiden)
Specimen type
Whole blood (EDTA)
F2Established
Prothrombin, prothrombin G20210A mutation
Diseases indicated
Venous thromboembolism, thrombophilia, Not primarily cancer-associated
Short description
F2/prothrombin G20210A is one of five classic inherited thrombophilias, tested selectively rather than universally.
Clinical significance
Current guidelines have moved away from using thrombophilia status to guide anticoagulation duration decisions.
Test methodology
Genetic testing (PCR, prothrombin G20210A)
Specimen type
Whole blood (EDTA)
ESR1Established
ER, estrogen receptor alpha
Diseases indicated
Not primarily disease-indicating outside oncology context, Breast cancer (hormone receptor-positive metastatic disease)
Short description
ESR1 mutations are a major acquired-resistance mechanism in hormone-receptor-positive breast cancer, now a treatment-selection biomarker.
Clinical significance
Directly created a new FDA-approved drug class (oral SERDs) built specifically around this mutation.
Test methodology
Molecular testing (NGS or PCR-based mutation analysis)
Specimen type
Tumor tissue biopsy or plasma (liquid biopsy/ctDNA)
ERBB2Established
HER2, human epidermal growth factor receptor 2, NEU
Diseases indicated
Not primarily disease-indicating outside oncology context, Breast cancer, gastric cancer, gastroesophageal junction cancer
Short description
HER2/ERBB2 overexpression drives aggressive breast cancer but also predicts response to targeted therapy.
Clinical significance
The HER2-low/ultralow reclassification since 2022-2025 has significantly expanded eligible patient populations for targeted treatment.
Test methodology
Immunohistochemistry (IHC); FISH/ISH for gene amplification
Specimen type
Tumor tissue (biopsy)
Epstein-Barr virus capsid antigen antibodyEstablished
EBV VCA antibody, EBV IgM/IgG
Diseases indicated
Infectious mononucleosis, Nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin lymphoma (EBV-associated)
Short description
EBV VCA antibodies help diagnose mononucleosis and support nasopharyngeal carcinoma evaluation in endemic regions.
Clinical significance
IgM versus IgG pattern is essential for correctly timing infection; supportive, not definitive, for cancer diagnosis.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Serum
EPOEstablished
Erythropoietin, EPO hormone
Diseases indicated
Anemia of chronic kidney disease, polycythemia vera, Not primarily cancer-associated (though relevant to some hematologic malignancy workups)
Short description
EPO is a kidney hormone used to distinguish causes of abnormal red blood cell counts and guide CKD anemia treatment.
Clinical significance
Also a well-known blood-doping target, subject to anti-doping regulation in competitive sports.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
EGFREstablished
EGFR, HER1, ErbB1
Diseases indicated
Not primarily disease-indicating outside oncology context, Non-small cell lung cancer
Short description
EGFR mutation status guides TKI therapy selection in lung cancer; the exon 20 insertion subtype is often resistant and can be missed by standard PCR testing.
Clinical significance
Standard PCR-based tests miss up to ~50% of exon 20 insertion variants, a genuine diagnostic gap requiring NGS for reliable detection.
Test methodology
PCR-based mutation testing or next-generation sequencing (NGS) panel
Specimen type
Tumor tissue (FFPE biopsy) or plasma (liquid biopsy/ctDNA)
DNASE1L3Emerging
DNase 1-like 3
Diseases indicated
Systemic lupus erythematosus (monogenic form), lupus nephritis, Not primarily cancer-associated
Short description
DNASE1L3 deficiency (inherited or via autoantibody) impairs DNA clearance, a proposed mechanism generating lupus autoantibodies.
Clinical significance
Connects mechanistically to the anti-dsDNA antibody discussion, offering insight into how these antibodies may arise.
Test methodology
Genetic testing (sequencing); autoantibody ELISA (research)
Specimen type
Whole blood (genetic) or serum (autoantibody)
Des-gamma-carboxy prothrombinEstablished
DCP, PIVKA-II, prothrombin induced by vitamin K absence-II
Diseases indicated
Vitamin K deficiency/antagonist use (non-cancer cause of elevation), Hepatocellular carcinoma
Short description
DCP is a complementary liver cancer marker used alongside AFP within composite scoring systems like GALAD.
Clinical significance
FDA-approved as a risk-stratification aid, but not currently approved for standalone HCC surveillance.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
D-dimerEstablished
D-dimer, fibrin degradation product
Diseases indicated
Deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, Cancer-associated venous thromboembolism (elevated in malignancy)
Short description
D-dimer is a clot-breakdown product used to rule out venous thromboembolism in low-risk patients.
Clinical significance
Requires age-adjusted or pregnancy-specific cutoffs for accurate interpretation in those populations.
Test methodology
Immunoassay (immunoturbidimetric or ELISA)
Specimen type
Plasma (citrate)
Cytosolic Beta-GlucosidaseEmerging
GBA3, cytosolic beta-glucosidase, klotho-related protein
Diseases indicated
No established clinical disease association, Not primarily cancer-associated
Short description
GBA3/cytosolic beta-glucosidase deficiency is a benign polymorphism, distinct from the disease-associated lysosomal GBA enzyme.
Clinical significance
More of a research and pharmacogenomic curiosity than an actionable clinical biomarker at this time.
Test methodology
Enzyme activity assay (research); genetic testing
Specimen type
Leukocytes or whole blood
CST3Established
Cystatin C
Diseases indicated
Chronic kidney disease, Not primarily cancer-associated
Short description
Cystatin C is a kidney function marker now central to the 2021 race-free eGFR equations.
Clinical significance
Reduces bias from muscle-mass dependence seen with creatinine; part of a major 2021 health-equity-driven guideline change.
Test methodology
Immunoassay (nephelometry/turbidimetry, PENIA/PETIA)
Specimen type
Serum
CSF1Emerging
CSF1, M-CSF, macrophage colony-stimulating factor
Diseases indicated
Not primarily disease-indicating outside oncology context, Tenosynovial giant cell tumor
Short description
CSF1 overexpression drives tenosynovial giant cell tumor, now treatable with two different CSF1 receptor inhibitor drugs.
Clinical significance
A 2025 second-generation CSF1R inhibitor (vimseltinib) reflects an actively evolving targeted therapy area.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum (primarily research use)
CRPEstablished
hsCRP, high-sensitivity C-reactive protein
Diseases indicated
Infections, autoimmune disease flares, atherosclerosis, Not primarily cancer-associated (though used in some oncology prognostic scores)
Short description
CRP is a general inflammation marker; its high-sensitivity form is now recommended for cardiovascular risk assessment.
Clinical significance
2025 ACC guidance expands its role in routine cardiovascular prevention alongside lipid testing.
Test methodology
Immunoassay (nephelometry/immunoturbidimetric); high-sensitivity CRP uses a more sensitive immunoturbidimetric method
Specimen type
Serum
CreatinineEstablished
Creatinine, serum creatinine, SCr
Diseases indicated
Chronic kidney disease, acute kidney injury, Not primarily cancer-associated
Short description
Creatinine is the standard kidney function marker, forming the basis of eGFR calculations and AKI diagnostic criteria.
Clinical significance
Muscle-mass dependence is a well-known limitation, addressed by cystatin C-based equations discussed elsewhere in this set.
Test methodology
Enzymatic assay or Jaffe colorimetric assay
Specimen type
Serum or plasma
Creatine KinaseEstablished
CK, CPK, creatine phosphokinase
Diseases indicated
Rhabdomyolysis, statin-associated myopathy, muscular dystrophy, Not primarily cancer-associated
Short description
CK is a muscle injury marker, now mainly used for rhabdomyolysis and statin myopathy rather than heart attack diagnosis.
Clinical significance
CK-MB's cardiac role has been superseded by troponin, which is more sensitive and specific.
Test methodology
Enzyme kinetic activity assay
Specimen type
Serum
CPEstablished
Ceruloplasmin, copper oxidase
Diseases indicated
Wilson's disease, copper deficiency, aceruloplasminemia, Not primarily cancer-associated
Short description
Ceruloplasmin is the first-line screening test for Wilson's disease, a genetic copper-metabolism disorder.
Clinical significance
Requires combination with urinary copper and genetic testing within a formal scoring system; not standalone diagnostic.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
Complement C4Established
C4, C4A, C4B
Diseases indicated
Systemic lupus erythematosus (via deficiency), Not primarily cancer-associated
Short description
C4 deficiency carries one of the strongest known genetic associations with lupus among complement defects.
Clinical significance
Note: this overlaps substantially with the C1q/C2/C3/C5-C9 complement group discussed together elsewhere; consider consolidating on a published site.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
COL9A1Emerging
Collagen type IX alpha 1
Diseases indicated
Multiple epiphyseal dysplasia, intervertebral disc degeneration (research association), Not primarily cancer-associated
Short description
COL9A1 mutations cause multiple epiphyseal dysplasia, a skeletal cartilage growth disorder, diagnosed via genetic testing.
Clinical significance
More of a genetic/research marker than a routine clinical blood test; disc degeneration link remains investigational.
Test methodology
Genetic testing (gene sequencing)
Specimen type
Whole blood (EDTA)
Coagulation Factor XIIEstablished
FXII, Hageman factor
Diseases indicated
Factor XII deficiency (asymptomatic), hereditary angioedema type III, Not primarily cancer-associated
Short description
Factor XII deficiency prolongs lab clotting tests without causing actual bleeding risk.
Clinical significance
An important diagnostic pitfall: prolonged aPTT from this cause should not be mistaken for a bleeding disorder.
Test methodology
Functional clotting assay (one-stage, aPTT-based)
Specimen type
Plasma (citrate)
Coagulation Factor XIEstablished
FXI, plasma thromboplastin antecedent
Diseases indicated
Hereditary Factor XI deficiency, Not primarily cancer-associated
Short description
Factor XI deficiency is a mild bleeding disorder; factor XI inhibitor drugs are a major, still-unsettled anticoagulant research area.
Clinical significance
One of the most actively-evolving areas in current cardiology/hematology drug development, with mixed trial results through 2026.
Test methodology
Functional clotting assay (one-stage, aPTT-based)
Specimen type
Plasma (citrate)
Coagulation Factor XEstablished
FX, Stuart-Prower factor
Diseases indicated
Hereditary Factor X deficiency, AL amyloidosis (acquired form), Not primarily cancer-associated (amyloidosis is a plasma cell disorder)
Short description
Factor X deficiency can be hereditary or acquired via AL amyloidosis, where amyloid fibrils sequester the factor.
Clinical significance
Low factor X in an unexplained bleeding patient can be a diagnostic clue pointing toward amyloidosis.
Test methodology
Functional clotting assay (one-stage or chromogenic)
Specimen type
Plasma (citrate)
Coagulation Factor VIIIEstablished
FVIII, antihemophilic factor
Diseases indicated
Hemophilia A, Not primarily cancer-associated
Short description
Factor VIII deficiency causes Hemophilia A; treatment has shifted toward non-factor replacement therapies.
Clinical significance
Emicizumab and newer agents have transformed treatment convenience; lab testing requires specialized assays in these patients.
Test methodology
Functional clotting assay (one-stage, aPTT-based) or chromogenic assay
Specimen type
Plasma (citrate)
Coagulation Factor VIIEstablished
FVII, proconvertin
Diseases indicated
Factor VII deficiency, Not primarily cancer-associated
Short description
Factor VII deficiency is a rare bleeding disorder diagnosed by prolonged PT with normal aPTT.
Clinical significance
Its approved therapy (rFVIIa) is used far more often off-label for other bleeding emergencies than for its labeled indication.
Test methodology
Functional clotting assay (one-stage, PT-based)
Specimen type
Plasma (citrate)
Coagulation Factor IXEstablished
FIX, Christmas factor
Diseases indicated
Hemophilia B, Not primarily cancer-associated
Short description
Factor IX deficiency causes Hemophilia B; treatment options have expanded dramatically since 2024.
Clinical significance
Multiple new gene therapies and non-factor drugs approved 2024-2025, though not all remain commercially available.
Test methodology
Functional clotting assay (one-stage, aPTT-based)
Specimen type
Plasma (citrate)
Cluster of Differentiation 163Emerging
sCD163, soluble CD163, macrophage scavenger receptor
Diseases indicated
Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, chronic liver disease, Not primarily cancer-associated
Short description
CD163 is a macrophage activation marker studied as a complementary test for hyperinflammatory syndromes and liver disease.
Clinical significance
Part of an evolving, still-developing diagnostic panel rather than a universally standardized clinical test at this time.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
Clostridium difficile glutamate dehydrogenaseEstablished
GDH, C. diff GDH antigen
Diseases indicated
Clostridioides difficile infection, pseudomembranous colitis, Not primarily cancer-associated
Short description
GDH is a sensitive but nonspecific screening step in multistep C. difficile testing algorithms.
Clinical significance
Excellent negative predictive value; positive results require confirmatory toxin or molecular testing.
Test methodology
Immunoassay (EIA)
Specimen type
Stool
ChymotrypsinEstablished
Fecal chymotrypsin
Diseases indicated
Pancreatic exocrine insufficiency, chronic pancreatitis, cystic fibrosis, Not primarily cancer-associated
Short description
Chymotrypsin is a stool-based pancreatic function marker, now largely superseded by fecal elastase-1.
Clinical significance
An older test whose modern equivalent (fecal elastase-1) is now generally preferred in practice.
Test methodology
Enzyme colorimetric activity assay
Specimen type
Stool
CHGAEstablished
CgA, chromogranin A
Diseases indicated
Atrophic gastritis (false-positive cause), Neuroendocrine tumors, carcinoid tumors, pancreatic neuroendocrine tumors, pheochromocytoma
Short description
CgA is the most widely used general biomarker for neuroendocrine tumors, though prone to false elevation.
Clinical significance
Real risk of false-positive elevation from proton pump inhibitors and other benign conditions.
Test methodology
Immunoassay (ELISA/RIA)
Specimen type
Plasma (EDTA, fasting, preferred over serum)
Chemokine interferon inducible protein 10Emerging
CXCL10, IP-10, interferon gamma-induced protein 10
Diseases indicated
Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, Relevant to CAR-T cell therapy-related toxicity monitoring in oncology
Short description
CXCL10, alongside CXCL9, supports HLH/MAS diagnosis as part of the interferon-gamma-driven inflammatory marker panel.
Clinical significance
Part of an actively evolving, more sophisticated cytokine panel approach to diagnosing hyperinflammatory syndromes.
Test methodology
Immunoassay (ELISA/multiplex bead assay)
Specimen type
Serum or plasma
CGB3Established
Beta-hCG, human chorionic gonadotropin beta subunit
Diseases indicated
Gestational trophoblastic disease, molar pregnancy, Choriocarcinoma, testicular germ cell tumor, ovarian germ cell tumor
Short description
Beta-hCG is a tumor marker for germ cell tumors and gestational trophoblastic disease, paired with AFP for staging.
Clinical significance
Serial monitoring confirms chemotherapy response; failure to decline as expected signals treatment resistance.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Carcinoembryonic antigenEstablished
CEA, carcinoembryonic antigen
Diseases indicated
Not primarily disease-indicating outside oncology context, Colorectal cancer, appendiceal cancer, pancreatic cancer, biliary tract cancer, medullary thyroid carcinoma, non-small cell lung cancer
Short description
CEA is a standard tumor marker for colorectal cancer surveillance, always used alongside imaging and colonoscopy.
Clinical significance
Surveillance compliance for CEA testing is consistently lower than for imaging or colonoscopy in real-world adherence studies.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
Carbohydrate Antigen 19-9Established
CA 19-9, sialyl Lewis A antigen
Diseases indicated
Chronic pancreatitis, biliary obstruction (false-positive causes), Pancreatic cancer, biliary tract cancer, colorectal cancer
Short description
CA 19-9 is the best-validated pancreatic cancer marker, but is falsely low/undetectable in Lewis-antigen-negative patients.
Clinical significance
A genuine false-negative trap exists in 5-10% of the population due to Lewis blood group status.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Carbohydrate Antigen 125Established
CA-125, cancer antigen 125, MUC16
Diseases indicated
Endometriosis, pelvic inflammatory disease (false-positive causes), Ovarian cancer, uterine/endometrial cancer
Short description
CA-125 is the standard blood test for ovarian cancer monitoring, though not specific enough for standalone diagnosis.
Clinical significance
Best used for treatment response and recurrence monitoring, not as a standalone screening or diagnostic test.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
CALCAEstablished
Calcitonin, thyrocalcitonin
Diseases indicated
C-cell hyperplasia, hypercalcemia disorders (calcium regulation), Medullary thyroid carcinoma
Short description
Calcitonin is the primary tumor marker for medullary thyroid carcinoma, guiding surgery and recurrence monitoring.
Clinical significance
Highly sensitive and specific for MTC; intermediate elevations require additional testing to distinguish cancer from benign hyperplasia.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum or plasma
C9Established
Complement component 9
Diseases indicated
Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated
Short description
C9 completes the membrane attack complex; deficiency causes a generally milder Neisseria susceptibility pattern.
Clinical significance
Notably more prevalent in some Asian populations; part of the shared terminal complement deficiency group.
Test methodology
Immunoassay (nephelometry); functional assay (CH50/AH50)
Specimen type
Serum
C8Established
Complement component 8
Diseases indicated
Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated
Short description
C8 is a terminal complement component; deficiency causes selective Neisseria infection susceptibility.
Clinical significance
Part of the shared C5-C9 terminal pathway deficiency syndrome.
Test methodology
Immunoassay (nephelometry); functional assay (CH50/AH50)
Specimen type
Serum
C7Established
Complement component 7
Diseases indicated
Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated
Short description
C7 is a terminal complement/MAC component; deficiency causes selective Neisseria infection susceptibility.
Clinical significance
Part of the shared C5-C9 terminal pathway deficiency syndrome.
Test methodology
Immunoassay (nephelometry); functional assay (CH50/AH50)
Specimen type
Serum
C6 ComplementEstablished
Complement component 6
Diseases indicated
Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated
Short description
C6 is a membrane attack complex component; deficiency causes recurrent Neisseria infections, sometimes atypical serotypes.
Clinical significance
Terminal pathway deficiency pattern shared with C5, C7, C8, and C9.
Test methodology
Immunoassay (nephelometry); functional assay (CH50/AH50)
Specimen type
Serum
C5 ComplementEstablished
Complement component 5
Diseases indicated
Recurrent Neisseria infections (via deficiency), Not primarily cancer-associated
Short description
C5 initiates the terminal complement pathway; its deficiency causes selective susceptibility to Neisseria infections.
Clinical significance
Also a therapeutic drug target (eculizumab) in unrelated complement-mediated diseases.
Test methodology
Immunoassay (nephelometry); functional assay (CH50/AH50)
Specimen type
Serum
C3Established
Complement component 3
Diseases indicated
Recurrent severe bacterial infections (via deficiency), Not primarily cancer-associated
Short description
C3 is the central complement protein whose deficiency causes severe recurrent bacterial infections.
Clinical significance
Central convergence point of all complement pathways; deficiency carries the highest infection-related mortality risk among complement defects.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
C2Established
Complement component 2
Diseases indicated
Systemic lupus erythematosus (via deficiency), recurrent bacterial infections, Not primarily cancer-associated
Short description
C2 is an early classical-pathway complement protein; its deficiency is the most common inherited complement defect.
Clinical significance
Follows the early-complement pattern of increased both infection risk and autoimmune (lupus) risk.
Test methodology
Immunoassay (nephelometry); functional assay (CH50)
Specimen type
Serum
C1q ComplementEstablished
C1q, Complement C1
Diseases indicated
Systemic lupus erythematosus (via deficiency), Not primarily cancer-associated
Short description
C1q is the first classical-pathway complement component; its deficiency carries a very high lupus risk.
Clinical significance
Roughly 90%+ of C1q-deficient patients develop SLE, one of the strongest known genetic lupus risk factors.
Test methodology
Immunoassay (nephelometry); functional assay (CH50)
Specimen type
Serum
C-X-C Motif Chemokine 9Emerging
CXCL9, MIG, monokine induced by gamma interferon
Diseases indicated
Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, Relevant to CAR-T cell therapy-related toxicity monitoring in oncology
Short description
CXCL9 supports HLH/MAS diagnosis as part of an interferon-gamma-driven inflammatory marker panel, alongside CXCL10 and IL-18.
Clinical significance
The IL-18/CXCL9 ratio specifically improves diagnostic accuracy for distinguishing HLH/MAS from other causes of cytokine storm.
Test methodology
Immunoassay (ELISA/multiplex bead assay)
Specimen type
Serum or plasma
C-terminal telopeptideEstablished
CTX, CTx, collagen telopeptide, crosslaps
Diseases indicated
Osteoporosis, medication-related osteonecrosis of the jaw, Bone metastases (as part of broader bone turnover assessment)
Short description
CTX is a bone resorption marker used to monitor osteoporosis treatment and estimate jaw osteonecrosis risk.
Clinical significance
Its use for predicting individual osteonecrosis risk before dental surgery remains scientifically debated.
Test methodology
Immunoassay (ECLIA/ELISA)
Specimen type
Serum
BRCA2Established
BRCA2, breast cancer gene 2, FANCD1
Diseases indicated
Hereditary breast and ovarian cancer syndrome, Fanconi anemia (biallelic inheritance), Breast cancer, ovarian cancer, pancreatic cancer, prostate cancer
Short description
BRCA2 germline mutations confer hereditary cancer risk across multiple organs and determine PARP inhibitor treatment eligibility.
Clinical significance
Biallelic (two-copy) inheritance causes Fanconi anemia, an important reproductive counseling consideration distinct from BRCA1.
Test methodology
Germline genetic testing (sequencing, blood or saliva); somatic tumor testing for treatment eligibility
Specimen type
Whole blood or saliva (germline); tumor tissue biopsy (somatic)
BRCA1Established
BRCA1, breast cancer gene 1
Diseases indicated
Hereditary breast and ovarian cancer syndrome, Breast cancer, ovarian cancer, pancreatic cancer, prostate cancer
Short description
BRCA1 germline mutations confer major hereditary breast/ovarian cancer risk and determine PARP inhibitor treatment eligibility.
Clinical significance
Testing criteria have broadened well beyond family history alone, especially in metastatic prostate cancer.
Test methodology
Germline genetic testing (sequencing, blood or saliva); somatic tumor testing for treatment eligibility
Specimen type
Whole blood or saliva (germline); tumor tissue biopsy (somatic)
Brain natriuretic peptideEstablished
BNP, NT-proBNP, B-type natriuretic peptide
Diseases indicated
Heart failure, Not primarily cancer-associated
Short description
BNP/NT-proBNP is the primary blood marker for diagnosing and staging heart failure.
Clinical significance
Widely used cutoffs may need age- and BMI-adjustment for optimal accuracy per current research.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Plasma (EDTA)
BRAFEstablished
BRAF, BRAF V600E, B-Raf
Diseases indicated
Not primarily disease-indicating outside oncology context, Melanoma, papillary/anaplastic thyroid carcinoma, colorectal cancer, non-small cell lung cancer, hairy cell leukemia
Short description
BRAF V600E drives multiple cancers via MAPK pathway activation, with opposite prognostic meaning in melanoma versus colorectal/thyroid cancer.
Clinical significance
Effectively universal in hairy cell leukemia, connecting to the historical TRAP/ACP5 diagnostic marker discussed elsewhere in this set.
Test methodology
PCR-based mutation testing, NGS panel, or immunohistochemistry (VE1 clone)
Specimen type
Tumor tissue (FFPE biopsy); plasma (liquid biopsy/ctDNA) increasingly used
BiotinidaseEstablished
BTD enzyme
Diseases indicated
Biotinidase deficiency, Not primarily cancer-associated
Short description
Biotinidase is an enzyme whose deficiency is detected via newborn screening and treated with biotin supplements.
Clinical significance
Standard component of newborn screening panels; excellent prognosis when treated before symptom onset.
Test methodology
Enzyme colorimetric activity assay
Specimen type
Dried blood spot (newborn screening) or serum
BGLAPEstablished
Osteocalcin, bone gamma-carboxyglutamic acid protein, BGP
Diseases indicated
Osteoporosis, Paget's disease of bone, vitamin K deficiency, Bone metastases (as part of broader bone turnover assessment)
Short description
BGLAP encodes osteocalcin, a bone-formation marker used to monitor osteoporosis treatment.
Clinical significance
A standard bone formation marker, often paired with a resorption marker like CTX for bisphosphonate monitoring.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Serum
Beta-GlucuronidaseEmerging
GUSB, beta-glucuronidase, Sly syndrome enzyme
Diseases indicated
Mucopolysaccharidosis type VII (Sly syndrome), Not primarily cancer-associated
Short description
Beta-glucuronidase (GUSB) deficiency causes Sly syndrome (MPS VII), now treatable with a 2017 FDA-approved enzyme replacement therapy.
Clinical significance
Follows the same enzyme replacement therapy model as other lysosomal storage disorders discussed in this biomarker set.
Test methodology
Enzyme fluorometric activity assay
Specimen type
Leukocytes or cultured fibroblasts
Beta-GalactosidaseEmerging
GLB1, beta-gal, acid beta-galactosidase
Diseases indicated
GM1 gangliosidosis, Morquio syndrome type B (mucopolysaccharidosis IVB), Not primarily cancer-associated
Short description
Beta-galactosidase (GLB1) deficiency causes GM1 gangliosidosis and Morquio syndrome type B, both rare lysosomal storage disorders.
Clinical significance
No approved enzyme replacement therapy yet exists, though gene therapy research is an active area for GM1 gangliosidosis.
Test methodology
Enzyme fluorometric activity assay
Specimen type
Leukocytes or cultured fibroblasts
BCR-ABL1Established
BCR-ABL1, Philadelphia chromosome, BCR::ABL1
Diseases indicated
Not primarily disease-indicating outside oncology context, Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia
Short description
BCR-ABL1 transcript monitoring (International Scale) is the standard for tracking CML treatment response and TKI discontinuation eligibility.
Clinical significance
Deep molecular response now allows roughly half of eligible CML patients to successfully stop lifelong TKI therapy (treatment-free remission).
Test methodology
Quantitative reverse-transcription PCR (RT-qPCR), standardized to the International Scale (IS); digital PCR increasingly used for higher sensitivity
Specimen type
Peripheral blood or bone marrow (whole blood, EDTA)
BCHEEstablished
Pseudocholinesterase, plasma cholinesterase
Diseases indicated
Pseudocholinesterase deficiency, prolonged succinylcholine apnea, Not primarily cancer-associated
Short description
BCHE is a plasma enzyme whose deficiency causes prolonged paralysis after certain anesthesia drugs.
Clinical significance
One of the earliest-known pharmacogenomic drug-gene interactions; genetic testing remains underutilized.
Test methodology
Enzyme kinetic activity assay; genetic testing for variant alleles
Specimen type
Serum or plasma
B2MEstablished
Beta-2-microglobulin, β2M
Diseases indicated
Kidney dysfunction, chronic inflammation, Multiple myeloma, chronic lymphocytic leukemia, lymphoma
Short description
B2M is a cell-surface protein used as a key prognostic marker in multiple myeloma staging.
Clinical significance
Core component of the International Staging System (ISS) for multiple myeloma.
Test methodology
Immunoassay (CLIA/ELISA)
Specimen type
Serum or urine
AVPEmerging
AVP, antidiuretic hormone, vasopressin, copeptin (surrogate marker)
Diseases indicated
Diabetes insipidus, SIADH (syndrome of inappropriate antidiuretic hormone secretion), Ectopic AVP/SIADH production (small cell lung cancer and other tumors)
Short description
AVP regulates water balance; copeptin, a more stable related marker, is now preferred for diagnosing water-balance disorders.
Clinical significance
A copeptin-based diagnostic protocol increasingly replaces the older, more burdensome water deprivation test.
Test methodology
Immunoassay (RIA) for AVP; immunoassay for copeptin surrogate
Specimen type
Plasma (EDTA, on ice)
ASTEstablished
Aspartate transaminase, SGOT, GOT1 (gene symbol)
Diseases indicated
Hepatitis, alcoholic liver disease, MASLD/NAFLD, liver fibrosis, Hepatocellular carcinoma (as component of broader liver assessment)
Short description
AST is a liver enzyme now mainly interpreted as part of the FIB-4 fibrosis risk score rather than alone.
Clinical significance
A core input into FIB-4, the first-line noninvasive liver fibrosis assessment recommended by major hepatology societies.
Test methodology
Enzyme kinetic (colorimetric) activity assay
Specimen type
Serum
APOEEmerging
ApoE, APOE genotype (ε2/ε3/ε4)
Diseases indicated
Alzheimer's disease, cardiovascular disease (lipid metabolism), Relevant to cognitive effects following cancer therapy in some research contexts
Short description
APOE ε4 is the strongest common genetic risk factor for Alzheimer's disease and now informs anti-amyloid therapy safety monitoring.
Clinical significance
Genotyping before anti-amyloid antibody treatment helps identify patients at higher risk of ARIA (a treatment side effect).
Test methodology
Genetic testing (genotyping, PCR)
Specimen type
Whole blood (EDTA)
APOBEmerging
ApoB, Apo B-100
Diseases indicated
Atherosclerotic cardiovascular disease, dyslipidemia, metabolic syndrome, Not primarily cancer-associated
Short description
ApoB directly counts atherogenic lipoprotein particles, now considered a superior cardiovascular risk marker to LDL-C in many patients.
Clinical significance
A major, very current (2025) cardiology guideline shift toward ApoB as a primary or co-primary lipid target.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
APOA1Emerging
Apo A-I, ApoA1
Diseases indicated
Cardiovascular disease, dyslipidemia, Breast cancer, gastric cancer, pancreatic cancer, hepatocellular carcinoma (prognostic research context)
Short description
APOA1 is the main HDL protein; low levels are linked to cardiovascular risk and, in research, worse cancer prognosis.
Clinical significance
An active but still largely investigational research marker in oncology prognosis, beyond its established cardiovascular role.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
Antineutrophil cytoplasmic antibodies against proteinase 3Emerging
PR3-ANCA, c-ANCA (cytoplasmic pattern), anti-proteinase 3 antibody
Diseases indicated
Granulomatosis with polyangiitis, Not primarily cancer-associated
Short description
PR3-ANCA is more specifically associated with granulomatosis with polyangiitis than the MPO-ANCA/p-ANCA pattern.
Clinical significance
Current best practice favors antigen-specific (PR3 vs. MPO) testing over immunofluorescence pattern alone for clinical correlation.
Test methodology
Antigen-specific immunoassay (ELISA)
Specimen type
Serum
Antineutrophil cytoplasmic antibodiesEstablished
ANCA, MPO-ANCA, PR3-ANCA
Diseases indicated
Granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, Not primarily cancer-associated
Short description
ANCA is the key serologic marker for a group of small-vessel vasculitis diseases.
Clinical significance
Present in ~90% of AAV cases; guides urgent treatment decisions per current 2024/2025 KDIGO guidelines.
Test methodology
Indirect immunofluorescence; antigen-specific immunoassay (ELISA)
Specimen type
Serum
Antimitochondrial antibodiesEstablished
AMA, AMA-M2, anti-PDC-E2 antibody
Diseases indicated
Primary biliary cholangitis, Not primarily cancer-associated
Short description
AMA is the hallmark diagnostic antibody for primary biliary cholangitis, a chronic liver disease.
Clinical significance
Highly specific for PBC; apparent AMA-negative cases often resolve as positive with more sensitive testing.
Test methodology
Indirect immunofluorescence; immunoassay (ELISA) for AMA-M2
Specimen type
Serum
Anticardiolipin antibodyEstablished
Anticardiolipin antibody, aCL
Diseases indicated
Antiphospholipid syndrome, Not primarily cancer-associated
Short description
Anticardiolipin antibody is one of three tests used together to classify antiphospholipid syndrome.
Clinical significance
Requires a qualifying clinical thrombotic or pregnancy event alongside positive serology for diagnosis.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Anti-TPO antibodyEstablished
Anti-TPO, TPOAb, thyroid peroxidase antibody
Diseases indicated
Hashimoto's thyroiditis, Graves' disease, postpartum thyroiditis, Not primarily cancer-associated
Short description
Anti-TPO is the most common autoimmune thyroid disease marker, found in both Hashimoto's and Graves' disease.
Clinical significance
Present in 10-15% of the general population without disease; positivity in pregnancy warrants closer postpartum thyroid monitoring.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Anti-Streptolysin antibodiesEstablished
ASO, antistreptolysin O titer
Diseases indicated
Rheumatic fever, post-streptococcal glomerulonephritis, Not primarily cancer-associated
Short description
ASO is an antibody marker of recent strep infection, supporting (not confirming) rheumatic fever diagnosis.
Clinical significance
Supportive evidence within the Jones criteria; roughly 15-20% of true rheumatic fever cases show no ASO rise.
Test methodology
Nephelometric/turbidimetric immunoassay
Specimen type
Serum
Anti-Smith AntibodiesEstablished
Anti-Sm, anti-Smith antibody
Diseases indicated
Systemic lupus erythematosus, Not primarily cancer-associated
Short description
Anti-Sm is a highly specific but insensitive autoantibody marker for lupus.
Clinical significance
One of two SLE-specific serologic markers in current classification criteria (with anti-dsDNA).
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Anti-Scl-70Established
Anti-Scl-70, anti-topoisomerase I antibody
Diseases indicated
Diffuse cutaneous systemic sclerosis, interstitial lung disease, Not primarily cancer-associated
Short description
Anti-Scl-70 is a specific marker for diffuse systemic sclerosis, associated with higher interstitial lung disease risk.
Clinical significance
Positivity prompts closer pulmonary surveillance given the strong association with lung involvement and mortality risk.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Anti-ribosomal P antibodiesEstablished
Anti-Rib-P, anti-P antibody
Diseases indicated
Systemic lupus erythematosus, neuropsychiatric lupus, Not primarily cancer-associated
Short description
Anti-Rib-P is a specific but insensitive marker for neuropsychiatric lupus, especially psychosis.
Clinical significance
No standardized assay exists; prevalence and clinical association vary notably by ethnicity.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Anti-Jo-1Established
Anti-Jo-1, anti-histidyl-tRNA synthetase antibody
Diseases indicated
Antisynthetase syndrome, polymyositis/dermatomyositis, interstitial lung disease, Not primarily cancer-associated
Short description
Anti-Jo-1 is the most common antisynthetase antibody, defining antisynthetase syndrome (myositis plus interstitial lung disease).
Clinical significance
Interstitial lung disease, not muscle weakness, is usually the primary driver of long-term prognosis in this syndrome.
Test methodology
Immunoassay (ELISA) or line blot, typically as part of a myositis-specific antibody panel
Specimen type
Serum
Anti-gliadin antibody IgGEstablished
AGA IgG, anti-gliadin IgG
Diseases indicated
Celiac disease (historical marker), Not primarily cancer-associated
Short description
Anti-gliadin IgG is an outdated celiac marker, superseded by deamidated gliadin peptide (DGP) IgG testing.
Clinical significance
Considered low-accuracy by current guidelines; DGP-IgG is the modern equivalent for IgA-deficient patients.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Anti-gliadin antibody IgAEstablished
AGA IgA, anti-gliadin IgA
Diseases indicated
Celiac disease (historical marker), Not primarily cancer-associated
Short description
Anti-gliadin IgA is an outdated celiac disease marker superseded by tTG-IgA testing.
Clinical significance
Low diagnostic accuracy per current guidelines; should not be used as a stand-alone celiac test today.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
Anti-double stranded DNA antibodiesEstablished
Anti-dsDNA, native DNA antibody
Diseases indicated
Systemic lupus erythematosus, lupus nephritis, Not primarily cancer-associated
Short description
Anti-dsDNA is a specific lupus marker often tracking disease activity, especially renal involvement.
Clinical significance
Reliability depends on assay specificity; used both diagnostically and to monitor lupus nephritis flares.
Test methodology
Immunoassay (ELISA); indirect immunofluorescence (Crithidia luciliae)
Specimen type
Serum
Anti-Dengue virus antibodyEmerging
Anti-dengue IgM, anti-dengue IgG, dengue serology
Diseases indicated
Dengue fever, severe dengue (dengue hemorrhagic fever/dengue shock syndrome), Not primarily cancer-associated
Short description
Combined NS1 antigen and IgM testing, correctly timed, is the current recommended approach for acute dengue diagnosis.
Clinical significance
Single-specimen IgG testing is explicitly discouraged due to inability to distinguish current from past infection and flavivirus cross-reactivity.
Test methodology
Immunoassay (ELISA); rapid immunochromatographic test
Specimen type
Serum
Anti-cyclic Citrullinated PeptideEstablished
Anti-CCP, ACPA, anti-citrullinated protein antibody
Diseases indicated
Rheumatoid arthritis, Not primarily cancer-associated
Short description
Anti-CCP is the most specific serologic marker for rheumatoid arthritis, useful for diagnosis, not monitoring.
Clinical significance
Can predate clinical RA onset by years; combined with RF in current classification criteria.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Serum
Anti-centromere antibodyEstablished
ACA, anti-centromere antibody, CREST antibody
Diseases indicated
Limited cutaneous systemic sclerosis (CREST syndrome), pulmonary arterial hypertension, Not primarily cancer-associated
Short description
Anti-centromere antibody is the classic marker for limited systemic sclerosis (CREST syndrome).
Clinical significance
Predicts pulmonary arterial hypertension risk specifically, a genuinely different complication profile than anti-Scl-70-positive disease.
Test methodology
Indirect immunofluorescence (centromere pattern) or antigen-specific immunoassay
Specimen type
Serum
Anti-beta2 glycoprotein1Established
Anti-β2GP1, anti-beta-2-glycoprotein I antibody
Diseases indicated
Antiphospholipid syndrome, recurrent pregnancy loss, Not primarily cancer-associated
Short description
Anti-β2GP1 is one of three antibodies used to classify antiphospholipid syndrome.
Clinical significance
Part of the 2023-revised APS classification criteria; requires a clinical event to establish diagnosis.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum or plasma
Anti-acetylcholine receptor antibodyEstablished
Anti-AChR antibody, AChR-Ab
Diseases indicated
Myasthenia gravis, Thymoma (associated with AChR-antibody-positive MG)
Short description
Anti-AChR antibody is the primary diagnostic marker for myasthenia gravis.
Clinical significance
Confirms diagnosis in ~80% of generalized MG; titer level does not reliably track disease severity.
Test methodology
Immunoassay (RIA); cell-based assay
Specimen type
Serum
Angiotensin IEmerging
Angiotensin I, Ang I
Diseases indicated
Hypertension (pathway context), Not primarily cancer-associated
Short description
Angiotensin I is the inactive precursor in the renin-angiotensin pathway, the conceptual basis for two major blood pressure drug classes.
Clinical significance
Not directly measured clinically; its relevance is entirely as an intermediate step connecting renin and ACE activity.
Test methodology
Immunoassay (RIA)
Specimen type
Plasma (EDTA, rarely measured directly)
Amyloid Beta42Emerging
A-beta 42, amyloid-beta 1-42
Diseases indicated
Alzheimer's disease, mild cognitive impairment, Not primarily cancer-associated
Short description
The Aβ42/Aβ40 ratio is central to modern Alzheimer's diagnosis and now gatekeeps eligibility for anti-amyloid antibody treatment.
Clinical significance
A rapidly evolving area given very recent (2024-2025) diagnostic criteria updates and new FDA-approved blood tests.
Test methodology
Immunoassay (CLIA/Simoa); mass spectrometry (LC-MS/MS)
Specimen type
CSF or plasma
AmylaseEstablished
Serum amylase, pancreatic amylase (isoenzyme)
Diseases indicated
Acute pancreatitis, salivary gland disorders, bowel obstruction, Not primarily cancer-associated
Short description
Amylase is a pancreatic/salivary enzyme historically used to diagnose pancreatitis, now superseded by lipase.
Clinical significance
Largely replaced by lipase in current pancreatitis diagnostic guidelines due to lower specificity.
Test methodology
Enzyme kinetic (colorimetric) activity assay
Specimen type
Serum
Aminolevulinic Acid DehydrataseEmerging
ALAD, delta-ALAD, porphobilinogen synthase
Diseases indicated
ALAD-deficiency porphyria (rare), lead poisoning/toxicity, Not primarily cancer-associated
Short description
ALAD is the most sensitive biological indicator of lead exposure, beyond its rare role in ALAD-deficiency porphyria.
Clinical significance
Genetic ALAD variants (ALAD1/ALAD2) influence individual susceptibility to lead toxicity, an active environmental health research area.
Test methodology
Enzyme kinetic activity assay; genotyping (ALAD1/ALAD2)
Specimen type
Whole blood (erythrocytes)
AMHEstablished
Anti-Mullerian hormone, Mullerian inhibiting substance
Diseases indicated
Diminished ovarian reserve, premature ovarian insufficiency, polycystic ovary syndrome, Granulosa cell tumor of the ovary
Short description
AMH is a reproductive hormone used to assess ovarian reserve and diagnose/monitor granulosa cell tumors.
Clinical significance
High diagnostic accuracy for granulosa cell tumor; preferred marker for ovarian reserve assessment.
Test methodology
Immunoassay (ELISA/CLIA)
Specimen type
Serum
ALPLEstablished
AP-TNAP, TNSALP, tissue-nonspecific alkaline phosphatase
Diseases indicated
Hypophosphatasia (genetic bone disease), bone mineralization disorders, Breast cancer, colorectal cancer (reduced ALPL linked to progression)
Short description
ALPL encodes an enzyme whose reduced levels indicate tumor aggressiveness in breast cancer, and whose mutations cause a distinct genetic bone disease.
Clinical significance
Reduced ALPL is linked to cancer progression and metastasis; also the causal gene in hypophosphatasia.
Test methodology
Enzyme kinetic activity assay (serum ALP); genetic testing for hypophosphatasia
Specimen type
Serum (enzyme); whole blood (genetic)
Alpha-GalactosidaseEstablished
Alpha-Gal A, GLA enzyme
Diseases indicated
Fabry disease, Not primarily cancer-associated
Short description
Alpha-galactosidase deficiency is diagnostic for Fabry disease, a lysosomal storage disorder.
Clinical significance
Diagnostic in affected males; unreliable in female carriers, who require genetic testing instead.
Test methodology
Enzyme fluorometric activity assay
Specimen type
Dried blood spot or plasma/leukocytes
Alpha-2-MacroglobulinEmerging
Alpha-2-macroglobulin, A2M
Diseases indicated
Chronic hepatitis, liver fibrosis, Not primarily cancer-associated
Short description
Alpha-2-macroglobulin is a component of the FibroTest composite panel, a noninvasive alternative to liver biopsy for fibrosis staging.
Clinical significance
Works alongside several other markers (haptoglobin, bilirubin, GGT, ApoA1) as part of a combined fibrosis risk score.
Test methodology
Immunoassay (nephelometry/turbidimetry)
Specimen type
Serum
Alkaline PhosphataseEstablished
ALP, ALKP
Diseases indicated
Paget's disease of bone, biliary obstruction, cholestasis, hyperparathyroidism, osteomalacia, Bone metastases, primary or metastatic liver tumors
Short description
ALP is a general enzyme marker for liver/biliary disease or increased bone turnover.
Clinical significance
Nonspecific but widely used; source (bone vs. liver) must be clarified with additional testing.
Test methodology
Enzyme kinetic (colorimetric) activity assay
Specimen type
Serum
ALKEstablished
ALK, ALK rearrangement, EML4-ALK fusion
Diseases indicated
Not primarily disease-indicating outside oncology context, Non-small cell lung cancer, anaplastic large cell lymphoma, neuroblastoma
Short description
ALK gene rearrangements define a distinct, highly drug-responsive lung cancer subtype, generally mutually exclusive with other driver mutations.
Clinical significance
Sequential ALK inhibitor generations have progressively improved control of brain metastases, a common site of disease progression.
Test methodology
Fluorescence in situ hybridization (FISH), immunohistochemistry, or next-generation sequencing (NGS) panel
Specimen type
Tumor tissue (FFPE biopsy)
ALDOBEmerging
Aldolase B, HFI enzyme
Diseases indicated
Hereditary fructose intolerance, Not primarily cancer-associated
Short description
ALDOB deficiency causes hereditary fructose intolerance, now diagnosed via genetic testing rather than a provocative fructose challenge.
Clinical significance
Represents a broader trend across metabolic disorders toward genetic confirmation over risky provocative testing.
Test methodology
Genetic testing (gene sequencing)
Specimen type
Whole blood (EDTA)
ALDEmerging
ALD, ALDP, ABCD1, X-linked adrenoleukodystrophy, X-ALD
Diseases indicated
X-linked adrenoleukodystrophy, Addison's disease (adrenal insufficiency), cerebral ALD, Not primarily cancer-associated
Short description
ALD/ABCD1 encodes a peroxisomal fatty acid transporter; its deficiency causes X-linked adrenoleukodystrophy.
Clinical significance
Newborn screening (C26:0-LPC) now covers most US states, enabling time-critical early treatment before irreversible cerebral disease develops.
Test methodology
Newborn screening biomarker assay (C26:0-LPC, tandem mass spectrometry); VLCFA profiling; genetic testing (ABCD1 sequencing) for confirmation
Specimen type
Dried blood spot (newborn screening) or plasma (VLCFA); whole blood (genetic)
ALBEstablished
Serum albumin
Diseases indicated
Malnutrition, liver disease, nephrotic syndrome, protein-losing enteropathy, Multiple myeloma (ISS staging component), general oncology prognostication
Short description
Albumin is a liver-made blood protein whose low levels signal poor nutrition, liver disease, or severe illness.
Clinical significance
A broad, independent prognostic marker across many diseases, not just liver or kidney disorders.
Test methodology
Colorimetric dye-binding assay (bromocresol green/purple)
Specimen type
Serum
AFPEstablished
Alpha-1-fetoprotein, alpha-fetoglobulin, FETA
Diseases indicated
Hepatocellular carcinoma, germ cell tumors, Hepatocellular carcinoma, testicular germ cell tumor, ovarian germ cell tumor, cholangiocarcinoma, pancreatic cancer
Short description
AFP is a fetal plasma protein used as a biomarker for liver and germ cell tumors.
Clinical significance
Elevated in hepatocellular carcinoma and testicular/ovarian germ cell tumors; core to HCC surveillance guidelines.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Serum
Adenylate kinase enzymeEmerging
AK1, adenylate kinase 1
Diseases indicated
Hereditary hemolytic anemia (AK1 deficiency), Not primarily cancer-associated
Short description
Adenylate kinase deficiency is a very rare cause of hereditary hemolytic anemia from impaired red blood cell energy metabolism.
Clinical significance
Far less common and less well-characterized than other red cell enzyme deficiencies like pyruvate kinase deficiency.
Test methodology
Enzyme kinetic activity assay
Specimen type
Whole blood (RBC hemolysate)
ADAEstablished
Adenosine aminohydrolase
Diseases indicated
Tuberculous pleural effusion, tuberculous pleuritis, Malignant pleural effusion (can cause false-positive ADA elevation)
Short description
ADA is a fluid-based enzyme test used mainly to diagnose tuberculous pleural effusion.
Clinical significance
A well-validated, inexpensive marker for TB pleuritis, with population-dependent optimal cutoffs.
Test methodology
Enzyme kinetic (colorimetric) activity assay
Specimen type
Pleural/body cavity fluid (or serum)
ACTHEstablished
Corticotropin, adrenocorticotropin
Diseases indicated
Addison's disease, Cushing's syndrome, secondary adrenal insufficiency, Ectopic ACTH-secreting tumors (small cell lung cancer, carcinoid)
Short description
ACTH is a pituitary hormone used to diagnose and localize disorders of cortisol production.
Clinical significance
Central to differentiating primary from secondary adrenal disorders and localizing Cushing's syndrome.
Test methodology
Immunoassay (CLIA/ECLIA)
Specimen type
Plasma (EDTA, collected on ice, light-protected)
ACP5Emerging
TRAP5b, tartrate-resistant acid phosphatase
Diseases indicated
Osteoporosis, Hairy cell leukemia
Short description
ACP5/TRAP5b is a bone resorption marker, with an unrelated historical use as a hairy cell leukemia diagnostic marker.
Clinical significance
Less affected by recent food intake than some other bone turnover markers, though less commonly used than CTX or P1NP.
Test methodology
Immunoassay (ELISA)
Specimen type
Serum
ACHEEstablished
Acetylcholinesterase, RBC cholinesterase, true cholinesterase
Diseases indicated
Organophosphate/carbamate poisoning, congenital AChE deficiency, Not primarily cancer-associated
Short description
AChE is a red-blood-cell enzyme whose depression signals pesticide or nerve-agent exposure.
Clinical significance
A key occupational safety biomarker for early detection of cholinesterase-inhibiting toxin exposure.
Test methodology
Enzyme kinetic (colorimetric) activity assay
Specimen type
Whole blood (RBC)
ACEEstablished
Angiotensin I-converting enzyme, peptidyl-dipeptidase A, CD143
Diseases indicated
Sarcoidosis, Gaucher disease, hyperthyroidism, Hodgkin lymphoma (elevated ACE reported)
Short description
ACE is a serum enzyme marker used mainly to support diagnosis and monitoring of sarcoidosis.
Clinical significance
Elevated in active granulomatous disease, especially sarcoidosis; low sensitivity/specificity limits standalone diagnostic use.
Test methodology
Enzyme kinetic/spectrophotometric activity assay
Specimen type
Serum
5-HIAAEstablished
5-HIAA, 5-hydroxyindoleacetic acid
Diseases indicated
Carcinoid syndrome, carcinoid heart disease, Neuroendocrine tumors (midgut/small intestinal carcinoid, lung carcinoid)
Short description
5-HIAA is the classic biochemical marker for diagnosing and monitoring carcinoid syndrome from serotonin-secreting neuroendocrine tumors.
Clinical significance
A 2025 study shows serum 5-HIAA (single blood draw) performs equivalently to the traditional, more burdensome 24-hour urine collection.
Test methodology
Immunoassay or HPLC/mass spectrometry (quantitative)
Specimen type
24-hour urine (traditional) or serum (increasingly validated alternative)